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Abstract 
 
It is a pivotal time in cervical cancer prevention for young South African (SA) women. Cervical 
cancer and infection with human immunodeficiency virus are both major public health concerns 
in SA. This study describes knowledge of female adolescents and young adults (AYA) about 
HPV, cervical cancer and explores predictors of HPV vaccine and HPV self-sample testing 
acceptability. In this cross-sectional study, questionnaires were administered to 122 female AYA 
who involved in a longitudinal study (AYAZAZI) which examined risk factors involved with 
HIV acquisition. Results indicated that although awareness and knowledge about these topics 
was very low among participants, as were perceptions of risk of acquiring HPV and developing 
cervical cancer, acceptability was very high towards HPV vaccines  for self (97%) and (future) 
children (95%), as well for self-sample testing (85%). No significant variables were found to be 
associated with risk perception or self-sample acceptance. A significant difference was found 
between participants’ perceived risk of acquiring HPV, HIV, and developing cervical cancer 
compared to the risk they felt other female AYA in their communities were at. The most 
influential sexual and reproductive health (SRH) information source and significant influences 
on HPV vaccine recommendations for participants were health care providers. Findings from this 
study are important in designing effective cervical cancer control programs that can attract more 
AYA for HPV vaccines and screening. As the HPV vaccine has only recently been introduced at 
a national level in SA, this study about awareness and vaccine acceptability is timely.  
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Chapter 1: Introduction 
It is a pivotal time in cervical cancer prevention for young South African (SA) women. It is a 
reality for many young women that they suffer from an array of sexual and reproductive health 
(SRH) challenges due to a lack of health services, low levels of awareness, and a health care 
system that is acute care than prevention focused. Cervical cancer and infection with human 
immunodeficiency virus (HIV) are both major public health problems in SA. As the HPV 
vaccine has only recently been introduced in SA, this study about awareness and vaccine 
acceptability is timely. This study describes knowledge of female adolescents and young adults 
(AYA) about HPV, cervical cancer and explores variables associated with HPV vaccine and 
HPV self-sample testing acceptability.  
The first section of this chapter provides profiles of the country and city where this research 
takes place followed by a description of the burden of HPV infection and cervical cancer at a 
global and national level for SA. It then discusses the nature and epidemiology of HPV, its 
causal link to cervical cancer, and the relationship of the human immunodeficiency virus (HIV) 
to the HPV. Next primary and secondary prevention of cervical cancer is outlined, conceptual 
frameworks of the study as well as a statement of the problem and purpose of the study.    
The Setting 
South Africa has a population of approximately 56 million people with black African peoples 
as the majority at an estimated 80%; colored1 and white people at 8.5% each of the total; Indian 
and Asian peoples 3%, and “other” populations representing the remaining 0.5% (Statistics 
South Africa, 2016). Figure 1 shows the ethnic populations in SA. The country has 9 provinces: 
Western Cape, Eastern Cape, Northern Cape, North West, Free State, Kwazulu-Natal, Gauteng, 
                                                          
1 A person of mixed European (“white”) and African (“black”) or Asian ancestry, as defined by the SA government 
from 1950-1991. This term is still used to describe persons of mixed race.  
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Limpopo and Mpumalanga. The province where this research takes place is Kwazulu-Natal 
(KZN), which is the most highly densely populated area in the country (Figure 2). Within KZN 
there are 11 metropolitan municipalities and Durban is located the eThekwini district. The 
municipality spans an area of approximately 2 297km² and is home to approximately 3.5 million 
people. The main language spoken in this district is IsiZulu (62 %) followed by English at 26% 
(Statistics SA, 2016).  
 
Figure 1. Ethnic Populations: South Africa 
Note. From “Statistics by Place”, by Statistics SA, 2016, http://www.statssa.gov.za 
 
 
 
 
 
 
 
 
 
Figure 2. Provinces of South Africa: Population Density 
Note. From “Statistics by Place”, by Statistics SA, 2016, http://www.statssa.gov.za 
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The population in Africa is the youngest in age globally, with over 40% of its population 
under 15 years. South Africa's population is predominantly made up of young people with those 
below 35 years of age representing the largest group at an estimated 66%; 19 percent are 
between the ages 10-19 and 24 percent are aged 15-24 (United Nations Population Fund, 2016). 
Over two thirds of the young population (69%) reside in four provinces (Eastern Cape, KZN, 
Gauteng and Limpopo). Black African peoples have the youngest residents with 34% of the 
overall population under the age of 15 and 22% from 15-24 years of age with a median age of 
21. The largest population represented in the eThekwini district is AYA aged 15-29. The district 
has more females (51%) than males (48%) and an overall mean age of 26.8 (Figure 3). The age 
and gender distribution in SA has important implications for cervical cancer prevention 
demonstrating the vital need to address prevention immediately. 
 
 
 
 
 
 
 
Figure 3. Sex and Gender Distribution: South Africa 
Note. From “The People”, by Statistics SA, 2016, http://www.statssa.gov.za/ 
 
Health Care System in South Africa  
Healthcare is the responsibility of the SA Government, Department of Health (DoH) and is a 
two-tiered system with public- and private-sectors. An estimated 85% of the population utilizes 
public sector health services, private insurance or health schemes cover the remaining 15% 
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(Statistics South Africa, 2015). There are currently 87 registered medical schemes in South 
Africa with approximately 8.5 million beneficiaries. Predominantly, the DoH is responsible for 
the public-sector with the overall priority of improving the health status of the entire population 
with five priority areas including, increasing life expectancy; decreasing maternal and child 
mortality; combating HIV and AIDS; decreasing the burden of tuberculosis (TB); and 
strengthening the efficacy of the health-systems (Republic of South Africa: South Africa 
Government, 2017). 
On September 12, 1978, the World Health Organization hosted the International Conference 
on Primary Health Care (PHC) with the goal of addressing the urgent need for all governments to 
protect and promote the health of their citizens. As defined by the conference in the Declaration 
of Alma Ata: 
“PHC is essential care based on practical, scientifically sound and socially acceptable 
methods and technology, made universally accessible to individuals and families in the 
community through their full participation, and at a cost that the community and country can 
afford to maintain at every stage of their development in the spirit of self-reliance and self-
determination. It forms an integral part both of the country’s health system, of which it is the 
central function and main focus, and of the overall social and economic development of the 
community” (World Health Organization, 1978, p. 3) 
 
South Africa has struggled to fulfill this commitment due, in large part, to poor leadership and 
corruption resulting in a quadruple burden of disease of HIV and AIDS, TB, non-communicable 
diseases as well as exponentially high rates of maternal and child deaths (Mostert et al., 2015). 
This burden of disease translates into SA having considerably low life expectancy rates. 
According to the WHO (2015) the average global life expectancy is 63.1 years old, while South 
Africa is at 62.5. By contrast, high-income countries have an average life expectancy above 80 
years of age.  Currently the SA government is in the pilot stage of establishing national health 
insurance (NHI) program designed to “pool funds to provide access to quality affordable 
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The SA National Cancer Registry (NCR), first established in 1986, has not been updated since 
2011 therefore current accurate cervical cancer incidence and mortality rates by ethnicity are 
difficult to obtain. However, historically, data has demonstrated that significant ethnic disparities 
in the incidence of cervical cancer exist nationally. For example, NCR data from 2011 showed 
that incidence rates of cervical cancer for all women was 21.67 per 100,000 (4,907 women). The 
ethnic breakdown for 2011 was: 21.67 (55) for Asian women; 25.49 (4,056) among black; 15.34 
(359) among colored; and 14.49 (437) among white (National Cancer Registry: South Africa, 
2011). Mortality rates were not reported by the NCR. Studies have estimated that of the 
approximately 80% of black African women who are diagnosed, 60% are latently diagnosed and 
die (Katz et al., 2016; Mqoqi, Kellett, Sitas, & Musa, 2004). However, there is currently no data 
available to support cases definitively.  
Cervical cancer is currently the leading cancer at an incidence rate of 26.6 per 100,000 for 
young women in SA between the ages of 15 to 44 years (see Figure 6), many of whom are HIV 
positive (Bruni et al., 2016; Crosbie, Einstein, Franceschi, & Kitchener, 2013; Denslow, Rositch, 
Firnhaber, Ting, & Smith, 2014).  
 
Figure 6. Incidence Female Cancers (age 15-44) in South Africa 
Note. From “Human Papillomavirus and Related Diseases in South Africa: ICO Information 
Centre on HPV and Cancer”, by Bruni et al., 2016, p.33 
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By contrast, breast cancer is the leading cancer for women of all ages in SA followed by cervical 
cancer and lung cancer (Bruni et al., 2016). Factors contributing to this high burden of cervical 
cancer include challenging socioeconomic conditions, competing health needs, disproportionate 
HIV rates, and health care infrastructure challenges (Denny, 2010; Finoacchario-Kessler et al., 
2016; Katz et al., 2016; UNAIDS, 2015). 
From a social determinants of health perspective, SA is faced with complex health issues 
stemming from a lack of access to the basic requirements of life including, affordable access to 
vital vaccinations, clean drinking water, adequate nutrition, reasonable housing conditions, 
education, and very low employment rates (Mayosi & Benater, 2014). South Africa has extreme 
levels of poverty with an estimated 31% of the population living on less than $2 per day 
(Republic of South Africa, 2016). Some of the largest economic disparities in the world are 
found in SA with the top 10% of the population earning 58% of the overall national income 
while the bottom 70% earn only 17% (Leibbrandt & Woolard, 2016).  
A chronic shortage of health workers, funding, and infrastructure have contributed to the poor 
health outcomes of SA citizens. For example, while the public health sector serves more than 
84% of the population (40 million), only 30% of the doctors in the country work in this sector 
while the remaining 70% work in the private-sector which serves the remaining 16% (8 million) 
peoples who can afford private health insurance either through employment or financial 
advantage (Coovadia, Jewkes, Barron, Sanders, & McIntyre, 2009; Mayosi & Benater, 2014).  
The Nature and Epidemiology of the Human Papillomavirus 
Papillomaviruses (PVs) are small DNA viruses identified to infect over 50 species of 
mammals, birds, and reptiles. Infectious cells are spread through close contact with infected skin 
cells or mucosal contact (Bonnez, 2014; Munoz, Castellsagué, de Gonzalez, & Gissmann, 2006). 
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There are 5 phylogenetic human associated PV’s and over 170 identified types that infect the 
skin or mucosal membranes with new HPV types continuously being found (Bzhalava, Guan, 
Franceschi, Dillner, & Clifford, 2013). Of the strains that affect humans, types are categorized or 
identified as either high-risk (HR-HPV) or carcinogenic in nature, or low-risk (LR-HPV) (see 
Table 2). Non-carcinogenic types are commonly associated with the development of benign skin 
lesions or warts whilst HR-HPVs are associated with the development of cancer.  
Table 2. HPV Types: High- and Low-Risk 
Strains HPV Types 
HR-HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, & 68 
LR-HPV 6, 11, 42, 43, 44 & 45 
 
The causal role of HPV in the development of cervical cancer is a well-established and 
universally accepted association (Crosbie et al., 2013; Schiffman, Castle, Jeronimo, Rodriguez, 
& Wacholder, 2007). Genital HPV is one of the most common occurring sexually transmitted 
infections in the world at an overall approximate prevalence rate of 10% (ranging from 6.1%-
35%) (de Sanjosé et al., 2007). The HPV infection is the first documented necessary cause of 
human cancer, meaning that cervical cancer does not develop in the absence of persistent HPV 
infections (Bosch, Lorincz, Muñoz, Meijer, & Shah, 2002; Crosbie et al., 2013; Munoz et al., 
2006). The HPV infection has been linked to six cancers to date: cervix, penis, vulva, vagina, 
anus and oropharynx (Bonnez, 2014; Dayyani et al., 2010; Munoz et al., 2006). The causal role 
of HPV infections in the aforementioned cancers has been documented beyond reasonable doubt. 
Most women will acquire HPV at some point in their lives (70-90%), however many HPV’s 
are asymptomatic and quite often the virus causes no harm and eventually regresses over time. 
Bruni and colleagues (2010) estimate that approximately 11% of the world population currently 
has an HPV infection. Between 5-10% of all women infected with HR-HPV will develop 
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persistent infections which can progress over decades into cervical cancer (Bosch et al., 2002; 
Munoz et al., 2006). Co-factors in the development of cervical cancer include smoking, multiple 
sexual partners, long-term hormonal contraceptive use, and co-infection with HIV (World Health 
Organization, 2014). 
In 2008, the number of all new cancer cases worldwide attributed to HR-HPVs infections was 
490,000 (30%) in lower income countries (LIC) and 120,000 (29%) in higher income countries 
(HIC), respectively. Notably, cervical cancer is associated with HPV types 16 and 18 in 70% of 
all cases worldwide (de Sanjosé et al., 2007; Walboomers et al., 1999). The most common HR-
HPV types associated with invasive cervical cancer in sub-Saharan Africa are HPV16, 18, 45 
and 35 (Bruni et al., 2016; Smith et al., 2007). In SA, the presence of HPV 16 and/or 18 in 
cervical cancer is estimated at 64% (see Table 3, Bruni et al., 2016). In SA, the highest rates of 
all HPV infections are among young women under the age of 25 (~43%) and decreases 
significantly after the age of 45 (~17%, ibid). 
Recent research demonstrates a high presence of HPV infections in young women in SA. For 
example, a recent study conducted with 224 young women under the age of 30 in the province of 
KwaZulu-Natal enrolled in a prospective cohort study revealed an overall HPV prevalence rate 
of 76.3% with a 54% HR-HPV infection rate (Ebrahim et al., 2016). Similarly, in the Western 
Cape 332 young women (16-24 years) enrolled in a HPV vaccine trial demonstrated to have a 
HR-HPV rate of 49% (Sudenga et al., 2016). Research examining HPV prevalence according to 
age and HIV status conducted in Cape Town with 406 women (18-66 years) found an overall 
HPV rate of 36.7% among the 208 HIV-negative women and 61% among negative women aged 
18-25. HPV prevalence in HIV-positive women was 74% with the highest prevalence (86.4%) in 
women between the ages of 18-24 (Mbulawa, Coetzee, & Williamson, 2015).   
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Table 3. Presence of HPV 16 & 18 in South African Cytology Results 
Note. From ICO Information Centre on HPV and Cancer, 2016 
 
Giuliano and colleagues (2015) found similarly high HPV rates with young women in the 
Western Cape. From a total of 479 young women (16-24 years), 402 participants were HIV-
negative, whereas 71% had more than 1 HPV type with rates highest among the youngest women 
(Giuliano et al., 2015). Finally, a larger scale study conducted in the Gauteng province testing 
1,524 women attending public sector primary health clinics found that the overall HR-HPV 
prevalence was 74.6% with the age-specific prevalence showing a plateau-shaped curve (Richter, 
Becker, Horton, & Dreyer, 2013).       
Overall, evidence from SA indicates that genital HPV infection is very common, particularly 
among young women. It is common for HPV infections to regress with age, however prolonged 
and multiple infections associated with suppressed immune activity (e.g., HIV), environmental 
factors in combination with latent diagnosis and treatment of cervical abnormalities are key 
contributors in the development of cervical cancer in SA. This is particularly the case among the 
most vulnerable populations of women with limited or challenging access to preventive health 
care services. 
Cytology Result N HPV 16/18 95% CI 
Normal 8661 3.2 % 2.8-3.6 
Low-Grade 
Lesions 
318 17.9 14.1-22.5 
High-Grade 
Lesions 
290 30.3 25.3-35.9 
Cervical Cancer 488 63.9 59.6-68.1 
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Cervical Cancer and HIV/AIDS 
South Africa has 0.7% of the world’s population and 17% of the global burden of HIV, which 
is the leading cause of death and illness among female adolescents and women of reproductive 
age (UNAIDS, 2015, 2016). The overall HIV/AIDS rate is 12% among children and 18.5% 
among adults, calculating to an estimated seven million people living with HIV with women 
representing over 60% of these infections (UNAIDS, 2015). In SA, HIV prevalence varies 
between regions. For example, in Kwazulu Natal, where this project took place, HIV prevalence 
is 12.2% compared 5.6% in Western Cape. 
Globally, women are particularly vulnerable to HIV and acquire the virus younger than their 
male counterparts. A plethora of factors increase women’s vulnerability to HIV acquisition 
including biological, behavioral, socioeconomic, cultural and structural risks (Ramjee & Daniels, 
2013; UNAIDS, 2015, 2016; World Health Organization, 2016). Physiologically, women have a 
greater risk of acquiring HIV than men due to the larger mucosal surface of the vagina and 
higher likelihood of tissue injury during intercourse  (Kalichman, Pellowski, & Turner, 2011). 
Adolescents and young women are particularly biologically vulnerable to HIV, as they have 
increased rates of asymptomatic and untreated STIs (linked to higher HIV acquisition rates) and 
immaturity of the inner vagina (cervix) to act as an effective barrier against these infections 
(Chersich & Rees, 2008; Kalichman et al., 2011; Wand & Ramjee, 2012).  
Sociostructurally, women and girls are often treated as socially inferior (UNAIDS, 2016; 
World Health Organization, 2009). Gender inequities affecting health are particularly evident in 
LICs, such as SA, resulting in challenging access to health resources. Factors contributing to 
poor health outcomes and general well-being of women include, inequitable resource allocation, 
lower incomes, and reduced levels of education. In cultures that limit women’s knowledge about 
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STIs and ability to negotiate safe sex further increase women’s vulnerability to both HIV and 
STIs (WHO, 2009; WHO, 2015; UNAIDS, 2016). Violence against women is a well-recognized 
risk factor in the acquisition of HIV; for example, SA women who are exposed to intimate 
partner violence were found to be 50% more likely to acquire the virus compared to women who 
are not exposed to violence (Jewkes, Dunkle, Nduna, & Shai, 2010). It is estimated that 82% of 
new HIV infections among adolescents in SA occur in young women totalling over 4 million 
women. This gender imbalance is particularly evident in SA, where the incidence rate of HIV in 
young women aged 15-24 is up to four times higher than young men (UNAIDS 2015, 2016). 
Cervical cancer is an AIDS-defining illness, meaning it develops much more rapidly and 
aggressively within a weakened immune system in women living with HIV (WHIV). For women 
with normal immune systems, cervical cancer can take between 15 to 20 years to develop, 
however for women with weakened immune systems it can take significantly less time at an 
estimated 5 to 10 years (Denslow et al., 2014). Research demonstrates that WHIV suffer from a 
wider range and higher rate of persistent cervical oncogenic HPV infections and as a result are 5-
8 times more at risk for developing cervical cancer than those not infected; this is particularly the 
case for WHIV who are untreated, have high viral loads and low CD4 T-Cell2 counts (Chen et 
al., 2014; Denslow et al., 2014). Conversely, genital inflammation as a result of HPV is 
associated with HIV acquisition at 3 times the rate for WHIV compared to uninfected women  
(Masson et al., 2015).  
Antiretroviral therapy (ART) is a combination of antiretroviral drugs to help suppress the HIV 
virus and stop the progression of disease, first introduced in 1996 (Hammer et al., 1997). The 
WHO recommends ART for all individuals immediately following diagnosis of HIV. 
                                                          
2 A CD4 count is a blood test that measures CD4 T lymphocytes (CD4 cells). For people living with HIV and a key 
indicator of how well the immune system is working and the strongest predictor of HIV progression. 
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Worldwide, the number of people currently on ART is 17.0 million. This number has vastly 
increased over the past 7 years, particularly in the hardest hit areas such as eastern and southern 
Africa reaching an estimated 10.3 million people and resulting in decreased mortality rates of up 
to 36% (UNAIDS, 2016). A national ART program was first introduced in SA in 2004 and now 
has the highest number of people on treatment globally (3.4 million) with women accounting for 
the majority of the infected population (WHO, 2015, 2016).  
Although ART has demonstrated to have little if no beneficial effects in the development of 
cervical cancer for WHIV, women’s life expectancy has increased exponentially as a result of 
increased access to treatment (De Vuyst, Lillo, Broutet, & Smith, 2008). With WHIV 
experiencing multiple and persistent HR-HPV infections, higher rates of cervical abnormalities, 
and living longer on ART, vaccinations, screening, and monitoring for cervical cancer is an 
essential component of preventive care for this group of women globally.     
Primary and Secondary Cervical Cancer Prevention  
In accordance with the WHO (2014), the goal of a comprehensive cervical cancer prevention 
and control program is to reduce the burden of cervical cancer by decreasing HPV rates, 
providing early detection and treatment, and access to timely treatment and palliative care (see 
Figure 7). Primary prevention is defined as reducing the risk of exposure by increasing resistance 
to infection, thereby avoiding the occurrence of infection (WHO, 2014). Primary prevention of 
cervical cancer also includes abstinence, mutual monogamy in virgins, condom use, and HPV 
vaccines (Manhart & Koutsky, 2002). Vaccines protecting against cancer-associated types of 
HPV are arguably one the most significant advances in the prevention of anogenital cancers 
(Bruni et al., 2016). 
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Figure 7. The WHO Health System Framework 
Note. From “Health System Framework”, 2016, 
http://www.wpro.who.int/health_services/health_systems_framework/en/ 
 
Worldwide, prophylactic bivalent (Cervarix), quadrivalent (Gardasil), and, more recently, 
nonavalent (Gardasil-9) vaccines are available for the prevention of HPV infections. The 
bivalent HPV vaccine is manufactured by GlaxoSmithKline and was released in 2007. The 
vaccine is based on virus-like particles (VLPs) of L1 (the major papillomavirus of the viral 
capsid or protein shell of the virus). The bivalent does not contain live virus therefore it does not 
infect the recipient, but rather neutralizes antibody response providing protection against the 
specific VLP types within the vaccine and strengthens immune response (Herrero, Gonzalez, & 
Markowitz, 2015). It is made up of HPV types 16 and 18 L1 proteins, two HPV types 
responsible for an estimated 70% of cervical cancer cases, and an AS04 adjuvant system3 
(Schiller, Casetlsague, & Garland, 2012; Schiller & Muller, 2015; Stanley, Pinto, & Trimble, 
2012).  
The quadrivalent vaccine manufactured by Merck was approved in 2006, and is similarly 
based on VLP technology, but rather contains an amorphous aluminum hydroxyphosphate 
                                                          
3 Trade name for combination of adjuvants or agents that modify the effect of the VLPs 
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Large clinical trials have shown both the bivalent and quadrivalent vaccines to prevent an 
estimated 90%-100% of HPV 16 and 18 infections and associated precancerous lesions among 
previously uninfected women (Herrero et al., 2015). Both vaccines have also been shown to 
induce partial cross-protection against related HR-HPV types in previously uninfected recipients 
(HPV 31, 33, 45, & 51) (ibid). However, the bivalent or quadrivalent HPV vaccines have not 
been shown to change clearance rates of HPV 16 and 18 when the infection is present (Haupt et 
al., 2011; Szarewski et al., 2012). 
The newest HPV vaccine (nonavalent) demonstrates similar results with 99% reduction in 
seroconversion or HPV acquisition rate following immunization also preventing infection or 
diseases related to HPV 31, 33, 45, 52, and 58, however in terms of cross-protection did not 
prevent infection or disease beyond the nine HPV types the vaccine protects against (Joura et al., 
2015). Overall, all three prophylactic HPV vaccines are well researched and have demonstrated 
to be highly efficacious in the prevention of anogenital cancers associated with HR-HPV 
infections.   
The HPV vaccine is a critical and effective primary prevention measure against HPV-related 
cancers particularly in low resource settings with limited screening resources and high HIV and 
HPV prevalence rates (De Vincenzo, Conte, Ricci, Scambia, & Capelli, 2014; Nakalembe, 
Mirembe, & Banura, 2015). The WHO (2016) currently recommends the primary target group 
for HPV vaccination is girls between the ages of 9-13, as young women have a most robust 
immune system and it is more efficacious as a prophylactic (i.e., before acquiring HPV). 
Efficacy trials have shown that the anti-body response of adolescents and young women (15-26 
years) for both the bivalent and quadrivalent vaccines are similar to that of girls aged 9-15 years, 
however concentration of the antibody or immune response in the younger group of women was 
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found to be significantly higher compared to older group (McCormack, 2014; Schwarz et al., 
2012). A secondary target population of older adolescents and young women as catch-up cohorts 
are important in reducing HPV rates among the general population (Bruni et al., 2016; Garland et 
al., 2016).   
Robust evidence indicates that HPV vaccines have a favourable safety profile (Stillo, 
Santisteve, & Lopalco, 2015). A recent global review examining data of over 1 million recipients 
of the quadrivalent vaccine from 2006-2015 found no serious adverse events (SAE) in recipients 
(Vichnin et al., 2015). Similarly, a review of the safety of the bivalent and quadrivalent vaccines 
by Stillo and colleagues (2015) found that although SAEs such as appendicitis, abdominal pain, 
spontaneous abortion, ovarian cysts, venous thromboembolisms, and Guillain-Barre syndrome 
had been reported, not one case had been found to be directly related to the vaccine by 
investigators but rather were due to pre-existing conditions and risk factors. For example, reports 
of most SAEs were shown to have occurred equally between both the control and active groups. 
Fatal outcome rates reported for the bivalent vaccine had virtually the same incidence rates 
between the vaccine (<0.06%) and control groups (0.07%) while the quadrivalent vaccine had 
one reported death that was attributed to a pre-existing cardiac condition. The most common 
adverse events (AE) documented within the literature for both vaccines included syncope, local 
reactions at the inject site, fever, and nausea (Vichnin et al., 2015). Evidence overwhelmingly 
shows that HPV vaccines are a highly efficacious and safe option in the prevention of infections 
and diseases caused by HPV and vital in locales with limited secondary screening, high HIV and 
HPV rates. 
As HIV significantly increases the risk of acquiring persistent HPV infections, it is also 
important to discuss the safety and efficacy of HPV vaccines within this population. For WHIV, 
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favourable safety profiles have been reported to be equal for both the bivalent and quadrivalent 
vaccines when compared to HIV negative women (Denny et al., 2013; Levin et al., 2010; Stillo 
et al., 2015). Further to this, a recent trial conducted with HIV positive and negative women in 
Canada demonstrated the quadrivalent vaccine to be well tolerated and effective for both groups 
of women. Post vaccination patients underwent follow-up at 24 months and although higher 
general seroconversion was found among WHIV, findings indicated that optimal response to the 
vaccine was among WHIV with a suppressed viral load. This meaning that HIV viral 
suppression was associated with higher antibody response against HPV infections. Findings from 
this study demonstrate the need to ensure ideal timing of the HPV vaccination for WHIV, with 
administration of the HPV vaccine following virologic suppression (Money et al., 2016).   
The HPV vaccine is a highly cost-effective health intervention and the WHO (2015) 
postulates that in LMICs the HPV vaccine could prevent an estimated 4 million cervical cancer 
related deaths among women over the next decade if a 70% vaccination coverage rate was 
achieved. However, many countries face significant financial and political barriers in achieving 
optimal uptake rates (Wigle, Coast, & Watson-Jones, 2013). While many eligible women from 
high-income and upper-middle income countries have received a full course of the HPV 
vaccination by the end of 2014 (33.6%), only a small portion of women (2.7%) had received the 
vaccine in less developed areas of the world (Bruni et al., 2016). Many women living in 
countries with the highest burden of HIV and cervical cancer cases with challenging access to 
screening remain unprotected.  
In 2014, a public school-based HPV vaccination program was rolled out by the SA Health 
Department using the bivalent vaccine (Cervarix) aiming to reach girls in grade 4 (aged 9 and 
older) in 80% of the poorest public schools targeting just under 500,000 girls. No private schools 
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were included in the program. Vaccinations were performed by Ministry of Health nursing staff 
once parental consent was received. To date, the targeted vaccination coverage rates for girls in 
grade 4 was reported at 92% with 412,617/454,652 girls receiving the first round and 
422,000/454,652 receiving two doses. The overall estimated coverage rate for children (male and 
female) born in 2004 due to this program is at an estimated 39% (Botha & Richter, 2015). 
South Africa’s Deputy Director-General of Strategic Health Programmes in the National 
Department of Health, Dr. Yogan Pillay, recently reported (2016) that the number of grade 4 
girls who had completed the required two doses of HPV vaccination reached 649,330. The goal, 
Pillay states, is to eventually reach all 18,000 primary schools across the country, as opposed to 
focus strictly on the poorest schools. With the wealthiest 20% of schools not covered in the HPV 
vaccination program, Health Minister Aaron Motsaeledi called on medical schemes to pay for 
the vaccines to help parents in for all learners to be covered by the program. HPV vaccines, 
however, have not been a priority for medical schemes to cover and have had unimpressive 
uptake rates to date.      
Private sector data from 2015 demonstrated that the HPV vaccine uptake rate in SA have been 
slow. Data estimates that of the 16 million women eligible for HPV vaccines between the ages of 
9-45, only 50,000 received vaccines through private health schemes between 2009 and 2014 
(Richter, 2015). An article in the Mail & Guardian reported three of the largest medical schemes, 
Bonitas, Discovery Health, and Fedhealth’s reactions to the Health Ministers message to have all 
medical aide schemes in the country pay for the HPV vaccine to help all parents be able to afford 
to have their daughters vaccinated. Bonita responded that they were considering looking into the 
HPV vaccine for upcoming years but urged its members to access Pap testing with their benefits 
package. With Discovery Health, the vaccine can be paid for using member savings accounts and 
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not widely accessed, as 3,578 of its 1.228-million female plan members received the HPV 
vaccine within the last year. When speaking about the high-cost of the HPV vaccine, a Discovery 
Health representative stated: 
“Vaccines are typically regarded as a public service or public goods in the sense that it 
benefits not only individuals who are vaccinated but also society at large, and ultimately the 
broader healthcare system. We believe that the department of health should consider making 
vaccines available in the private sector at state tender prices. These prices are well below 
current private sector vaccine prices, and access to state tender prices would make vaccines 
significantly more affordable for medical schemes and their members. This would also have 
the very positive effect of reducing the burden of patients attending public sector clinics” 
(Green, 2013).    
 
Fedhealth expressed similar concerns about the financial feasibility of offering the HPV vaccine 
in a benefits package, nothing that “it is unlikely that private patients will be able to get the 
vaccine at the same price as government can procure it. Legislation states there can only be one 
single exit price so it is illegal to negotiate prices in the private sector” (Green, 2013). In 
summary, the government feels the HPV vaccine, specifically for those young women in the 
20% of higher income schools and private schools, should be the responsibility of the private 
sector while the health schemes distinctly feel that the Ministry of Health should be responsible 
for vaccinating all young women or at the least be able open to negotiating cost-share pricing for 
the vaccine4.     
Secondary prevention refers to the early detection and treatment of diseases using 
interventions strategies such as screening (WHO, 2014). Current recommended cervical cancer 
approaches recommended by the WHO (2014) include cytology (Papanicolaou or Pap test), 
visual inspection using acetic acid (VIA) and HPV testing. The intention of cytology and VIA 
screening tests are to identify cervical dysplasia or abnormalities while HPV testing aims to 
detect the presence of HR-HPV types most commonly associated with anogenital cancers. Using 
                                                          
4 Within the private health sector and with extended insurance the vaccine cost is R650. While in the public sector 
with no insurance, to buy the vaccine from a pharmacy would cost approximately R2300. 
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cytology, abnormal changes are categorized by the extent of the dysplasia or cervical 
intraepithelial neoplasia (CIN) from mild (CIN1) to severe (CIN3). VIA, on the hand, uses acetic 
acid and a health care professional can visually examine abnormal cellular changes (ibid).  
A recent systematic review comparing test accuracy of the HPV test, cytology, and VIA in 
women over the age of 18 years and HIV negative (or undiagnosed) women found HPV testing 
to have the highest sensitivity compared to cytology or VIA screening for diagnosing CIN2+. 
The findings also indicated that the most common form of overtreatment occurred using VIA. 
The pooled estimates for VIA sensitivity and specificity were 0.77 and 0.82, respectively, and for 
cytology-based screening was 0.84 and 0.88 while HPV testing was 0.95 and 0.84 (Mustafa et 
al., 2016). Similarly, a cross-sectional study evaluating screening methods among WHIV in 
South Africa demonstrated HPV testing to be the most sensitive screening method for detecting 
CIN 2+, however it was less specific than cytology and VIA. The estimated sensitivity and 
specificity for VIA was 0.65 and 0.69, respectively, while cytology-based screening was 0.76 
and 0.84 and HPV testing 0.92 and 0.51 (Firnhaber et al., 2015).  
In SA, cytology-based screening is currently the most common screening tool followed by 
VIA, with HPV testing being used in pilot projects. A National Cervical Screening Program was 
established in 2000 and every woman within the public sector over the age of 30 is eligible for 3 
free Pap tests administered at 10 year intervals. Despite the free screening, uptake rates in the 
public health sector are poor and estimated by the SA government to be at 54% for the 2014/15 
time period (Ministry of Health, South Africa, 2015). However, uptake rates of Pap tests by 
Bruni et al. (2015), using multiple small scale studies, are significantly lower averaging annual 
overall rates of an estimated 14%. Challenges to cytology based screening also include a 
significant loss to follow-up after receiving abnormal results, competing national and local 
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healthcare priorities (e.g., tuberculosis; HIV/AIDS), inadequate numbers of health care 
professionals, and a lack of awareness about HPV and cervical cancer among women (Botha & 
Richter, 2015; Chidyaonga-Maseko, Chirwa, & Muula, 2015; Francis et al., 2011).   
The WHO (2014) notes that cervical cancer prevention efforts in SA are significantly 
hindered by the absence of an active national cancer registry (which as mentioned earlier was 
last updated in 2011) and screening program stating that, “irrespective of how good a screening 
test is, it will have no impact unless introduced as part of a well-planned and implemented 
program” (p. iv). The central success of a cancer registry and screening program begins with 
political will, as it requires significant national planning and adequate funding. Creating linkages 
between vaccine administration and cervical screening and cancer registries would be beneficial 
for monitoring and needs to be a national priority. Cancer control planning and monitoring is 
vital for SA; an area of the world with the highest rates of cervical cancer (Bray et al., 2014).  
The relationship of HPV in the development of cervical cancer is well-established and 
therefore HR-HPV testing, which can be clinician-administered or self-administered, is a well-
researched and highly recommended approach for underserved and under-resourced areas of the 
world as an alternative to cytology-based screening. It has also been demonstrated to be a highly 
accurate and acceptable screening method among women worldwide (Gravitt, Belinson, 
Salmeron, & Shah, 2011; Racey, Withrow, & Gesink, 2013; Verdoodt et al., 2015). Currently 
only 6 countries have national HPV testing programs including, Argentina, Italy, Mexico, 
Netherlands, Spain and the United States with pilot programs in 11 additional countries (see 
Figure 9).  
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Figure 9. Global Progress in HPV Testing for Cervical Cancer Screening 
Note. From “Global Progress in Cervical Cancer Prevention”, by Cervical Cancer Coalition, 
2016, http://www.cervicalcanceraction.org/comments/maps.php 
From a macro perspective, political will and dedicated financing are greatly required to 
expand HPV vaccination and screening to achieve and maintain a reduction in cervical cancer 
incidence in SA (Botha & Richter, 2015; Harries, Moodley, Barone, Mall, & Sinanovic, 2009). 
On an individual level, the global literature from LMICs demonstrates that women’s knowledge 
about these topics is generally poor (Cunningham, Davison, & Aronson, 2014). Additional key 
factors in the willingness to vaccinate or promote vaccination in SA include being able to better 
understand the infection and its link to cancer, having a healthcare provider recommend the 
vaccine, and integrating traditional healers as educators. Within the literature, awareness and 
knowledge about these topics were positively associated with HPV vaccine acceptance and 
uptake. Therefore, a successful HPV vaccine campaign would largely benefit from better 
understanding women’s awareness and knowledge, as these factors play a key role in making 
informed health decisions (Chidyaonga-Maseko et al., 2015; Cunningham et al., 2014; Perlman 
et al., 2014).  
National Programs Pilot Programs 
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Conceptual Frameworks 
This research was designed with the health belief (HBM) and vaccine hesitancy (VHM) 
models in mind. The HBM is one of the commonly used theories in health behaviour research 
and identifies contributors that are predictive of health behaviours (i.e., vaccine acceptance or 
Pap testing) including: risk susceptibility, risk severity, benefits to actions, barriers to action, 
self-efficacy, and cues to action (Glanz & Bishop, 2010). More specific to my research, and 
personally preferential, is the VHM5 which considers not only individual but also historical, 
political and socio-cultural factors influencing vaccine uptake (Dubé et al., 2013). The model 
also recognizes the important role that trust in vaccine safety, health care professionals, and 
policy makers as well as the messages women receive, play in vaccination decision-making 
(Figure 10). Overall, understanding vaccine acceptance is complex and involves many factors 
that are not purely cognitive in nature but also emotional, cultural, social, spiritual and political. 
This research was influenced by both conceptual frameworks by inclusion of these variables in 
the questionnaire and analysis of covariates in vaccine and self-sample acceptability.  
 
 
 
 
 
 
 
                                                          
5 It is important to note that although the VMH accounts for a variety of factors the play a role in decision-making 
about vaccines, it has not been adapted for LMICs and does not account for factors such as socioeconomic status. 
Figure 10. Vaccine Hesitancy Model 
Source: Dubé et al. 2013 
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Social Determinants of Health Perspectives 
Disease and health conditions, using this perspective, are thought to be a result of social, 
economic, as well as political forces, collectively referred to as social determinants of health 
(Wilkinson & Marmot, 1998). Social determinants of health perspectives outline the remarkable 
sensitivity to and relationship of health to our social environment. These factors are recognized 
on both an international (e.g., WHO) and national level (e.g., Public Health Agency of Canada; 
PHAC) as contributors to health. Many diseases determined by networks of interacting 
determinants, all of which have the ability to contribute to or negatively affect one’s health. 
Organizations have different ideas about what constitutes a social determinant. For example, the 
WHO identifies ten main social determinants while the PHAC identifies twelve (see Table 4). By 
asking questions about social determinants, this research examined these factors and whether 
they influenced awareness about HPV, cervical cancer, and ultimately acceptance the HPV 
vaccine.  
Table 4. Social Determinants of Health: WHO & PHAC 
 
Youth Engagement Approaches 
The aforementioned conceptual frameworks and perspectives are complimentary to a youth 
engagement (YE) approach, which was integrated into the project by the AYAZAZI Research 
Team before my HPV, cervical cancer, and vaccines section of the survey was introduced. The 
 Determinants 
WHO Social Status; Stress; Early Life; Social Exclusion; Work; Unemployment; 
Social Support, Addiction; Food; Transportation.   
PHAC Income & Social Status/Support; Education & Literacy; Employment/ 
Work Conditions; Social Environments; Physical Environments; Personal 
Health Practices; Coping Skills; Child Development; Biology/Genetics; Health 
Services; Gender; Culture 
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AYAZAZI research team has a cohort of AYA in Soweto and Durban, SA to identify, 
understand and link socio-behavioural, clinical, and biomedical patterns of risk for HIV 
acquisition and vaccine trial preparedness using a mixed method approach. The rationale behind 
using a YE approach was because the topics being studied were highly personal with the team 
recognizing the need to collaboratively develop innovative, creative, and culturally appropriate 
HIV interventions with and for AYA; those most affected by HIV. The AYAZAZI research team 
believes that AYA voices need to be integrated into SRH health research and policy 
programming, as they know best.  Youth engagement recognizes young people’s right to 
participate in decisions that impact them and recognizes the knowledge and skills they bring to 
the table. In a research setting, youth engagement involves leadership that is able to see the 
potential and impact of adults and young people working together (Powers & Tiffany, 2006). 
This means that youth are included as partners in the design and implementation of research 
involving key issues that affect their lives thus generating key knowledge to inform future 
interventions and community mobilization. This project relied on the knowledge of and direction 
from AYA throughout all stages; from planning to dissemination. Research assistants for this 
project were two female AYA who assisted in conducting an awareness workshop, questionnaire 
design and pilot testing, as well as knowledge translation (KT) activities.  
Statement of the Problem 
Globally, the highest HIV rates are found in SA and more particularly within the province of 
KwaZulu-Natal where this research takes place. AIDS and related illnesses are currently the 
leading cause of death among adolescents (10-19) in SA with young women most acutely 
affected. Cervical cancer is a preventable and significant global health concern. Globally, SA has 
some of the highest rates of cervical cancer in the world and is currently the leading cause of 
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cancer among young women in SA, many of whom are HIV positive. HIV/AIDS and cervical 
cancer are the most serious health challenges faced by South African adolescents and young 
adolescents (AYA) requiring an immediate global response.  
Purpose of the Study 
The aims of this study were to describe the knowledge, awareness, and beliefs about HPV 
infection, cervical cancer, and HPV vaccine among a cohort of AYA and explore factors 
associated with vaccine acceptability.  
Summary 
Cervical cancer is a preventable and significant global health concern. South Africa and, in 
particular, the province of KwaZulu-Natal with the highly dense population and extremely high 
rates of HIV, is the ‘epicentre’ of both the HIV and cervical cancer epidemic. Young women 
specifically are at a significant risk of acquiring HIV and HPV infections, resulting in 
disproportionately high rates of cervical cancer nationally. It is a pivotal time in global cervical 
cancer prevention. The HPV vaccine is a safe and efficacious prevention tool with promising 
outcomes for women of all ages, particularly WHIV. It is the only vaccine available worldwide 
that has been demonstrated to prevent cancers. Although ‘elite responders6’ to the HPV vaccine 
are young women, many factors demonstrate the importance of increasing the uptake of vaccine 
to all women in SA.  
The severity of the HPV crisis among young women stems partly from the barriers and 
disconnection between primary and secondary prevention measures. Lack of education, access to 
screening services (including follow-up of abnormal results), and low rates of HPV vaccination 
acceptability and uptake warrants an immediate response from the global research community. 
                                                          
6 A child/youth with a robust immune system that has not yet engaged in sexual activity and acquired HPV. 
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Unlike treatments such as ART that do not provide a long-term solution, HPV vaccinations are 
preventative and have been shown to have cross-protection benefits with minimal adverse 
outcomes. 
Despite national efforts in SA to rollout the HPV vaccines, the uptake remains alarmingly 
low, particularly among those at the highest risk of acquiring and developing HPV related 
cancers. It can be argued that governmental approaches alongside embedded societal and cultural 
barriers contribute to low vaccine uptake. First, government needs to make HPV education and 
vaccination a national priority that should be seen as a public health investment. Second, barriers 
to social determinants of health experienced by a significant proportion of vulnerable populations 
must also be addressed; education, employment, poverty and access to health care services are a 
few of the factors that must be considered by when developing future health policy and vaccine 
initiatives in this part of the world. It is also important to have research examine the target 
population of young women, specifically assessing levels of education around efficacy and 
safety of vaccinations in general as well as link between HPV and cancer. Further, with the use 
of the VHM conceptual framework, causal links can be made between societal structures and 
public trust in vaccinations and recommendations from health care professionals. Finally, closer 
examination of predictive factors associated with primary and secondary prevention in an area of 
the world with the highest HIV and cervical cancer rates is required.    
This study will address gaps in the literature, help inform preventive health policy, and assist 
in expansion of the national vaccine initiative in SA by better understanding awareness of HPV 
and cervical cancer and acceptability of the HPV vaccine among the most vital and affected 
group of women globally.  
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Chapter 2: Literature Review 
Background 
Cervical cancer is the leading cause of cancer deaths among young women in SA. 
Contributors in the disproportionate morbidity and mortality associated with cervical cancer in 
this area of the world include high HPV infection rates, high HIV endemicity, challenging access 
to primary and secondary preventive services, competing health priorities, high levels of sexual 
violence and poverty and an overall lack of awareness about HPV and its relationship to cervical 
cancer.  Since the introduction of the HPV vaccine worldwide, the availability of and subsequent 
uptake rates of the HPV vaccine in South Africa remain alarmingly low. Only a small proportion 
of the population have access to private medical insurance, leaving the majority (~80%) most at 
risk for HPV acquisition unable to access the vaccine. In 2014, the Health Department in South 
Africa began a national rollout of HPV vaccines among girls in grade 4 in some public schools, 
however the overall national coverage rate for eligible females currently remains inadequately 
low. The greatest public health impact of HPV vaccination will be in countries with limited or no 
access to screening. The high rate of cervical cancer combined with the current lack of access to 
the HPV vaccine warrant the expansion of vaccine availability to those who need it most in 
South Africa, which will ultimately require a better understanding factors influencing women’s 
decision to be vaccinated.  
Key Global Reports 
Two key reports about HPV vaccine delivery strategies in LMICs exist: one was authored by 
the World Health Organization (WHO; 2011) and the second by the Program for Appropriate 
Technology in Health (PATH; 2015). Both are important starting points or background for this 
literature review. Both reviews provide details of large-scale demonstration projects and provide 
insight on HPV vaccine program development for informing decision makers. PATH routinely 
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provides HPV vaccines at a subsidized rate for LICs. It is important to note that while PATH 
provides vaccines for a variety of LICs, SA does not qualify for their subsidy programs due to its 
designation as a middle-income country. However, lessons learned in areas with low resources 
and high rates of HPV and cervical cancer are beneficial to compare and can serve as examples 
for South Africa’s current National HPV vaccination program.    
Since 2006, PATH and GAVI Alliance have worked with these four countries to better 
understand how to most efficiently deliver the vaccine; reasons behind acceptance or refusal of 
the vaccine; and on outcomes which are used to inform government and aid in the development 
or scale-up of HPV vaccine programs. The first report, by PATH, was conducted with parents of 
girls eligible for HPV in LICs in four countries, including Peru (264 schools and 161 health 
facilities), Uganda (417 schools and 69 health facilities), India (537 schools and 672 health 
facilities), and Vietnam (38 schools and 72 health facilities) (LaMontagne et al., 2011). Findings 
showed from the cross-sectional study included the uptake rate for 7,269 young women between 
the ages of 9-14 and response surveys with parents, most of whom were mothers. Overall, 
findings demonstrated moderate HPV vaccination coverage within the demonstration projects, 
with the exception of one program in Uganda that coupled with an existing Child Days Plus 
program (52.6%). School-based programs uptake ranged from 88.9-96.1% in Peru, Uganda, and 
Vietnam. The combination approach used in India (delivered in schools and health centres) 
averaged from 77.2% to 87.8% (urban vs. rural). Solely health-centre based HPV vaccine 
delivery approaches in Vietnam had the highest coverage rates at 98.6%. Parent responses 
indicated that they had a positive perception about the HPV vaccine and its benefits to their 
daughter’s health in general, despite a lack of awareness about cervical cancer or HPV. A belief 
in and support of vaccines in general was associated with HPV vaccine acceptance. Finally, the 
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messaging surrounding the vaccine was a factor in parent decision-making. Barriers reported by 
parents included absenteeism of students, limited awareness about the vaccination program; lack 
of knowledge about cervical cancer, HPV and vaccine; as well as challenges in determining 
girl’s eligibility. The authors conclude that “more attentive planning and communication” (p.8) 
could help to address some of the barriers faced in the demonstration projects.  
A recent report by PATH (2016) in collaboration with the London School of Hygiene and 
Tropical Medicine outlines lessons learned from HPV demonstration projects and national 
programs in LMICs. The objectives of the report were to synthesize lessons learned, generate 
recommendations on vaccine delivery strategies and best practices for both demonstration and 
national programs. A variety of HPV vaccine support programs are available for low-resource 
countries through Merck & Co, GARDASIL® Access Program (GAP), GAVI Vaccine Alliance, 
the Australian Cervical Cancer Foundation and PATH (funded by the Bill and Melinda Gates 
Foundation). This cross-sectional retrospective review includes 46 countries, a systematic review 
(72 articles), unpublished literature (188 reports) and key informant interviews (56) from 40 
different countries. Delivery experiences were reviewed from 12 national programs; 66 
demonstration projects or pilots with a total of 92 distinct experiences within the countries. 
Overall, findings demonstrate that the delivery of the HPV vaccine is feasible and highly 
acceptable resulting in impressive coverage rates in LMICs. The total number of young women 
vaccinated through the projects and programs is ~1.8M, with 1.4M achieving full vaccination 
status (all three doses). Findings were organized by general topics including, national decision-
making and planning, service delivery, health workforce, monitoring and evaluation, financial 
support and sustainability, and scale-up. Given the scope of the project and literature review, all 
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factors mentioned will be reported and considered, however findings regarding acceptance or 
refusal of the HPV vaccine and successful delivery strategies will be reviewed in greater detail.  
Key findings and lessons learned from the demonstration projects and national programs 
include adequate preparation, communication, and delivery strategies. This meaning that high-
level political commitment plays a vital role in the success of any project or program and that 
time has to be allotted to gain acceptance with proper education and stakeholders prior to the 
administration of the vaccine while recognizing that each locale has unique needs needing to be 
addressed. An intersectoral planning approach is key to successful implementation and 
sustainability of the HPV vaccine program. In addition, the integration of the HPV vaccine with 
other routine vaccination programs also proved to be an effective way to increase participation. 
In terms of the most effective delivery strategies, projects or programs that included school-
based HPV vaccine delivery had higher uptake rates. Knowledge about HPV and its association 
to cervical cancer, as well as the vaccine throughout countries involved in demonstration projects 
was generally low. However, messaging that focused on the safety profile and efficacy of the 
vaccine, and endorsement the vaccine by national government and international standards 
(WHO), contributed to more successful uptake rates of the vaccine. The most influential 
individuals in the delivery of the HPV vaccine are health workers, teachers, and community 
leaders. Community mobilization activities are vital to introduce prior to vaccination by both 
health workers and community leaders with appropriate messaging. Face-to-face communication 
with community members and parents helped to decrease the spread of misinformation regarding 
the vaccine and program thus improving acceptance of the vaccine.  
Overall, the lessons learned in the development and implementation of HPV vaccination 
strategies include the benefit of integrating HPV vaccines in a school setting, identifying eligible 
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girls based on grades or class rather than age, and integrating the HPV vaccine to other national 
immunization schedules. Adequate preparation, coordination, monitoring and supportive 
supervision within the health and education system, as these factors facilitate higher HPV 
vaccine uptake. Evidence-based education and outreach needs to begin at least one month before 
rollout with locale specific materials to help raise community awareness. Findings outline the 
low levels of awareness and knowledge about these topics in all areas of the world and the 
importance of reframing the message from HPV as an STI to receiving the HPV vaccine as a 
means of preventing cervical cancer and HPV related cancers.  
Factors Associated with HPV Vaccine Acceptability and Uptake: Literature Search 
The objective for the remainder of the chapter is to provide an examination of peer-reviewed 
literature about factors associated with HPV vaccine acceptability and uptake among AYA and 
parents (caretakers) in LMICs. A search was conducted in the electronic database: Ovid 
MEDLINE, to identify studies related to strategies used to increase HPV vaccination uptake and 
vaccine acceptability in LMICs with specific focus on females with a total of 198 articles first 
identified (see Appendix A for the search strategy). Based on the key questions, inclusion and 
exclusion criteria were determined. Included were full articles written in English. Articles written 
before the year 2000 were excluded. Studies conducted with male participants were excluded 
with the exception of articles about health care professionals in training. Articles that were not 
research based were also excluded (e.g., opinion papers). Because understanding perspectives, 
knowledge, and awareness about these topics from future health care professionals is important 
to answering questions about acceptability of the vaccine among female AYA, studies about 
medical and nursing students with male participants were also reviewed. If a study had parents or 
caregivers paired with daughters receiving vaccines, the articles were reviewed. Articles 
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including parental attitudes and acceptance towards the HPV vaccine were also included. 
Inclusion criteria for the review included: research measuring uptake and acceptability (actual 
and theoretical) of the HPV vaccine among female adolescents (16-19 years) and young adults 
(15-29 years). Due to the ‘elite responder’ age of 9-13, articles including all young women 9- 29 
years were included. The review did not explore studies with cohorts of females older than 29 
years of age (unless it was a parent or caregiver study). If a study had groups of women ranging 
in ages, only studies with cohorts of women with a mean age of 23 years (median of ages of 
interest 15-29) and younger were included.  
Two review articles, including one systematic review about factors associated with HPV 
vaccine acceptability in African countries and a general review about contributory factors 
associated with cervical cancer prevention strategies in LMICs were reviewed. Eleven articles 
featuring the work of seven teams working to better understand factors influencing or associated 
with HPV vaccine uptake among adolescents and caregivers in LMICs were reviewed.  
Seventeen studies regarding attitudes, perceptions, and acceptability (theoretical) of the HPV 
vaccine among AYA were reviewed. Although literature about parental or caregiver’s attitudes 
towards and acceptance of the HPV vaccine for daughters is not directly related to the topic of 
this dissertation research and AYA acceptability specifically, twenty eight articles about this 
subpopulation were reviewed and a brief summary is provided to give context and better 
understand the educational needs and correlates or predictors of HPV vaccine acceptance among 
parents and caregivers who are, in some cases, the decision-makers for children and adolescents. 
Although a total of 198 articles were identified, once inclusion and exclusion criteria was 
implemented and articles were reviewed, a total of 140 articles were excluded (see Appendix B 
for search strategy flow diagram).  
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A wide range of literature exists about knowledge of HPV, vaccines, and women’s 
acceptability (intention) of the HPV vaccine, however very few articles are available which 
specifically examine the direct role of interventions in or specific factors associated with HPV 
vaccine uptake among female AYA and caretakers in LMICs. Findings from this review 
indicates a common theme among AYA and parents that knowledge about HPV and its 
associated diseases are very low in LMICs despite cervical cancer being a leading cause of death 
among women in these areas of the world. Acceptability of the vaccine among both AYAs and 
parents and willingness to participate in interventions which aid in the prevention of cervical 
cancer, despite having very little awareness about these topics, was consistently very high 
throughout all studies; this was the similar for both acceptability in-theory and actual uptake 
studies. Comprehensive education campaigns which included a wide variety of stakeholders 
(nurses; educators; policy-makers, media and parents) for periods of time prior to the 
administration of the vaccine, demonstrated to be an important contributor to successful 
acceptability and uptake rates for AYA and parents. Key features cited in the literature 
commonly associated with reluctance towards the HPV vaccine include: confusion or 
misinformation regarding the safety profile of the vaccine; a lack of awareness about how 
cervical cancer can be prevented; challenging medical infrastructure and quality of vaccine 
program; affordability of the vaccine; and the stigma associated with HPV being a STI. Health 
care provider attitudes towards, opinions about, and recommendation to patients demonstrated to 
play a critical role in the willingness to participate in the HPV vaccine for both the female AYA 
and parents.  
 
 
 37 
 
Review Articles 
A recent review article examined contributing factors of cervical cancer prevention services in 
LMICs and categorized barriers as individual, community, and health system-related 
(Chidyaonga-Maseko et al., 2015). From the 31 articles reviewed by the authors, the most 
common individual barrier in cervical cancer prevention services was inadequate knowledge 
about HPV and cervical cancer in general. More particularly, a lack of awareness about the 
association of HPV to cervical cancer and a familiarity with preventive health. Other notable 
contributory individual factors included challenging economic circumstances and geographic 
inaccessibility to preventive services. Cultural beliefs and embarrassment were also cited as 
important factors in the decision to participate in screening and HPV vaccination. Community-
related factors include social norms, gender roles, and women’s predominantly subordinate 
positions in LMICs. The way in which HPV is viewed (social stigma) and sex education is 
offered, plays a role in women’s willingness to participate in preventive measures. Finally, health 
system-related factors such as having an organized cervical cancer prevention program requires 
adequate financial resources, infrastructure, health care professionals, and surveillance. The 
political will of a country and national prioritization is arguably one of the most significant 
factors in the uptake of preventive cervical cancer services for women living in LMICs.  
A systematic review about HPV vaccine acceptability from a parental perspective by 
Cunningham and colleagues (2014) and included fourteen studies from ten sub-Saharan African 
countries. Overall, acceptability of the vaccine was high (59-100%) however similar to the 
previous review, awareness and knowledge about the topic of HPV, cervical cancer, and HPV 
vaccines were low and strongly associated with acceptability of the vaccine. Using a health 
belief model framework, the authors found that perceived personal risk of acquiring HPV 
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infection and developing cervical cancer was low and corresponded with a lower vaccine 
acceptance rate. Conversely, the higher the perceived severity associated with cervical cancer the 
more likely women were to accept the vaccine. In terms of perceived effectiveness and benefits 
of the HPV vaccine, the literature demonstrated higher acceptability among participants with 
previous positive experiences with vaccines and in areas with higher levels of sexual violence 
towards young women. The perceived barriers ranged in the literature from cost, availability or 
accessibility, and uncertainty about the safety profile of the vaccine, however these factors did 
not deter participants from accepting the vaccine. Finally, recommendations from health care 
professionals played an important role in vaccine acceptance in over half of the studies reviewed. 
Most importantly, public endorsements by the government and community attitudes were also 
found to be key factors in HPV vaccine acceptance among women in Africa.  
Uptake of the HPV Vaccine: South Africa 
Six articles about three demonstration studies related to uptake of the HPV vaccine among 
adolescents in South Africa were reviewed. The HPV vaccine demonstration teams conducted 
research in KwaZulu-Natal, Gauteng, and Western Cape provinces.  The first demonstration 
project conducted was in 2011 (before the national rollout in 2014) and included 31 primary 
schools (1000 learners aged 9-14 in grades 4 and 5) in the province of KZN (Moodley, Tathiah, 
Mubaiwa, & Denny, 2013). The demonstration sites were based in settlements characterized by 
high HIV rates, poverty, and poor access to services. A working group was established prior to 
the project that included various key stakeholders such as provincial and district health and 
education representatives. Information sessions were held with a wide array of community 
members including principals, teachers, school governing bodies, parents, community and 
religious leaders, traditional leaders, traditional healers, school health teams, hospital nurse and 
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doctors and private practitioners prior to the administration of the program. Training, education, 
and administration of the vaccines was offered by teams consisting of a nursing sister, a 
registered nurse, and 2 enrollment nurses. Results from the study indicate successful vaccine 
uptake rates, with 963 of the learners receiving the first dose, 943 (97.9%) the second, and 938 
(97.8%) the third, respectively. With educational materials provided about cervical cancer 
screening and prevention the authors hoped to promote Pap testing at the local clinics. A school-
based setting for HPV vaccination programs are ideal and it is very important to begin planning 
well before the implementation of the program. This project demonstrates high acceptance rates 
of the HPV vaccine, credited in part to the inclusion of the community in the discussion about 
outreach and educational messaging and effective training strategies.    
A qualitative study conducted by Katz and colleagues (2013) in Soweto, the province of 
Gauteng, examined factors influencing HPV vaccination (bivalent) uptake among a sample of 
low-income South African adolescents between the ages of 12-19 years (N=224) and their 
female caregivers (N=39). Of the youth recruited, 201 agreed to partake in the HPV vaccine and 
received the first dose; 192 (95.5%) received a second; and 164 (81.6%) completed all three 
doses. Adolescents and caregivers of youth who had accepted the vaccine were chosen randomly 
to participate in a semi-structured interview to better understand perspectives regarding their 
decision-making. All but two caregivers identified as single-parents with many women not 
having a steady source of income. Four themes emerged from this study including, single-headed 
households lead to adolescent autonomy in decision-making; the role of health care providers 
(HCP) and peers in influencing vaccine uptake and providing support; STI vaccination as a 
harm-reduction strategy in the setting of endemic gender-based violence; and the influence of the 
HIV epidemic in understanding of the HPV vaccine. Caregivers expressed concerns about not 
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being able to keep their children safe and the vaccine represented a way in which they could 
better protect their daughters against cervical cancer. High levels of sexual violence against and 
exploitation of young women was also important drivers for caregivers and adolescents in 
vaccine uptake. Adolescents described having a high degree of autonomy in their health-decision 
making and commonly educated the caregivers about sexual health matters, in particular about 
the benefits of vaccination. Both caregivers and adolescents described the role of and 
relationships with the health care professionals as essential in providing sexual health education 
in this setting which significantly influenced decisions about health. Peers also played a role in 
encouraging one another to initiate the vaccine (Katz et al., 2013).    
The Vaccine and Cervical Cancer Screen (VACCS) project (4 articles) was conducted in a 
total of 34 low resource schools in rural Gauteng and Western Cape and focused on multi-
generational learning, educating female caregivers of adolescents being offered the HPV vaccine 
for females in grades 4-7 (Dreyer et al., 2015; Snyman, Dreyer, Botha, & van der Merwe, 2015; 
Snyman, Dreyer, Botha, van der Merwe, & Becker, 2015). The demonstration studies were 
coordinated in a way that first educated all key stakeholders, educators, administrators of 
schools, and then placed focus on parents and adolescents. The school-based approach gave an 
opportunity to increase knowledge about cervical cancer therefore also improving acceptance of 
preventive measures for both mothers and daughters. A key focus was also on messaging to the 
community about the vaccine, as a preventive vaccine rather than STI related. Findings overall 
demonstrated an improvement in screening (using HPV testing and cytology) among the mothers 
involved in the projects and uptake of the vaccine was very high. The first project, conducted in 
19 primary schools (2,000 school girls) administered both the Cervarix and Gardasil vaccines 
with girls younger than 10 receiving Gardasil and all others Cervarix. The first dose of the 
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vaccine to 2,030 girls (99.2% of invited cohort) with a total of 1,859 (91.6%) considered 
‘adequately’ vaccinated. For the purpose of this study, girls who had received at least 2 doses 6 
months apart and those who received 3 doses were considered sufficiently vaccinated. Findings 
demonstrated that parents who attended the information night were significantly more likely to 
have their children vaccinated, however girls aged 12 and over were eligible to participate in the 
vaccine without parental consent. Offering the vaccine throughout one school calendar year also 
improved uptake completion rates. Education is a key ingredient in the roll-out of the vaccine 
and school-based settings are the ideal place in which multi-generational learning can occur7.  
In the second paper by the VACCS team (2015), HR-HPV self-screening and vaccine uptake 
rates are reported for girls and their mothers in 10 schools across the province of Gauteng. This 
implementation study was conducted among 1,654 eligible girls and mothers. Of the invited girls 
for vaccine, 1,053 girls received the first vaccine and 941 (89.4%) were considered adequately 
vaccinated or completed two doses within 6 months or three full doses. Findings demonstrated a 
significant completion rate difference between schools with vaccination schedule completed 
within the same calendar year compared to over two calendar years. Consent for vaccination was 
higher among the parents who attended the education seminar about cervical cancer. Uptake of 
the test for HR-HPV was offered to 596 parents or guardians who attended the education events 
at schools and 795 test kits were handed out. A total of 253 (44%) kits were returned. The 
presence of HR-HPV was found in 75 (29.6%) of the samples tested with 23 (9.1%) positive for 
HPV 16 and/or 18. A significant portion of women (45) reported not participating in cervical 
cancer screening for 5+ years despite the mean age of 38 years. The authors measured 
knowledge and behaviour following education sessions with pre- and post- findings 
                                                          
7 It is important to note that an estimated 4% of children between the ages of 7-13 years are not enrolled in school in 
South Africa; therefore strategies also need to exist for outreach to these special populations.  
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demonstrating the key elements of education, communication, and team involvement make a 
difference in effective delivery of the HPV vaccine. It also shows the interest and acceptability of 
hrHPV self-collection testing (an approach with increased sensitivity and predictive value) 
among a group of women with high rates of HPV and limited access to screening services.         
The project was offered in two stages using lessons learned in VACCS1 to inform VACCS2 
(Snyman, Dreyer, Botha, & van der Merwe, 2015). The second project involved five schools in 
the province of Gauteng. From the 965 girls invited for vaccination 519 (53.7%) consented and 
518 (99.8%) of these received the first dose and 495 (95.4%) completion rate. For this study, the 
project provided a two-dose schedule of the vaccine, taking into account preliminary data 
showing sufficient immunogenic response from the two-dose schedule (when administered 
within a 6-month time period between doses). Similar to stage one of the project, the aim was to 
also link feasibility of offering HPV self-testing for female caregivers of girls (grade 4-7) 
receiving the vaccine. A total of 1,135 self-screening kits were given out to caregivers and 575 
(50.7%) were returned. Results showed that 27 (16.9%) of women tested positive for oncogenic 
HPV while 15 (9.4%) were positive for HPV 16 and/or 18. Findings demonstrate the benefits of 
offering self –testing with HPV vaccination, or a multi-generational approach, as it increases 
acceptability and yields high uptake rates. All studies suggest that school-based programs can be 
implemented quite successfully in a range of urban and rural locales and should be designed to 
target those most at-risk of acquiring HPV and related cancers in South Africa.  
Uptake of the HPV Vaccine: Low- and Middle-Income Countries 
  Five articles related to factors influencing HPV vaccine uptake among AYA in other LMICs 
published from 2012-2015 were included in the literature review. The studies were conducted in 
Uganda, Brazil, Peru, Tanzania, and Cameroon. Participants in these articles ranged between the 
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ages of 9 – 19 years. Vaccine uptake rates for completion were found to be fairly high ranging 
from 65-88% within the articles. The study designs were all demonstrations/interventions. 
Studies were conducted from 2012-2015 and sought to describe factors involved in uptake or 
refusal of the vaccine and/or lessons learned from projects.  
A study examining the feasibility of HPV vaccines for girls in Uganda, interviews and focus 
groups were conducted with key informants including health workers, teachers, and national 
health officials. The goal of the cross-sectional study was to better understand the most 
appropriate HPV vaccine (bivalent) delivery strategy for young women aged 10-15 years 
(Mugisha et al., 2015). Vaccine uptake and acceptability rates were reported and evaluated for 
two different delivery strategies in two Ugandan districts: grade-based (grade 5) and age-based 
(10-year-olds). Vaccines in both strategies were administered during an existing national child 
program distributing medications and vitamins. Findings from this study indicated the difficulty 
with both establishing eligibility using an age-based delivery strategy but also higher dropout 
rates between dose 1 and dose 3 of the HPV vaccine. For age-based the drop out between doses 
was as high as 27%, while in the grade-based strategy, the dropout rate was only 12%. 
Interviews and focus groups with key informants were then conducted to better understand 
factors involved in the success and obstacles in both strategies. Further to this, interviews with 
key informants demonstrated that several key factors contributed to the successful delivery of the 
HPV vaccine including: coordination between health workers and teachers; appropriate delivery 
strategy designs based on synergistic working relationships; positive responses and actions from 
teachers in delivery; and visible government endorsements and ownership of the program.  
Lessons learned included the need to administer all three doses to students within the same 
school year, as the loss to follow-up was identified to be problematic due to students moving to 
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new districts the following year. A challenge identified by teachers was absenteeism during days 
which vaccines were being administered which was more easily able to be addressed within the 
grade-based strategy as teachers knew their students and could follow up for missed does. With a 
limited workforce the authors posit that delivery of the HPV vaccine be co-administered with 
routine national vaccines and a grade-based rather than age-based strategy be implemented. 
A unique demonstration project took part in the Peruvian jungle examining the role of pairing 
mothers and daughters in a screen, treat, and vaccination program (Abuelo et al., 2013). Using a 
community-based participatory research approach, community health leaders were hired and 
trained to educate and collect data in rural and urban areas along the Amazon, Peru. The health 
leaders were given 2.5 days of training prior to recruiting participants. In total, 320 women (30-
45 years) and their daughter, niece, granddaughter, or “child of the community” (aged 10-13 
years) were recruited from soup kitchens, schools, and health posts in 175 rural areas and 145 in 
the city. Girls aged 10-13 were administered the quadrivalent vaccine while mothers were given 
an HPV self-sample test to perform at home. Results demonstrated that 37 (11.5%) women tested 
positive for HR-HPV with most (30; 80%) attending follow-up (colposcopy, biopsies, and 
cryotherapy). A total of 312 (98%) girls received the first dose of the HPV vaccine, 280 (90.6%) 
the second, and 200 (71.5%) the third or final dose. Issues cited as barriers to completing the 
three-dose schedule included, not being able to locate participants, pregnancy, or parent refusal. 
Challenging retention was also due to a severe flood in the areas involved in the study and 
participants needing to be relocated. Evaluations of the program indicated that participants were 
highly satisfied with self-sample testing (99.7%) and most felt competent and comfortable 
conducting HPV self-sample tests without assistance (97%). The author’s stated that the concept 
of a mother-daughter program is appealing however may be less effective for vaccination 
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compared to a stand-alone school-based vaccination program. This is particularly the case 
because the study encountered problems of vaccine retention and challenging terrain, and many 
health leaders were conducting research door-to-door. Having a program within an organized 
system would achieve higher HPV vaccination uptake and completion rates. The authors also 
note the need to vaccinate girls early in this area of the world, due to higher than usual pregnancy 
rates among 11-year olds. Using a community based preventive care model, this study displays 
the need for community specific researchers, materials, and awareness campaigns. Ultimately, 
the need for buy-in from educators, community, parents, and girls themselves was essential in 
the successful uptake of the vaccine in this project.  
Acceptability, feasibility, and best delivery strategies for the HPV vaccine were explored in 
an HPV vaccine demonstration project in Cameroon to inform the government in the rollout of 
the vaccine nationally. An HPV vaccine demonstration project that took place in the capital city, 
Yaoundé, Cameroon (Ogembo et al., 2014). At the start of the study, there was reluctance to 
offer the vaccines in schools for fears of adverse reactions due to misinformation. The authors 
note that once no adverse events were reported at the first stages of the project after vaccinating 
the first 1,600 girls in a clinic setting (to best monitor for events), the vaccine was then moved in 
schools and communities (using mobile clinics and door-to-door or peer-tracking approaches). 
The study group was given donations of the vaccine (19,200 doses) by the International Gardasil 
Access Program and offered the HPV vaccine to girls aged 9-13 years in a variety of settings. 
Awareness campaigns were delivered in schools, churches, clinics, and community gatherings 
prior to the administration of the vaccine. Nursing staff designed print materials for their local 
clinics to educate girls in their own communities. The initial goal was to enroll 6,400 girls while 
a total of 6,851, 6,517 and 5,796 girls received the first, second, and third doses of the vaccine, 
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respectively. The authors note the very challenging circumstances they had to work with, 
including the publication of an inflammatory local newspaper article about the harms of the HPV 
vaccine during the time of the project. The project shows that with adequate information to 
stakeholders, HPV vaccination is feasible and if fears continue to persist in a community about 
the safety profile of the vaccine, ensuring a setting within a clinic is accessible to first administer 
the vaccine may help as a starting point. The success noted in this project can be attributed to 
“training, commitment, and leadership” (p. 4402) of the health facility staff, better understanding 
religious and socio-cultural conflicts related to the HPV vaccine, and that high uptake is directly 
linked to education of parents, caregivers, teachers, traditional and religious leaders, and 
communities.       
In a school-based HPV vaccination demonstrative study in Brazil, Frehnani and colleagues 
(2013) evaluated the uptake and completion rate for girls in the sixth and seventh grade (mean 
age of 11.9 years). The study included two public and six private schools in the rural town of 
Barretos with 1,574 eligible adolescents for vaccination. One month prior to the administration 
of the HPV vaccine (quadrivalent) the study was advertised throughout the community using a 
variety of approaches including billboards, television, newspaper, internet, and local radio 
stations. All educators involved in the project were scheduled for an education week with 
nursing staff. An education week was also offered to eligible female students to discuss sexual 
health, STIs, and the vaccine. Students were then also encouraged to have their parents attend a 
parent meeting. The parent meeting was led by physicians and nursing staff and parents were 
asked to fill out a questionnaire. Most parents reported being informed of the vaccine 
demonstration project by the school followed by local media and medical professionals. The 
parents of 124 girls refused the vaccine (~9%). The most commonly cited reason for refusal was 
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incorrect information about the vaccine and fear of adverse events (28.4%), undisclosed personal 
reasons (20.2%), and the child not wanting the vaccine (14.5%). Other reasons included feeling 
the child was too young, health problems, a belief that vaccines are not necessary, physician 
advise against it, no knowledge or trust of the vaccine and difficulties travelling to receive the 
vaccine. Overall, parent acceptance was 91.8% (1,389). Vaccine uptake rates for the first, 
second, and third doses were 87.5%, 86.3%, and 85.0%, respectively. This study demonstrates 
the feasibility of school-based HPV vaccination as a prime vaccine administration site. It also 
outlines the importance of information being made available through the education system and 
ensuring that educators, girls, and their parents are properly educated prior to the rollout of HPV 
vaccines.   
A cluster-randomized trial conducted in Mwanza, Tanzania by Watson-Jones and colleagues 
(2012) aimed to better understand the most ideal delivery strategy for the HPV vaccine for girls 
in grade 6 or 14 years of age at the time of the study. The study compared two strategies, class- 
versus age-based, in 134 schools (60 urban, 60 rural, and 14 private schools) among 5,532 young 
women. Vaccines (quadrivalent) for the demonstration project were provided by Axios 
Healthcare Development and administered by government nursing staff in selected schools. Prior 
to vaccination rollout, teachers, parents/guardians, and girls were given verbal and written 
information about the vaccine in community meetings. Awareness was also raised using 
pamphlets and posters, radio messages, and community drama groups in Mwanza. The project 
used an opt-out consent approach whereby parents not wanting their daughters to receive the 
vaccine were given the opportunity to indicate this prior to administration. In total, 67 schools 
used an age-based approach and 67 schools were selected for class- or grade-based vaccination. 
Three private schools refused to participate in the project. Vaccine coverage rates were 84.7% 
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for the first dose, 81.4% for the second dose, and 76.1% received all 3 doses. Class-based 
vaccination uptake was significantly higher than age-based for all three doses (78.7% vs. 72.1%). 
Among the 848 (15.3%) girls who did not receive the first dose parent refusal and absence 
from school on the day of vaccinations were the main cited reasons. Parent refusal was 
particularly evident in private schools and several urban government schools. As the first 
randomized trial to examine delivery strategies for HPV vaccination, evidence indicates the 
efficacy of using a class-based delivery strategy due to logistical advantages of having all girls in 
one location and being able to work closely with school staff and parents in one class rather than 
multiple classrooms. The reluctance of parents in private schools was, in part, attributed to 
teacher responses and refusal to hold parent-teacher meetings prior due to fears about losing 
income from parents who did not approve. The author’s noted that a national campaign of 
information about cervical cancer and the benefits of HPV vaccination would be needed which 
specifically addressed staff and parents in private schools. The study demonstrates that the HPV 
vaccine is highly acceptable in the population with class-based delivery strategies having higher 
coverage rates (Watson-Jones et al., 2012).     
Findings from all studies demonstrate that appropriate education about the virus and its 
association to cervical cancer as well as dispelling myths about the safety of the vaccine were 
key factors in the decision to participate in vaccination. Studies also examined the delivery 
strategy of the vaccine and found the most successful uptake rates were in a school-based or 
multiple delivery site approaches (i.e., school and clinic based). A common theme among all 
articles was the vital role that HCPs, educators, and government or social media messaging 
played in women’s decisions to both screen and vaccinate. Finally, the involvement and 
education of various stakeholders (i.e., school staff; parents; government) plays a critical role in 
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the acceptance of the HPV vaccine in multiple settings. In addition, areas with high levels of 
HIV, sexual violence, poverty and predominantly female single-headed household’s 
interventions need to focus on ensuring that adolescents receive extensive education about 
cervical cancer prevention.  
School-based vaccination programs are effective way to ensure three dose completion and 
ability to track young women by grade. Reasons for refusal include questions about the safety 
profile, mistrust, the belief that girls were ‘too young’, and a lack of knowledge about HPV and 
cervical cancer. Credible information sources play a critical role in HPV vaccine uptake and 
needs to be done well in advance to administration of the vaccine in both demonstrative projects 
and programs. Ensuring the messaging regarding the vaccine is focused on cancer prevention 
rather than STI and normalizing the topic within the community with locally curtailed awareness 
campaigns (e.g., radio advertisements; television; internet; posters and adverts). Highest uptake 
rates are found in school-based program rather than clinic or door-to-door approaches. CBPR 
designs and community involvement can contribute to successful recruitment and ensure locale 
specific approaches are used in the implementation of the project. High satisfaction was reported 
using a community-based approach with the added bonus of having high vaccine uptake rates, 
this was particularly reported to be the case in challenging locales. Careful planning needs to be 
done prior vaccine programs being implemented, in any setting and adequate training needs to 
take place with all staff involved in the program, applicable government officials, and 
community members.   
HPV Awareness HPV Vaccine Acceptability among AYA 
A total of seventeen articles were reviewed about attitudes, perceptions, and acceptability of 
the HPV vaccine among young women in LMIC’s and are organized by area of the world the 
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research was conducted in. Six studies that met search criteria took place in Africa (South Africa; 
Nigeria; Cameroon; and Uganda), ten studies were conducted in Euroasia (Turkey; Thailand; 
India; Lebanon; China; and Malaysia), and one in South America (Argentina). Of the six studies 
conducted in Africa, four studies had female University students as participants and two 
recruited adolescent females from high schools. Of the ten studies from Euroasia, three were 
conducted with medical and nursing students, five of the studies recruited undergraduate 
students, one study was with middle school students and one study recruited female AYA from 
community clinics. The research conducted in Argentina, South America, was conducted with 
young women in a hospital setting.  
A cross-sectional study conducted with female undergraduate students in Durban (N=440), 
SA, examined correlates of HPV vaccine acceptance (Hoque, Ghuman, & Van Hal, 2013). The 
mean age of respondents was 20.39 years with 63% of participants reporting to have engaged in 
sexual activity of which the majority, 79.4%, had only one prior sexual partner. Among female 
university students who had never had sex, many (58.9%) had heard of cervical cancer prior to 
the study and only 12 women were aware that a sexually transmitted virus caused cervical 
cancer. Many participants (36.5%) believed cervical cancer to be a disease that is inherited. 
Despite the low rates of awareness about HPV and cervical cancer, of the 163 (37%) participants 
with no prior sexual history, 125 (77.3%) reported that they would be willing to receive the HPV 
vaccine. The most common reasons for refusal of the vaccine included being afraid of the 
injection and fears about side effects and pain. Acceptance of the vaccine was significantly 
associated with family members having been diagnosed with HPV or cervical cancer. Women 
who reported to know about the Pap smear test and were informed about risk factors associated 
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with cervical cancer (multiple partners; early sexual debut; smoking and STIs) were more likely 
to accept the vaccine compared to others (Hoque et al., 2013).  
Similarly, a study conducted in Lagos, Nigeria among female University students also found 
low levels of knowledge about HPV, cervical cancer, and vaccines (Makwe, Anorlu, & 
Odeyemi, 2012). The mean age for the 362 respondents was 21.5 years with 41.4% reporting to 
have engaged in sexual activity with 21% having one prior sexual partner. A total of 56.4% 
women were aware of cervical cancer and 17.7% knew about HPV prior to the study. The 
connection between HPV and cervical cancer was reported to be known by only 11.1% of the 
participants. Overall, from the 15 true or false questions about HPV, the median score was 2. 
Perceived risk for acquiring HPV infection and developing cervical cancer was low at 6.25% and 
6.9%, respectively. Of the 362 participants, 14% were aware that an HPV vaccine existed, 57.7% 
of which reported to be willing to receive the vaccine. Reasons for refusal of the vaccine were 
not reported nor was the relationship between knowledge and/or risk perception in vaccine 
acceptability. 
 Two studies were conducted in Nigeria examining knowledge about HPV and acceptance of 
vaccination among university students. The first study took place at a University in Kano, 
northern Nigeria with 375 female undergraduate students recruited from various academic 
departments (Iliyasu, Abubakar, Aliyu, & Galadanci, 2010). Participants had a mean age of 22.7 
years with 21% reporting to have previous sexual experience with 67.1% having sexual relations 
with only one partner. A total of 202 (53.9%) women were aware of cervical cancer and 133 
(35.5%) knew about HPV prior to the study. The relationship between HPV and cervical cancer 
was reported to be known by 18.4% of the participants. Many respondents reported they thought 
cervical cancer was inherited (39%). A total of 277 (74%) of participants reported HPV vaccine 
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acceptance with significant predictors including age (older women more likely to engage), 
medical education (compared to other education departments), and having higher levels of HPV 
knowledge and awareness about cervical cancer. Documented reasons for refusal of the vaccine 
were most commonly because of fear of side effects and controversies around vaccines.  
 A more recent cross-sectional study (2015) was conducted in Southwest Nigeria to determine 
knowledge of HPV and cervical cancer as well as acceptance of the HPV vaccine among 169 
female medical students (Adejuyigbe, Balogun, Sekoni, & Adegbola, 2015). The authors note 
the importance of gauging medical students as future healthcare providers who will inevitably 
play an important role in patient decisions about the HPV vaccine. The mean age of participants 
was 20.8 years with most reporting to never have had sex before (77.1%). Most women reported 
having between 1-5 sexual partners in their lifetime (81%). Most participants had heard of 
cervical cancer (95.4%), HPV (85.4%), but fewer had heard about the HPV vaccine (69.3%) 
prior to the study. Of the cohort of students, 95.9% had never received the HPV vaccine. Most of 
the women (75.7%) would accept the vaccine if it was free, 3.6% were not willing and 20.7% 
said they were unsure about the vaccine. Participants noted that barriers to the vaccine include 
inadequate information, high cost, challenging access, worry regarding the safety and efficacy, 
and religious reasons. The factors found to be significantly associated to HPV vaccination 
acceptance were having good knowledge about HPV and the HPV vaccine and age, with older 
participants significantly more knowledgeable about the topics.        
Evidence demonstrates that a significant number of elite responders exists in university 
settings with a fair proportion of young women who have had sexual relations with only one 
partner. HPV vaccine acceptability, therefore, is important to explore among this group of 
women. Overwhelmingly data shows that awareness and knowledge about HPV, cervical cancer, 
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and vaccines is fairly low as is the self-perceived susceptibility of acquiring the virus or related 
cancers. The studies conducted in medical schools outline how imperative it is that medical 
students have adequate knowledge about cervical cancer, HPV, and vaccines, as they provide 
counsel and recommendations for cervical cancer prevention. With the low levels of knowledge 
found in all of the studies, a key take home message is the need to provide better education about 
HPV, cervical cancer and vaccines. Many of the young women in university settings have not yet 
had sexual relations (with many only reporting one previous partner), therefore are prime 
candidates for the HPV vaccine.    
Two studies looked at awareness, knowledge and acceptability of the HPV vaccine among 
adolescent females in educational settings. The first study, conducted in five schools in North 
West Cameroon, was a cross-sectional study with 553 AYA aged 12-26 years (Ayissi et al., 
2012). The mean age of participants was 17.2 years with most (78%) reporting to not yet had 
sexual relations. Prior to the study, the study team organized an awareness campaign targeting 
adolescents, parents, principals, teachers and the community in general. Pamphlets and posters 
were distributed to the school, churches and among community members and awareness talks 
were hosted at various venues. Participants were administered a questionnaire following the 
educational campaign. Compared to the previously reported studies, awareness about HPV 
(87%), cervical cancer (82%) and HPV vaccines (76%) reported in this Cameroonian study using 
awareness sensitization strategies prior to the survey, is much higher. Similar to other studies, 
age (older) and education were found to be associated with HPV knowledge. However, no 
sociodemographic characteristics or any other factors (risk perception or knowledge) were found 
to predict (prior) uptake or acceptability of the HPV vaccine in this study. A total of 34% of 
respondents had been vaccinated against HPV prior to the survey. The adolescents who were not 
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yet vaccinated (76%) most reported to “agree” (29.5%) or “strongly agree” (46.8%) about their 
willingness to be vaccinated against HPV infections.    
In 2014, Turiho and colleagues assessed adolescent females’ knowledge about cervical cancer 
and HPV vaccines and acceptance of the vaccine in Ibanda and Mbarara districts, Uganda. 
Adolescents in Ibanda had been part of previous HPV vaccine demonstration projects with 
sensitization strategies used before vaccine rollout, while Mbarara did not yet have access to 
vaccines therefore was used as a comparison district. Using a comparative cross-sectional mixed 
methods approach, 777 young women (mean age of 13.4 years) completed a questionnaire and 
five focus groups with 8-12 participants from the vaccinated districts were conducted with 
adolescents from the cohort. Findings showed that knowledge levels about cervical cancer and 
the HPV vaccine were significantly higher among vaccinated girls with 85% considered 
knowledgeable compared to the unvaccinated at 15%. However, knowledge levels among 
unvaccinated participants were not found to make a significant difference in the role of HPV 
vaccine acceptance nor did perceived susceptibility or severity. Overall, most respondents (91%) 
supported HPV vaccination for their daughters and friends. Results from the focus groups 
indicated that girls’ primary motivation for receiving the HPV vaccine was to protect against 
cervical cancer. Other motivations included protecting their bodies to be able to bear children in 
the future and having a clear understanding that no side effects existed that would harm 
reproductive health. Deterrents reported by attendees to the focus groups in the acceptability of 
the HPV vaccine included negative rumours and anxiety about infertility and unknown side 
effects (Turiho et al., 2014).   
From the twelve studies conducted in Euroasian areas, three studies examined HPV awareness 
and acceptance of the vaccine among medical and nursing students, six were conducted with 
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post-secondary students from a range of programs, two within a community clinic setting, and 
one with female secondary school students.  Studies took place in Turkey, India, China, Lebanon 
and Malaysia. The first article with health care professionals in training took place in Ankara, 
Turkey with 752 female postsecondary students (n=520 nursing students; 232 control group). 
The purpose of this cross-sectional study was to assess the awareness and knowledge regarding 
HPV, HPV-related conditions and the vaccine among nursing students versus a control group of 
undergraduate students in various programs (Uzunlar et al., 2013). The average age of the 
participant in both groups was 20.4 years. Nursing students were found to have significantly 
higher awareness rates than the control group with 86% of them having heard about HPV 
compared to 24% among the other participants. Knowing the HPV virus was associated with 
cervical cancer was reported to be known for 88% of the nursing students compared to 31% 
among the control group. Of the entire cohort vaccination status was 3.8%. Among unvaccinated 
participants, however, the percentage of willingness to be vaccinated was 50%, 66%, and 13% 
among all the participants, nursing students and control group, respectively. Vaccine willingness 
for future daughters was 67%, 76% and 48% for the aforementioned groups. Significant factors 
related to acceptability of the vaccine included previous knowledge about the HPV vaccine and 
being a health care provider student. Age and having an understanding of the relationship 
between HPV and cervical cancer demonstrated to be related to the acceptance of the vaccine 
among the cohort of nursing students.  
Two cross-sectional studies were conducted with medical and para medical students regarding 
knowledge about HPV, cervical cancer, and willingness to receive the HPV vaccine in India with 
AYA aged 17-25 years (Pandey, Vanya, Bhagat, Binu, & Shetty, 2012; Swarnapriya, Kavitha, & 
Reddy, 2015). The first study, conducted in 2012 looked at awareness and attitudes among 618 
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students at Karturba Medical School. While no mean age is reported, the majority of participants 
were between the ages of 20-22 (49%) and 17-19 (37%) years. Similar to the nursing study 
previously reviewed, the study stratified recently accepted medical students (55% in control 
group) and those in the final year of medical school (45%) to look at the role medical education 
played in awareness and acceptance. A total of 258 (43%) of participants were male and 350 
(57%) were female. Overall, most participants knew about HPV and that it was a necessary 
factor in the development of cervical cancer (89%) with no differences found between sexes but 
a significant difference found between the education control (83%) and test  group (97%).  The 
protective efficacy was also reported to be significantly higher among the late stage medical 
students (84%) compared to group of new medical students (70%). The acceptance rates for the 
HPV vaccine was 68% for all participants with female students significantly more likely to 
accept the vaccine the males (79% vs 53%). Education levels did not play a role in HPV vaccine 
acceptance. Obstacles to HPV vaccination reported by participants included high cost (21%), 
fear of complications (17%0 and worry about efficacy (17%).   
The second study was conducted in 2015 in Southern Indian with 957 medical and para 
medical students.  The mean age of student participants was 19 years with mostly female (72%). 
Participants were recruited from medical, dental, and nursing departments. Knowledge, attitude 
and practices regarding HPV vaccination were examined with an overall 45% reporting to have 
good knowledge about the topics. Specifically, 60% of participants had heard about HPV and 
knew that the causal relationship between the infection and cervical cancer. The age of 
participant nor gender made a significant influence on the knowledge about HPV and the vaccine 
however medical and nursing students had significantly better knowledge levels about these 
topics than dental students. Despite the reported high levels of awareness about HPV among the 
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medical and para medical students, only 7% (65) students reported to be HPV immunized. Of 
those unvaccinated 51% said they would be willing to receive the vaccine. From the group 
unwilling to be vaccinated the top reasons for unwillingness included doubts regarding the 
efficacy, fear of side effects (26%), cost (22%), and minimal risk reception of developing 
cervical cancer (15%).   
A total of six articles were reviewed about knowledge and attitudes towards HPV and 
vaccination among female postsecondary students in the Euroasia region. In 2010, a cross-
sectional study was conducted with 650 ethnically diverse female students from a public 
university in Kuala Lumpur, Malaysia (Wong & Sam, 2010). The mean age of participants in 
this study was 21.4 years. Most respondents had not previously heard about HPV prior to the 
study with 22% reporting not to have heard of HPV and only 10% reported knowing about a 
vaccine for HPV. Age was the only factor to significantly correlate with knowledge. Across the 
entire sample, the mean awareness score was 3.25 out of the 14 questions (SD=2.41) indicating 
very low levels of awareness. Despite the low levels of knowledge, 48% of participants reported 
willing to receive the HPV vaccine. The intention to receive the vaccine was significantly related 
to reported awareness levels. The most commonly cited reasons for HPV vaccine refusal was 
concern about the safety and efficacy (51%), low risk perception (42%) and embarrassment 
related to receiving vaccine for an STI (11%). A study conducted by Juntasopeepun and 
colleagues (2012) in Chiang Mai, Thailand with 738 female college students (M=19.9 years). 
Using an online questionnaire, the cross-sectional study examined factors influencing acceptance 
of the HPV vaccine. A large proportion (64%) of students did not have a history of sexual 
experience. Only 9 women (1.2%) reported to have received the HPV vaccine previous to the 
study. A total of 65% participants knew about HPV and how it was contracted while 60% 
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reported understanding the link between HPV and cervical cancer. Overall acceptability rates for 
the vaccine was 55% with high intention significantly related to age, previous sexual experience, 
received a recommendation to be vaccine, and be more knowledge about these topics than the 
low intention group. Other significant variables found to be associated with vaccine acceptability 
were perceived susceptibility to cervical cancer and perceived benefits of vaccination 
(Juntasopeepun, Suwan, Phiamongkhol, & Srisomboon, 2012).   
Dany and colleagues (2015) examined knowledge, attitudes, and intentions of 215 female 
college students in Beirut, Lebanon. The mean age of participants was 22.7 with equal ratios of 
undergraduate and graduate students and most reporting no previous sexual experience (68.3%). 
Only 17% of participants reported to have received the HPV vaccine with many never having 
heard of HPV (37%) prior to the study. The mean knowledge score for knowledge questions 
about HPV and vaccination of 52.7 (from a possible score of 160) demonstrated poor overall 
awareness among students.  Many of the participants reported they did not feel at risk for 
acquiring HPV (60%) however believed that all college females should have the vaccine (62%) 
(Dany, Chidiac, & Nassar, 2015). Again, similarly to previous research with post-secondary 
students a significant predictor of acceptability of the HPV vaccine is knowledge scores and that 
despite low levels of knowledge there is still a general positive attitude and high acceptability 
towards the vaccine. A similar cross-sectional study was conducted in Changsha, China with 117 
university students with a mean age of 21 years (Gu, Niccolai, Yang, Wang, & Tao, 2015). Most 
participants (90%) reported that they had heard of HPV and cervical cancer (78%) prior to the 
study. HPV vaccine acceptability rates for this study are lower than previously reported studies, 
at 44%. In terms of correlates or predictors of acceptability the only variable significantly related 
to intention to vaccinate was knowledge levels about cervical cancer and vaccines. Among the 
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women who did not have an intention to receive the vaccine, most reported possible side effects 
(60%) as the reason for declination. The top influencers reported to make a difference in 
participants’ decision to uptake the HPV vaccine included doctors (48%) and parents (13%).  
The last study with female post-secondary students in LMICs reviewed was conducted in 
Turkey (undisclosed city) with 800 university students in a variety of departments (Koc & 
Cinarli, 2015). The mean age of participants was 20.4 years with 28% reporting having no 
previous sexual experience. Only 12% of students had heard of HPV previous to the study with 
10% reporting knowing the relationship between HPV and cervical cancer. A small portion of 
students knew that an HPV vaccine existed (9%). Overall and similar to previously reviewed 
studies, low levels of knowledge were found among participants but dissimilar was the low 
acceptance HPV vaccination rates reported (33%). The most commonly cited reasons for 
declination of the vaccination were: not having enough information about the vaccine (38); not 
feeling it is necessary (23%); possibility of adverse events following vaccination (21%); and the 
cost associated with the HPV vaccine (7%). No correlates or predictors of acceptability were 
reported in this study. Findings outline the urgent need for post-secondary educational programs 
to increase awareness about cervical cancer prevention, particularly because a large proportion of 
AYA are sexually inexperienced and therefore would be prime candidates for the HPV vaccine.  
One article was reviewed with secondary school girls in Euroasia (Al-Naggar, Bobryshev, Al-
Jashamy, & Abdulghani, 2012). The cross-sectional study was conducted in Melaka, Malaysia 
with 612 school girls aged 13-17 (M=13.9) and examined factors associated with prior HPV 
vaccination uptake. The prevalence of HPV vaccination was 80% with the majority of girls 
reporting to have received the vaccination from their schools (77%). Most participants reported 
to have heard about HPV (78%) and cervical cancer (69%) prior to the study. Cited reasons for 
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vaccination uptake were being encouraged by a health care professional or teacher (49%), parent 
influence (29%), and encouragement from friends (0.2%). Reported significant factors in the 
uptake of the HPV vaccine included income of the parent, parent education level, having 
knowledge about HPV and cervical cancer, and receiving the vaccine in a school setting. Again, 
findings from this study echo all previous findings in the literature that recognize knowledge as a 
significant factor influencing HPV vaccination acceptability and uptake among AYA.  
The last article reviewed from Euroasia was conducted in a research hospital in Ankara, 
Turkey (Ozyer et al., 2013). A total of 408 young women with a mean age of 18.5 years were 
administered questionnaires examining awareness about HPV and attitudes about vaccination. A 
large proportion of the cohort (98.5%) reported not to have previous sexual experience. Of the 
young women participating in the study, 42% had heard about HPV with 33% knowing that HPV 
can cause cervical cancer. Young women were significantly more likely to know about HPV that 
older participants, which is contrary to findings from the previous studies with older AYA being 
more knowledgeable about these topics. Only 1.4% of the cohort had been vaccinated while only 
11.2% were willing to receive the HPV vaccine. Cited reasons for declining or reporting to be 
disinterested in receiving vaccination were a lack of information (66%), being unmarried (20%), 
and doubts about the safety and efficacy of the vaccine (3.4%). Findings from this study are 
unique, in that knowledge about HPV and cervical cancer were high however acceptability rates 
very low.    
The last study reviewed was conducted in Maipu, Argentina and examined HPV vaccine 
acceptability among 174 young women with a median age of 23 years. The cross-sectional study 
took place in a hospital setting and explored correlates of HPV vaccine acceptance. Only 3 
participants reported never having engaged in sexual activity. A small proportion of young 
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women had heard of HPV (17%) while 19% reported to have heard of cervical cancer prior to 
the study. Altogether 95% of young women reported to be willing to receive the HPV vaccine. 
Statistically significant correlates in participants’ HPV vaccination acceptability was the belief 
that the vaccine is safe with lower confidence about safety associated with lower acceptance. The 
authors also found that most women (75%) reporting to be vaccine acceptant were willing to pay 
for vaccination, despite low socioeconomic status of many of the participants. The authors 
conclude that high acceptance of the HPV vaccination whether free or out-of-pocket for young 
women in the study. Perceived safety of the HPV vaccine in this study was found to be an 
important correlate of acceptability as opposed to previously significant factors associated to 
knowledge or awareness about these topics (Alder et al., 2013).  
Parent Awareness about HPV and Acceptability of the HPV Vaccine for Daughters 
Parents are critical decision makers for vaccine delivery in young children and adolescents. A 
literary review of 28 articles, subdivided into the geographical categories of Africa, Euroasia and 
South America, found that rates of parental acceptability of the HPV ranged from 44%-96%. The 
majority of these articles examined parental acceptability for daughters getting vaccinated, with a 
predominant portion also examining the opinions and knowledge of mothers. Overall, despite the 
majority of articles reporting limited knowledge about HPV and the HPV vaccine, most parents 
were found to be highly accepting of having their daughters receive the vaccine. A dominant 
theme throughout this global review, rightly so, is that all parents just want to keep their children 
safe and healthy. Concerns over vaccine efficacy and safety were prominent reasons why 
reluctant parents were not interested in having their children vaccinated. 
When examining literature from Africa, the nine articles reviewed on parental acceptability to 
get their child vaccinated included studies from Cameroon, multiple areas in Kenya, Nigeria, 
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South Africa, Morocco, Tanzania, Malawi and Botswana. Of these articles, parent acceptability 
ranged from 67%- 95%, with responses varying based on the convenience of vaccine 
administration (Becker-Dreps, Otieno, Brewer, Agot, & Smith, 2010; DiAngi, Panozzo, 
Ramogola-Masire, Steenhoff, & Brewer, 2011; Ezeanochie & Olagbuji, 2014; Francis et al., 
2011; Mouallif et al., 2014; Ports, Reddy, & Rameshbabu, 2013; Vermandere et al., 2014; 
Wamai et al., 2012). The three most common variables associated with parental acceptability 
throughout all studies were higher education, having higher levels information around the 
disease and the HPV vaccine, as well as increased perceived risk. Respondents that had higher 
education were more likely to have at least heard of cervical cancer and thus were able to more 
easily acknowledge the potential severity of the disease. Of the articles that did examine uptake, 
acceptance was associated with uptake, but education level as well as disease-specific knowledge 
were more significant correlates. Additional correlates to uptake also included convenience of 
vaccination administration and knowledge of when and where the multiple doses would be 
offered. 
The most prominent predictors reported in HPV vaccine acceptability among parents and 
caregivers were education level and specific understanding of the disease and vaccine. Lower 
education and respondents living in rural areas were found to be more unaware of the 
preventative measures available including screening and vaccination. Participants most 
commonly cited the unknown side effects of the vaccination as a reason for declining their 
child’s participation. Specifically, reasons for the distrust with the HPV vaccine included 
concerns of causing infertility, that the vaccine would not be administered safely or that it would 
not be effective. Additionally, three articles cited parental beliefs that their daughters would be 
more likely to become sexually active if vaccinated against HPV (DiAngi et al., 2011; Mouallif 
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et al., 2014). Cost, comparatively, was not a dominant drawback for parental acceptability or 
uptake but many survey respondents reported a maximum willingness to pay: the highest amount 
from all the articles was equivalent to $5 USD. 
Sixteen Eurasia-based studies on parental acceptability of vaccinating their child with the 
HPV vaccine were reviewed. The countries included: Turkey, Vietnam, Fiji, Malaysia, 
Indonesia, Eastern India, Thailand and China. From all articles in this geographical area, parental 
acceptability ranged from 44%-96%, with significant increases in acceptability in China, Fiji and 
Vietnam if some sort of government program was established in support specifically for the HPV 
vaccination (Alsaad, Shamsuddin, & Fadzil, 2012; Basu & Mittal, 2011; Dinh et al., 2007; 
Jaspers, Budiningsih, Wolterbeek, Henderson, & Peters, 2011; Kilic, Seven, Guvenc, Akyuz, & 
Ciftci, 2012; Kruiroongroj, Chaikledkaew, & Thavaorncharoensap, 2013; Madhivanan et al., 
2009; Madhivanan et al., 2014; Mairaing, Suwannarakark, THaweekul, & Poomtavorn, 2012; 
Songthap, Pitisuttithum, Kaewkungwal, Gungladda, & Bussaratid, 2012; Vincente et al., 2015; 
Wang et al., 2015; Wong, 2009; Zhang et al., 2013). The most dominant predictor for parental 
acceptability in these countries was higher education and increased knowledge specifically 
around HPV, cervical cancer and protective measures the vaccine offers. Multiple articles in this 
geographic category also examined the impact of HPV and cervical cancer knowledge 
campaigns and parental acceptability, seeing a positive correlation. One interesting finding to 
this correlate was found in China where a study by Wang and colleagues discovered that prior 
knowledge increased parental acceptability but higher education actually decreased parental 
acceptability. Among reasons why parents would not accept getting their child vaccinated, the 
two dominant predictors mentioned in most articles were vaccine efficacy and safety. Included 
under efficacy, there were varying opinions on when adolescents should actually receive the 
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vaccination. Two other drawbacks worth noting were cost and the need for greater information 
around the disease and the vaccination.  
Three studies about parental acceptability of HPV vaccination in South America were 
examined from the countries of Argentina, Honduras and Brazil. Parental acceptability rates 
were at 74% in Argentina, 91% in Honduras and 95% in Brazil. All three studies referenced the 
correlate of increased knowledge as well as increased education as predictors to parental 
acceptability (Arrossi, Maceira, Paolino, & Sankaranarayanan, 2012; Osis, Duarte, & Sousa, 
2014; Perkins, Langrish, Cotton, & Simon, 2011). In Argentina, there was a mass media 
campaign put on by a cancer Non-Governmental Organization followed by a government-
initiated vaccination program significantly contributed to the public’s general knowledge base 
around HPV the vaccination (Arrossi et al, 2012). In Honduras, a majority of study participants 
knew about the preventative measures for cervical cancer but were unaware of specific 
knowledge around HPV. Tied to education and knowledge, socio-economic status of these South 
America countries also showed to be a predictor of parental acceptability. When examining 
drawbacks on reasons why parents would not accept getting their child vaccinated, the dominant 
predictor was perceived low risk; either participants believe their daughters were not yet sexually 
active and/or they also believed they will only have one sexual partner in their lifetime (Perkins 
et al, 2011).  
Summary 
Vaccine readiness is important to understand among AYA females. Although most studies 
were not conducted with “elite responder” age group (9-13 years), the literature outlines that 
many AYA in LMICs have not yet engaged in sexual relations even up to university level. This 
has important implications because these populations are not currently being targeted, 
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particularly in South Africa. The literature demonstrates the importance of implementing 
effective sensitization strategies prior to the administration of the HPV vaccine for adolescent 
females. Misinformation and rumours need to be counteracted and addressed upfront. Primary 
prevention of HPV for adolescents includes using creative and responsive education strategies to 
teach about HPV, cervical cancer, and the HPV vaccine. Improved understanding of AYAs 
knowledge about these topics and factors that influence the acceptance of the HPV vaccine will 
help inform HPV vaccination programs. The literature also demonstrates the effectiveness of 
using well organized community-based awareness programs with key stakeholders. It is 
important that decision-makers in education, parents, and adolescents are well-informed, as this 
will promote participation in HPV vaccination programs. It is imperative that individuals on all 
levels are well-prepared and involved. A better understanding about how women with diverse 
ethnicities and religious beliefs feel about HPV and vaccination will help to create more effective 
immunization strategies. In terms of literature about awareness and vaccine acceptability among 
health care professionals in training, overall rates of awareness compared to other groups of 
AYA was generally higher. However, some gaps still exist in the understanding or application, 
as even these groups had fairly low HPV vaccine uptake and acceptability rates. There is room 
for improvement in education for nursing and medical student because of the critical role they 
play in patients’ acceptability of and adherence to screening and vaccination. Medical training 
will have a definitive impact on the understanding of this important public health issue.         
The major obstacles reported within the literature regarding the implementation of the HPV 
vaccine include cost, acceptability, perceived susceptibility for infection and cervical cancer, 
lack of public awareness or sensitization programs and infrastructure, worries regarding the 
safety profile and efficacy of the vaccine as well as social and religious aspects. It is important 
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that programs address individual, community, and health system related factors in attempts to 
increase the uptake, and accessibility of the HPV vaccine in parts of the world with highest 
prevalence and mortality rates associated with HPV related cancers. In South Africa, arguably 
one of the largest barrier has been the lack of accessibility to the HPV vaccine, as it is 
unaffordable for the majority of women with no access to health schemes or private insurance. 
SA women suffer disproportionately higher rates of cervical cancer and have some of highest 
mortality rates compared to women in the rest of the world. Young women in SA are a 
particularly vulnerable population given high rates of HIV and urgently need to be targeted in the 
expansion of the HPV vaccine. The conversation about extending the HPV vaccine program in 
South Africa requires immediate action at the National and Global level, as it is the most 
effective solution to reduce the incidence of cervical cancer for women who are most at-risk. 
HPV vaccination is a safe, effective, ethical, and acceptable solution to the global cervical cancer 
crisis in LMICs, particularly in areas coping with high HPV and HIV infection rates and 
challenging access to screening services. 
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Chapter 3: Methods 
Introduction 
Previous research conducted in LMICs has demonstrated that very low levels of knowledge 
exist about HPV and the viruses’ relationship to cervical cancer (Abdullahi et al., 2014; 
Cunningham et al., 2014; Tsu, Cernuschi, & LaMontagne, 2014). Prevention of the virus and 
cervical cancer is also poorly understood with concerns voiced by both recipients and parents 
about the safety profile of the HPV vaccine. Overwhelmingly, literature shows the efficacy of 
including an educational component with community prior to any HPV vaccine program rollout, 
as normalizing the topic of HPV, reframing the message about vaccine being an “STI 
prevention” to a “cervical cancer prevention” tool, and ensuring that stakeholders such as leaders 
and influencers in the community are made well aware of the safety and benefits concerning the 
HPV vaccine, as to decrease misinformation and ensure appropriate dissemination for AYA and 
parents. Despite the reported low levels of awareness about HPV, cervical cancer, and the HPV 
vaccine the acceptability and uptake rates of the vaccine in studies are surprisingly high, which 
was more so the case when education components were built in to the program (Cunningham et 
al., 2014; Snyman, Dreyer, Botha, van der Merwe, et al., 2015).   
Cervical cancer is an entirely preventable disease and we now have the tools to protect girls 
globally. The recent development of HPV vaccines offers great potential for primary prevention 
of cervical cancer in SA. The questions guiding this study are: 
 What are female AYAs awareness and attitudes towards HPV, cervical cancer, and HPV 
vaccines;  
 What correlates, if any, exist between AYA who are and are not HPV vaccine acceptant; 
how do female AYA feel about HPV self-sample testing;  
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Based on the literature and geographical context, the hypothesis for the study is that 
participants will have low-levels of awareness about these topics but despite the lack of 
knowledge will report high acceptability rates for the HPV vaccine and self-sample testing. From 
a HBM perspective, key predictors for acceptability of the vaccine include higher perceived 
likelihood of developing HPV infection and cervical cancer, severity of the diagnosis, and 
perceived benefits and efficacy of the vaccine in reducing the risk of HPV and cervical cancer. 
While this is found in higher income countries, these themes were not reported to be 
predominant factors in LMICs. The most commonly cited barrier to the HPV vaccine in the 
literature for both AYA and parents was apprehension due to concerns over the safety profile and 
side effects of the vaccine as well as community perceptions (Abdullahi et al., 2014; 
Chidyaonga-Maseko et al., 2015; Dreyer et al., 2015). Cost barriers were also reported in some 
of the articles if a project did not cover the cost of the vaccine. Cues to action are situational and 
social factors that contribute to vaccination acceptability or uptake.  
Based on the aforementioned factors, the author proposes that AYA who feel at higher risk 
for HPV infection and cervical cancer and those that rated having an infection or associative 
cancer as more ‘severe’ will be more likely to engage in primary and secondary prevention 
strategies. In addition, participants who view the vaccine as beneficial and highly efficacious will 
be more likely to be vaccine acceptant. The cost of the vaccine (as it is not covered in SA for 
AYA) is also proposed to play a significant role in HPV vaccination acceptance.    
Broadly speaking, the aim of the study is to address gaps in the literature, help inform 
preventive policy, and assist in the introduction and propagation of HPV vaccination in SA. 
Being able to better understand correlates of acceptability of the HPV vaccine and innovative 
screening strategies such as HPV self-sample testing among the most acutely affected group of 
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women globally is the main goal of this work. Based on the literature and geographical context, 
the hypothesis for the study is that participants will have low-levels of awareness about these 
topics but despite the lack of knowledge will report high acceptability rates for the HPV vaccine 
and self-sample testing. Further to this, participants with higher levels of awareness, perceived 
severity and likelihood of viral acquisition are proposed to have higher vaccine acceptance rates.  
Research Questions 
With the enormous burden of cervical cancer among young women in SA, a focus needs to be 
placed on research about primary prevention for oncogenic HPV infections. Effective screening 
and preventive technologies exist to reduce the risk of cervical cancer and this project examines 
acceptability and correlates of these technologies: the HPV vaccine and HPV self-sample testing, 
in an area of the world with the highest HIV and HPV rates.  The research questions for this 
study were:  
 What do female AYA in Durban know about HPV, cervical cancer, and the HPV vaccine; 
 What determinants (socioeconomic and behavioural factors) are related to AYAs acceptability 
of the HPV vaccine and HPV self-sample testing; 
 What are female AYAs attitudes towards the HPV vaccine for (future) children; 
 Where do female AYA receive sexual and reproductive health information from; 
 What are female AYAs perceptions (risk; severity) of the HPV infection and cervical cancer? 
 
Sampling 
This research was conducted collaboratively with a youth-centered study entitled, 
“AYAZAZI: Investigating Patterns of Behavioural and Biomedical Risk for HIV Acquisition 
and Vaccine Trial Preparedness among Adolescents and Young Adults in a priority setting”. 
AYAZAZI, an HIV prevention study, is a multi-site, inter-disciplinary, prospective cohort study 
focused on understanding linked patterns of socio-behavioural and biomedical HIV risk among 
youth in Soweto and Durban, SA using a youth engagement approach. The AYAZAZI research 
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team consisted of two AYA research assistants, a social worker, a registered nurse, a coordinator, 
a medical doctor, a local principle investigator and two AYA HIV counsellors. The team’s 
objective was to better understanding how to help AYA make informed decisions about their 
sexual health and offer them access to testing for sexual and genital tract infections and 
counselling services.  
A relationship was formed with a principle investigator (PI) on the AYAZAZI study through 
course work attended, as well prior relationships and collaborative work between the PI, A.K, 
and the PhD co-supervisor, G.O. As a result of the similarities in topics, relevance of HPV 
prevention to this particular cohort of AYA females, and former positive working relationships, 
an HPV sub-section was collaboratively created and imbedded into the existing AYAZAZI 
questionnaire. The HPV sub-section was administered to 122 females who had formerly 
participated in the study and were returning for follow-up 12-month visits in Durban and was 
administered at the end of the AYAZAZI survey.   
Participant Recruitment 
 
Participants in Durban were recruited through though active community recruitment via 
locations such as schools, tertiary institutions, community centres, clinics, and hostels, through 
posters, flyers and pamphlets, and face-to-face recruitment. Individuals enrolled for the 
AYAZAZI study at the Commercial City Centre MaTCH Research Unit (MRU) site8. Inclusion 
criteria for enrollment in the study at baseline included:  
 Reside in Durban; 
 Aged 16-24 years (at baseline); 
 Are either known to be HIV-negative or do not know their HIV status; 
 Willing to undergo HIV testing as specified according to the visit schedule; 
                                                          
8 MRU is a Division of the Wits Health Consortium (Pty) Ltd in the Department of Obstetrics and Gynaecology in 
the Faculty of Health Sciences at the University of the Witwatersrand. 
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 Able and willing to provide written informed consent and assent for minors for socio-
behavioural assessments and biological specimen collections. 
 
Individuals were excluded from the study if they meet any of the following criteria: 
 Have an obvious psychological/psychiatric disorder that would invalidate the informed 
consent process or otherwise contraindicate participation in the assessment; 
 Minors (under age 18) without written informed consent from a parent or legal guardian; 
 Are shown to be participating in clinical or observational studies as determined by finger-
print co-enrolment system9. 
 
Study Area Description 
The province of KZN, where this research took place, is the most highly densely populated 
area in SA. Durban is located the eThekwini district and home to approximately 3.5 million 
people. South Africa's population is predominantly made up of young people with those below 
35 years of age (66%). Black African peoples have the youngest residents with 34% of the 
overall population under the age of 15 and 22% from 15-24 years of age with a median age of 
21. The largest population represented in the eThekwini district is AYA aged 15-29. The district 
has more females (51%) than males (48%) and an overall mean age of 26.8 (Statistics South 
Africa, 2015, 2016). Currently, cervical cancer is the leading cause of death among young 
women in SA, therefore the age and gender distribution have important implications for cervical 
cancer prevention and outline the vital need to better understand attitudes and acceptability 
towards the HPV vaccine, particularly in KZN.  
Procedure and Time Frame 
The AYAZAZI survey was administered at baseline, 3-, 6-, and 12-month time points. At 
baseline 132 female AYA were enrolled and at 12-month 128 (97%) were retained, with a total 
of 122 participants who were willing to complete the HPV questionnaire. Both the AYAZAZI 
and HPV survey were administered by AYAZAZI research assistants in isiZulu or English. The 
                                                          
9 The finger-print enrolment system is used at the MRU to determine participants eligibility based on prior 
enrolment with studies.  
 72 
 
HPV questionnaire was administered to participants after the AYAZAZI survey and took 
approximately 15 minutes. Before data collection, the author facilitated a two-day arts-based 
workshop about HPV, cervical cancer, and vaccines with all AYAZAZI staff members with the 
goal of equipping the research team with awareness about the topics. This also was helpful to 
mirror what would happen as part of an HPV intervention program to identify gaps in 
knowledge, receive input from the research team about contextually appropriate wording 
regarding the topics, and how to best work with the female AYA to raise awareness about a 
highly prevalent health issue. During this time pilot testing and training on the questionnaire also 
took place with the research assistants who were working on the study. Data collection took 
place between September 30th, 2016 and May 3rd, 2017 at the MRU site in the central business 
district of Durban. For AYA 18+ years, consent was from the participant and those under 18, an 
assent form was signed by the participant and a consent form was signed by the parents of 
guardian prior to data collection at baseline (Appendix C, D, & E). The lead institutions for the 
AYAZAZI study were Simon Fraser University, the University of Witwatersrand, and the 
University of KwaZulu-Natal. Ethical approval for this study was obtained from Research Ethic 
Boards from all participating institutions prior to the commencement of the study. An additional 
harmonized ethics proposal (to add HPV and cervical cancer section) was approved by all 
institutions as well as institution of the researcher, the University of Northern British Columbia 
(see Appendix F).  
Instrumentation  
Using a HBM and VHM lens, the HPV survey was compiled by the author and her committee 
and organized into four sections including, Section I: HPV and Cervical Cancer Awareness; 
Section II: Risk Perception and Impact; Section III: HPV Vaccine Awareness & Acceptability; 
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and Section IV: Cervical Cancer screening (Appendix G).  The survey has a total of 30 
questions. Half of the questions (15) are standardized questions related to screening, treatment, 
and vaccines from a core module from the WHO (2016) Improving Data for Decision Making in 
Global Cervical Cancer Programs Toolkit (IDCCP). Seven questions were from the Knowledge 
and Perceptions Survey (KAPs), a standardized questionnaire designed by McPartland and 
colleagues (2005) and examine perceived severity, susceptibility, and knowledge of HPV. The 
remainder of the questions examined awareness about the existence of HPV and cervical cancer 
and the sources of knowledge about these topics, locale specific barriers (availability and cost), 
as well as questions examining perceived barriers and benefits.  
Questions and scales from the 12-month AYAZAZI survey were merged with the HPV 
survey data. Self-efficacy was measured using validated perceived stress and resiliency scales in 
the AYAZAZI questionnaire. The Perceived Stress Scale (PSS) is one the most widely used 
psychological instrument for measuring the perception of stress (Cohen, Kamarck, & 
Mermelstein, 1983). The scale measures the degree to which one appraises and deals with stress 
in their lives. It is also determines how unpredictable, uncontrollable and overloaded respondents 
find their lives overall. Questions 1-10 were coded for response options ranging from ‘never’ (0), 
to ‘very often’ (4). Four items of the scale were reverse coded and the total was calculated with 
scores possibilities ranging from 0-40. The higher the PSS-10 score, The higher the PSS-10 
score, the most likely it is the participant perceives their environmental demands to exceed their 
ability to cope indicating higher levels of stress.  
The Connor-Davidson Resiliency Scale 10 (CD-RISC-10) was used to measure resiliency 
levels among participants. The CD-RISC-10 is one of the best-known instruments in the field of 
resilience assessment (Connor & Davidson, 2003). Responses from the 10-items ranged from 
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‘never’ (0), to ‘very often’ (4). When the items are added the score should be between 0-40 with 
higher scores reflecting greater resilience or ability to endure difficult experiences, including 
“change, personal problems, illness, pressure, failure, and painful feelings”.  The higher the CD-
RISC score, the more likely the individual demonstrates resilient behaviours despite being faced 
with adversities and possess positive coping skills. 
As part of pilot testing with representative individuals, the HPV survey underwent revisions 
to ensure that the questions were locale appropriate and easily translatable for the AYA. Once 
the survey was finalized, the research assistant’s conducted pilot testing with seven members of 
the MRU team in both English and isiZulu. All HPV survey data was collected using paper 
format and later entered into a template in Excel by the research assistants and on the project. 
Data quality checks were performed by the research assistants routinely and then double checked 
by the PI (VR) and later entered into a SPSS for analysis. Pre-determined variables from the 
AYAZAZI questionnaire (12-month time point) were extracted and merged with the HPV survey 
data and analyzed by the author. 
Data Analysis 
Descriptive statistics were used to analyze characteristics at the 12-month time point, 
frequencies and proportions to describe categorical variables and medians and interquartile 
ranges for continuous variables. Socio-demographic variables included: the age of participant; 
dichotomized age categories youth (16-19) and young adults (20-25);  sexual orientation 
(heterosexual vs. LGBTQ); relationship status (in a relationship/living together vs. in a 
relationship/not living together vs. single); student status (current student vs. not a student); type 
of student (high school vs. post-secondary); type of housing (formal vs informal housing, which 
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included RDP housing10, shacks, hostels and informal settlements); head of the household  
(females vs. males); monthly income (<400 ZAR11 vs. 401-1600 vs. 1601+); parental status 
(have child(ren) vs. do not have child(ren)); the number of children; and pregnancy status 
(currently pregnant vs. not currently pregnant). Finally, the current clinical HIV status of 
participants was also reported (HIV + vs. HIV-).  
Health behaviour descriptors were chosen based on factors associated in the development 
of cervical cancer including, smoked cigarettes over the past 30 days (smoked 1-10 cigarettes per 
day on average vs. did not smoke in past 30 days); non-medicinal drug use12 (ever used drugs vs. 
never used drugs). Sexual health behaviours included, age (M; SD) at first consensual sex 
defined as oral, vaginal or anal sex; number of consensual sexual partners ever; dichotomized 
sexual partners categories (1 sexual partner vs. ≥ 2 sexual partners); whether a condom used at 
time of first consensual sexual experience (used a condom vs. did not use a condom); and 
consistency of condom use (consistent use “always”, vs. inconsistent use “sometimes and 
never”).  
Healthcare utilization descriptors were chosen based on whether participants would have 
access to cervical screening or vaccines and whether services specific to women’s needs were 
needed and accessed by participants. The level of violence towards women in SA is an important 
determinant of women’s SRH outcomes and therefore was also reported. The descriptors 
included, whether participants had access to medical aid (have health insurance vs. do not have 
health insurance); whether participants had i) needed and ii) received services for: mental health, 
physical and sexual violence, addiction, faith-based or traditional healers (“yes/no”); and 
                                                          
10 Reconstruction and Development Programme (RDP) is subsidized government housing. 
11 400ZAR is roughly equivalent to $40CND. For scale the average monthly income in SA for 2017 was 19608ZAR.  
12 AYAZAZI questionnaire defined “drugs” as substances used for recreational/enjoyment (non-medicinal) 
purposes, including marijuana/dagga, other street drugs, over-the-counter drugs (available at pharmacies without a 
prescription) taken in excess of directions or prescribed drugs taken in excess of prescription.  
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experiences with sexual or physical violence over the past 6-months (experienced sexual or 
physical violence vs. did not experience sexual or physical violence vs. prefer not to answer).  
Mental Health: mental health descriptives included a perceived stress (PSS-10) and 
resiliency (CD-RISC 10) scales and were chosen based on literature about the role of self-
efficacy in health behaviours. In accordance with both a HB and VH models, self-efficacy plays 
a role in health decisions. The PSS-10 had 10 statements with responses ranging from, Never = 
0; Almost Never = 1; Sometimes = 2; fairly often = 3; and Very often = 4. Scores were obtained 
by reversing the scores on the four positive items (questions d, e, g and h): 0=4, 1=3, 2=2, 3=1, 
4=0 and then summing across all 10 items with score range possibility of 0-40. The higher the 
score the higher perceived stress the participant was experiencing. Overall mean and standard 
deviations for all participants are reported are dichotomized low (score of 0-20) vs. high (20+) 
stress scores.  Similarly, the CD-RISC 10 scale consisted of 10 statements and scores with 
responses ranging from, Never = 0; Almost never, 1 or 2 days = 1; Sometimes, between 3 and 10 
days = 2; fairly often, between 11 and 20 days = 3; Very often, over 20 days = 4. The scores of 
responses were added with a score potential ranging from 0-40 and obtained by adding questions 
(all positive) with the higher score reflecting higher levels of resilience. The overall mean and 
standard deviation as well as dichotomized scores, low (scores of 0-20) vs. high (20+), resilience 
scores are reported.  
Outcomes    
Objective 1: SRH information sources and influences were measured by asking 
participants about where they received information about these topics from. Women were asked 
if they were aware of the following topics: i) contraceptives, ii) HPV, iii) cervical cancer, iv) 
HPV vaccine, and v) cervical cancer screening. Responses were collapsed into four groups: (1) 
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friends and family (mother, father, aunt, sibling, grandmother, partner, or friend) vs. (2) health 
care professional (doctor or nurse), vs. (3) media (television, internet, or radio), vs. (4) school 
(school and counsellors) vs. (5) AYAZAZI and other community groups vs. I don’t know or 
never heard of it (99). Frequencies for each 5 topics are reported.  
Recommendation sources and cost factors about decisions to vaccinate against HPV were 
measured by asking women, “would you consider getting the HPV vaccine if, i) it cost you 
2300ZAR to purchase, ii) it was free, iii) it was recommended by your doctor or a nurse, and iv) 
it was recommended by family or friends”. A 4-point Likert scale for all questions ranged from 
“definitely would not (1); probably would not (2); neutral (3); definitely would (4); and I don’t 
know (97)”.  
Frequencies will be calculated for consideration factors in decisions to receive the HPV 
vaccine and t-tests will be used to examine mean differences in the importance of cost (paying 
2300 ZAR vs. receiving the HPV vaccine for free) and recommendation source (receiving a 
recommendation from a health care provider vs. friend and family) in AYA participants’ 
consideration of receiving the HPV vaccine.   
Objective 2: HPV, cervical cancer, and HPV vaccine awareness was measured by first 
asking participants if they had heard of HPV, cervical cancer, the HPV vaccine, or cervical 
cancer screening prior to the study, using a “yes/no/I don’t know” response. A series of 8 true or 
false statements about HPV, cervical cancer, and the HPV vaccine formed an awareness scale 
with possible scores ranging from 0-8. Awareness scores were summed, with the mean and 
standard deviation reported. Participants will also be stratified into two groups based on the 
median calculated from awareness scores (0-2 = ‘little to no awareness’; 2+ = ‘some 
awareness’).   
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Objective 3: HPV vaccine and vaginal self-collection acceptability was measured by 
asking participants, “Would you be willing to receive a vaccine to help prevent HPV infections 
and cervical cancer?” (Yes vs. No vs. I don’t know) and, “Would you want your child/ren (or 
future children) to receive the HPV vaccine?” (Yes vs. No. vs. I don’t know).  Cross-tabs will be 
run to examine current mothers and pregnant participant’s acceptability of the HPV vaccine for 
children. Acceptability rates for the HPV vaccine and self-collection, as well the preferred 
location of testing (clinic vs. home) will be reported (count; percentage). Women were also 
asked to rate the level of importance regarding whether the HPV vaccine protected against 
cancer and genital warts. This is important because currently the rollout for government program 
is administrating Cervarix (bivalent) protecting against only HPV 16 and 18, strains associated 
with cervical cancers but not genital warts. A Likert scale ranging from, (1) not important at all, 
(2) of little importance, (3) moderately important, (4) important, and (5) very important, was 
used. Frequencies and distributions will be reported about prevention priorities.  
Objective 4. Risk Perceptions for acquiring HPV, HIV and developing cervical cancer 
were measured using 4-point Likert scales. Participants were asked, “How much at risk do you 
think you are of becoming infected with, i) HIV, ii) HPV, and iii) cervical cancer”. The scale 
ranged from, (1) not at all at risk of becoming infected with HIV/HPV/Cervical cancer, (2) low 
risk, (3) medium risk, or (4) high risk. Scores were dichotomized to low (1-2) and high (3-4) risk 
groups and frequencies will be reported. Participants were then asked “how much at risk do you 
think other women in your community are of becoming infected with i) HIV, ii) HPV, and 
developing iii) cervical cancer”. The same Likert scale was used as described above with 
answers dichotomized into low and high perceived risk categories. 
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Objective 5. Risk Perceptions of Self Compared to Other AYA Females. In accordance 
with literature about perceived STI risk, AYA commonly have lower perceived levels of risk 
associated with themselves acquiring viruses and developing diseases in comparison to how they 
perceive others to be at risk for the same infections and diseases. Therefore, t-tests were run to 
examine the mean differences between participants’ risk perception of self vs. risk perception of 
other women in the community to acquire HIV and HPV as well as to develop cervical cancer.  
Objective 6. Perceptions of severity and vaccine efficacy beliefs were measured asking 
participants “how much of a negative impact would having i) HPV and ii) cervical cancer have 
on you and your life?” A Likert scale with responses ranging from (1) no impact at all, (2) low 
impact, (3) medium impact, and (4) high impact, were used to gage perceptions of severity. 
Similarly, HPV vaccine effectiveness beliefs were measured asking, “how likely do you think 
the HPV vaccine would reduce your chance of, i) getting infected with HPV, and ii) developing 
cervical cancer”. The response scale ranged from “(1) very likely, (2) fairly likely, (3) not likely, 
and (4) very unlikely. Both severity and efficacy belief variables will be dichotomized and 
frequencies reported.  
Objective 7. Factors associated with perceived risk. Risk perceptions can be affected by a 
variety of mediating factors such as sociodemographic and sexual health behaviours. A Chi-
square test of independence will be calculated to compare the frequency of risk perception (high 
vs. low) of 1) acquiring HPV and 2) developing cervical cancer with: age (16-19 vs. 20-25); 
sexual orientation (heterosexual vs. LGBTQ); income level (<400ZAR vs. 401-1600 vs. 1601+); 
student status (student vs. not a student); housing type (formal vs. informal); head of household 
(female vs. male); stress scale score (high vs. low); resiliency scale score (high vs. low); HIV 
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status (HIV+ vs. HIV-); condom use consistency (consistent vs. inconsistent; and sexual partners 
(1 vs. 2+).  
Objective 8. Factors influencing willingness to participate in self-sample collection are 
related to a variety of social, contextual, and personal factors in the literature. A Chi-square test 
of independence was run to compare the frequency of HPV self-sample collection acceptability 
(yes vs. no) with: age (16-19 vs. 20-15); sexual orientation (heterosexual vs. LGBTQ); income 
level (<400ZAR vs. 401-1600 vs. 1601+); student status (student vs. not a student); housing type 
(formal vs. informal); HIV status (HIV+ vs. HIV-); sexual partners (1 vs. 2+); sources of 
information about 1) HPV, 2) cervical cancer and 3) cervical screening (friends/family vs. HCP’s 
vs. media vs. school vs. AYAZAZI/community groups); knowledge or awareness about topics 
(none to low vs. some to high); perceptions of 1) risk and 2) severity (high vs. low); stress scale 
score (high vs. low); and resiliency scale score (high vs. low). Where associations were found 
with bivariate analysis, binomial logistic regression analysis will be used to identify predictors of 
willingness to participate in HPV self-sample testing. 
Objective 9. Uptake of cervical cancer prevention services included questions asking 
women, “Have you received the cervical cancer vaccine” (yes vs. no. I don’t know) Women 
were also asked, “Has a healthcare provider ever tested you for cervical cancer” with a “yes”, 
“no”, or “I don’t know” response. Frequencies for participation in HPV vaccines and cervical 
cancer screening were calculated and cross-tabulated by HIV status in accordance to current 
guidelines following HIV diagnosis that a woman receive cervical screening. Reasons for 
receiving a test for cervical cancer included, (1) following up on abnormal or inconclusive 
results, (2) recruited for testing by a HCP, (3) experiencing pain or other symptoms, and (4) 
heard about test and wanted to get tested. Results for the most recent test were reported with 
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response options, (1) did not receive a result, (2)normal/negative, (3) abnormal/positive, (4) 
suspect cancer, (5) inconclusive and (6) “I don’t know”.  Frequencies for reasons for receiving 
cervical screening and results will be reported.  
Summary 
The objectives of the research were to determine the level of awareness about HPV infection, 
cervical cancer, and vaccines among female AYA in an area of the world with the highest HIV 
and HPV rates; describe attitudes and beliefs of female AYA towards the HPV vaccine, evaluate 
the acceptability of vaginal self-sample testing for HPV, and analyze associations and/or 
predictors of HPV vaccine and self-sample testing acceptability. The most commonly cited 
barriers in the literature to receiving the HPV vaccine, a part from cost, were misconceptions 
about the efficacy and safety of the vaccine. Low levels of awareness are attributed to a lack of 
appropriate education campaigns prior to the administration of the HPV vaccine in both school 
and clinic settings for young women and parents. This research about acceptability of the HPV 
vaccine and innovative preventative cervical cancer screening tools will help to inform cervical 
cancer prevention initiatives.   
This study was a collaborative project with a youth centered study examining HIV acquisition 
in Durban, SA. The age of the cohort (16-26) are key to focus on for cervical cancer prevention 
efforts in SA. Data analysis included descriptive statistics, health behaviour descriptors, health 
care utilization descriptors, and mental health measures. Outcome objectives included, AYA 
SRH information sources; HPV, cervical cancer, and HPV vaccine awareness; HPV vaccine and 
vaginal self-collection acceptability; risk perceptions for acquiring HPV, HIV and developing 
cervical cancer (self-versus other women); perceptions of severity and vaccine efficacy beliefs; 
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factors associated with perceived risk; factors influencing willingness to participate in self-
sample collection; and uptake of cervical cancer prevention services.  
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Chapter 4: Results 
Introduction 
The findings of ‘A Pivotal Time in Global Cervical Cancer Prevention” study on HPV 
vaccine and screening awareness and acceptability are presented in this chapter. Descriptive data 
will first be presented followed by the nine outcomes:  SRH information sources and influences; 
HPV, cervical cancer, and HPV vaccine awareness; HPV vaccine and self-sample acceptability; 
perceptions of risk for acquiring HIV, HPV and developing cervical cancer; perceptions of risk 
for acquiring HIV, HPV and developing cervical cancer for self, compared to other women in the 
community; perceptions of severity associated with HPV and cervical cancer as well as efficacy 
beliefs about the HPV vaccine; factors associated with perceived risk; factors associated with 
willingness to participate in self-sample collection; and uptake of cervical cancer prevention 
services.    
Descriptives 
Of the 132 female AYA enrolled in the AYAZAZI study at the Durban site, 122 completed 
the HPV questionnaire at the 12-month collection point. Characteristics are shown in Table 5. 
Participants ranged from 17-25 years of age (M = 20.16; SD = 2.05) with 55 (45%) adolescents 
(16-19 years) and 67 (55%) young adults (20-25 years). Participants were mostly heterosexual 
(113; 92.6%), with six (4.9%) reporting to be lesbians, and three bi-sexual (2.5%). Most 
participants were currently in a relationship but not living with their partner (100; 82%), while 19 
(15.6%) reported to be single and three (2.5%) currently lived with their partner. Most 
participants reported attending school (78 or 63.9%), enrolled in high school (14; 11.5%) or post-
secondary education (63; 51.6%). The amount of monthly income participants reported was most 
commonly between 401-1600 ZAR (45%). 
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Table 5. Descriptive Characteristics 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Characteristics (n = 122) n (%) 
Socio-demographics  
Age category, years 
     16 to 19 
     20 to 25 
 
55 (45.1) 
67 (54.9) 
Sexual orientation 
    Heterosexual 
    LGBTQ 
 
113 (92.6) 
9 (7.4) 
Currently in school 
     Yes       
     No  
 
78 (63.9) 
44 (36.1) 
Relationship Status 
In relationship  
Single  
 
103 (84.5) 
19 (15.5) 
Housing 
    Formal  
    Informal 
 
88 (72.1) 
34 (27.9) 
Head of Household 
Female 
Male 
More than one 
 
84 (68.9) 
35 (28.7) 
3 (2.5) 
Have Children 
Yes 
No 
 
34 (27.8) 
88 (72.1) 
Monthly personal income 
    <400 ZAR 
    401-1600 ZAR 
    1601+ ZAR 
 
31 (25.4) 
55 (45.1) 
3 (2.5) 
Sexual history, behaviours, and violence  
Ever had consensual sex 
Yes 
No 
 
98 (80.3) 
24 (19.7) 
≥2 Sexual partners in lifetime 
    Yes 
    No 
 
67 (68.4) 
31 (31.6) 
Condom use in past 6 months 
   Consistent (“always”) 
   Inconsistent (sometimes/never) 
 
0 (0) 
48 (100) 
Condom use first consensual sex 
Yes 
No   
 
30 (31.3) 
66 (68.8) 
Ever experienced physical/sexual violence                                           
    Yes 
No 
Prefer not to say 
 
3 (2.5) 
113 (92.6) 
6 (4.9) 
HIV Status 
     Positive 
     Negative 
 
8 (6.6) 
106 (93.4) 
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Overall, most participants reported to be living in formal housing (72.1%) while the 
remainder in informal housing situations this included RDP housing13 (20.5%), shacks in 
informal settlements (4.1%), and hostels (3.3%). Participants’ homes were mostly headed by 
women (68.9%). The head of the household most often was an adult female (18-60 years) at 
49.2%, followed by males (18-60) 24.6%, and older females (<60) at 12.3%, respectively. Of the 
122 women, 34 (28%) were mothers with most having one child (33) and one mother had two 
children. Seven women (5.7%) were currently pregnant. Of the 122 AYA participants, 8 (6.6%) 
were HIV positive and been diagnosed by the AYAZAZI team at a prior point of contact14. 
Health Behaviour Descriptors  
Most women (85.2%) had not smoked cigarettes in the past 30 days, while 18 (14.8%) 
smoked 1 or more cigarettes on average per day. The majority of women reported to have 
participated in non-medicinal drug use (64.8%) at least once in their lifetime. Sexual health 
behaviours including whether AYA had engaged in consensual sex, the age of first consensual 
sex, use of condoms during first sexual encounters, number of sexual partners, and male condom 
use and frequency, as well as any experiences with sexual or physical violence. Of the 122 
participants, 98 (80.3%) said they had engaged in consensual sexual activity. The age of first 
sexual activity ranged from 14-21 (M = 17.48; SD 1.54). Many participants (68%) reported to 
have had consensual sex with ≥ 2 sexual partners throughout their lifetime. The number of sexual 
partners ranged considerably from 1 – 25 (M = 3.27; SD = 3.69), with participants most often 
reporting having had one (N = 31; 25.4%), two (N = 25; 25.5%), or three partners, respectively 
(N = 15; 12.3%). One participant reported having 21 and another 25 consensual sexual partners.  
                                                          
13 Reconstruction and Development Programme (RDP) is subsidized government housing. 
14 All participants in the study were either diagnosed HIV- or undiagnosed at time of enrollment.  
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Participants were asked if they used a condom during their first consensual sexual encounter, 
most 68 (68.8%) said “no” while 30 (31.2%) said “yes”. Women who reported to be sexually 
active, 67 (54.9%) stated that they use male condoms ever, while only 1 woman reported to use 
female condoms. No participants reported using condoms consistently (every time) and all 
women who answered the question (48) reported to use male condoms inconsistently. Of the 48 
(39.3%) females who used male condoms, all said they used them only ‘sometimes’.  
Healthcare Utilization Descriptors 
Very few participants reported having access to medical aid (health insurance programs) at 
16.4% (N = 20) which means very few had access to health services above and beyond basic 
coverage. However, when asked about health services that AYA needed 18 (15%) reported 
needing services for mental health, physical and sexual violence, addictions and faith- or 
traditional-based healers over the past 6 months. Four women stated that since their last visit, 
they had required services for gendered-based violence, while 3 of those women received 
services. Many of the participants (12%) needing additional services reported having received 
them from the aforementioned health care services providers. Table 6 details healthcare services 
examined for need and whether women received.  
Table 6. Health Services Needed and Received 
 
Type of Service 
 
Needed (N) 
 
Received 
Mental Health 2 1 
Physical Violence 1 2 
Sexual Violence 3 1 
Addictions 1 2 
Faith-Based 6 5 
Traditional Healers 5 4 
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Overall, three women reported to have experienced sexual or physical violence over the past 6 
months with six women stating they “prefer not to say”. Two participants reported to be 
physically hurt or threatened by a sexual partner and three selected “prefer not to answer”. 
Similarly, one woman stated that she had been forced to have sex with someone when she didn’t 
want to over the past six months, while six women said they preferred not to answer the 
question. Not surprisingly, there are incongruences between services required, particularly for 
physical and/or sexual violence support, and those received among this cohort of young women.   
Mental Health Descriptors  
 
Mental health scale findings measuring perceived stress and resiliency are presented next. 
From a possible score of 40, participant PSS-10 scores ranged from 0-30 and were normally 
distributed (M =15.7; SD =6.59). Scores higher than 20 indicated higher levels of stress. The data 
was stratified for high- (score > 20) versus low-levels (0-20) of perceived stress. Findings 
showed that most of participants reported feeling low levels of perceived stress (N = 85; 69.7%) 
compared to higher levels (N = 37; 30.3%). Scores for the CD-RISC-10 measuring resiliency 
ranged from 7-40 yielding a mean score of 27.96 (SD = 7.3) with a positively skewed 
distribution. Scores higher than 20 indicated higher levels of resilience. Stratified scores showed 
that most AYA women had high levels of resilience (105; 86.1%) compared to those with low 
levels. This finding indicates that most participants reported having fairly high levels of 
adaptability, coping skills, and positive outlooks on life.  
Sexual and Reproductive Health Information Sources and Influences 
Participants were asked if they had heard about and where they received SRH information 
such as contraception, HPV, cervical cancer, cervical cancer screening, and the HPV vaccine and 
social influences (friends/family vs HCP’s) in their decision to receive the HPV vaccine. Results 
 ???
 
????????????????????????????????????????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????????????????????????? ????
????????????????????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????? ????????????????????????
?????????????? ??????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????? ??????????????????????????
???????????????????????????????????????????????????????????????????????????????????????????
?????????????????????
??????????????????????????????????????????????
?
? ??????????????
?????????
???????
?
????
????
????????
?
??????????
??????????????? ??? ??? ?? ?? ???
?????????????? ????? ??? ??? ?? ?? ???
?????????????????????????? ??? ??? ?? ?? ???
?????????????? ????? ??? ?? ?? ?? ??
??????? ??? ??? ?? ?? ??
???????????????? ??????????????????
???
???
???
???
???
?????????????? ?????????????? ???? ????????????????????????? ??????? ??????
???????????????????????????????????????????????????
 89 
 
Participants were asked how likely they would have the HPV vaccine if recommended by a 
health care professional compared to friends/family members. Most stated they “definitely 
would” if recommended by a HCP (77.9%), whereas fewer women said they “definitely would” 
receive the vaccine if recommended by friends/family members (20.6%; see Table 8). Health 
care professionals (M=4.69; SD=.69) played a significant role in influencing AYA females to 
consider the receiving the HPV vaccine compared to recommendation from family or friends (M 
= 3.38; SD=1.37) at t (120) = 74.48, p = .000.  
Table 8. Likelihood of Receiving HPV Vaccine from Recommendations 
 
 Doctor or Nurse 
 
 
Friends or Family 
  % % 
Definitely would not .80 15.6 
Probably would not 1.6 11.5 
Neutral 3.3 10.7 
Probably would 15.6 38.5 
Definitely would 77.9 20.5 
  
The role of affordability in acceptance of the HPV vaccine was also explored. Two questions 
were asked about the importance of affordability including, 1) how likely would you consider the 
HPV vaccine if it cost you 2300ZAR to purchase? And, 2) how likely would you consider the 
HPV vaccine if it was free? Questions were measured on Likert scales with importance of 
affordability ranging from, 1 -“Definitely would not receive the vaccine” to 5 - “Definitely 
would receive the vaccine”.  Most participants were significantly more favourable towards the 
vaccine if it was free (M = 4.84; SD = .50) then if the vaccine cost 2300 ZAR (M = 2.17: SD = 
1.55) at t (112) = -19.39, p = .000. The inverse relationship between cost variables is shown 
below in Figure 12.  
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Figure 12. Fiscal Considerations for Receiving the HPV Vaccine 
Awareness about HPV, Cervical Cancer, Vaccines, and Screening     
Awareness about HPV, cervical cancer, and screening, as well as the HPV vaccine was 
examined by first asking women if they had ever heard about these topics prior to the study. 
Women were then administered an awareness scale, to measure levels of awareness. Of the 122 
women, very few (6.6%) had heard of HPV or the HPV vaccine (16.4%), prior to participation in 
the study. However, most women had heard of cervical cancer (89.3%) and a test to check for 
cervical cancer (61.5%). The participants were asked to mark a series of eight statements about 
HPV, cervical cancer, and the HPV vaccine as ‘true’ or ‘false’. If participants said “I don’t 
know” or the incorrect answer they were marked with a score of zero whereas correct statements 
were worth a score of one.  
Statements were combined for a total knowledge and awareness score (0-8). Women’s scores 
ranged from 0-7 (M = 1.71; SD = 1.89), with just under half scoring “0” (42.6%). When scores 
were stratified (0-2 = ‘little to no awareness’; 2+ = ‘some awareness’) most AYA women 
(66.2%) had ‘little to no awareness’ about these topics. Importantly, most women indicated they 
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did not know that an HPV vaccine was available (87%) nor were aware of most of the statements 
about HPV and cervical cancer presented to them (See Figure 13). 
HPV Vaccine & Self-Collection Acceptability 
Participants were asked about HPV vaccine acceptability for self and children (or future) 
children as well as their willingness to participate in vaginal self-sample testing or collection. 
AYA women were also asked about the importance that the HPV vaccine reduces warts and/or 
cervical cancer. Most women (N = 118; 96.7%) said they would be willing to receive the 
vaccine, while three women stated “I don’t know”. Acceptability for children and future children 
was also high at 95.1% (N = 116), with four participants declining the vaccine and two stating “I 
do not know”. A cross tabulation was run to explore whether current mothers and those who 
were pregnant were HPV vaccine acceptant for their children. All mothers in the cohort (N = 34) 
and women who were currently pregnant (N =7) stated they would want the HPV vaccine for 
their child (ren).  
The acceptability of vaginal self-collection (for HPV) was measured by asking women if they 
would be willing to collect a sample by themselves to test for cervical cancer if they were given 
instructions on how to collect the sample. Most women stated they would be willing to 
0 20 40 60 80 100 120 140
HPV can cause herpes
Genital warts are caused by HPV
HPV can cause cervical cancer
Many people with HPV have non visible signs or symptoms
I can transmit HPV to my partner even if I do not have symptoms
Having one type of HPV means that you cannot acquire new types
A vaccine exists to prevent HPV infections and cancers
The HPV vaccine is approved and available in South Africa
Incorrect Correct
Figure 13. Awareness Scores: HPV, Cervical Cancer and Vaccine 
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participate in self-collection (N = 103; 85.1%), with 15 (12.4%) would not, and the remaining 3 
(2.5%) women stating, “I don’t know”. Just over half of the women indicated they would prefer 
to collect the self-sample at a clinic (N = 68; 61.8%) while 35 (38.2%) women said they would 
prefer to collect the sample in their homes and two said they would participate in self-collection, 
but did not know where they would prefer to collect the sample.  
Last, women were asked to rate the level of importance regarding whether the HPV vaccine 
protected against cancer and/or genital warts. Most AYA rated the importance of the HPV 
vaccine to prevent genital warts as “Important” or “Very Important” (N = 118; 96.7%). 
Similarly, the importance of the vaccine to prevent cancer was rated as “Important” or “Very 
Important” by 119 participants (97.5%). This indicates equal level of importance for participants 
that the HPV vaccine protect against both genital warts and cancers.  
Risk Perceptions for Acquiring HPV, HIV, and Developing Cervical Cancer 
Participants were asked to rate their perceived risk of acquiring HIV, HPV, and cervical 
cancer. A Likert scale was used to rate perceived risk with responses ranging from, 1 ‘not at all 
at risk of becoming infected’; 2 ‘low-risk’; 3 ‘medium-risk’; and 4 ‘high-risk of becoming 
infected’. Risk perception scores for self for all three categories (HIV, HPV and Cervical 
Cancer) were then recoded and dichotomized into low- and high-risk groups (See Table 9).  
Table 9. Stratified Perceived Risk Scores: Self 
Perceived Risk HPV 
 
 
Cervical Cancer HIV 
 N (%) N (%) N (%) 
Low Risk 49 (43) 42 (39.6) 84 (75) 
High Risk 
 
 
65 (57) 64 (60.4) 28 (25) 
 
The perceived risk that participants felt other AYA females in their communities was rated and 
similarly dichotomized into low- and high-risk groups (See Table 10).  
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Table 10. Stratified Perceived Risk Scores: Other AYA Females 
Perceived Risk HPV 
 
 
Cervical Cancer HIV 
 N (%) N (%) N (%) 
Low Risk 5 (4.4) 12 (10.8) 13 (11.1) 
High Risk 
 
 
108 (95.6) 99 (89.2) 104 (88.9) 
 
Consistently for all categories, participants perceived themselves to be at much lower risk of 
acquiring HIV and HPV as well as developing cervical cancer compared to other AYA females 
in their communities. Figure 14 shows a comparison of participants who perceived themselves to 
be at high-risk for acquiring HIV and HPV as well as developing cervical cancer in relation to 
other AYA females in their community.     
 
 
 
 
 
 
 
 
 
 
 
Risk Perceptions of Self Compared to Other AYA Females 
In all three domains, participants rated other young women as being at a much higher risk 
compared to themselves of acquiring HIV, HPV, and cervical cancer. The means and standard 
deviations for perceived risk of self compared to others is below in Table 11. 
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Figure 14. Perceptions of Risk (High): Self vs. Others 
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Table 11. Perceived Risk for HIV, HPV, and Developing Cervical Cancer: Self vs. Others 
Perceived Risk Self 
 
 
Other AYA Females 
 M (SD) M (SD) 
HIV 2.2 (.79) 3.5 (.69) 
HPV 
 
 
2.7 (.95) 3.6 (.60) 
Cervical Cancer 2.8 (.95) 3.5 (.71) 
 
Participants commonly have lower perceived levels of risk associated with themselves acquiring 
viruses and developing diseases in comparison to how they perceive others to be at risk for the 
same infections and diseases. Results demonstrate that participants believed that other young 
people in their community were at a significantly higher risk than themselves of acquiring HIV 
at t (116), = 55.2, p = .000, HPV at t (112), =64.2, p =.000 and developing cervical cancer at t 
(110), = 51.73, p = .000.  
Perceptions of Severity and Vaccine Efficacy Beliefs  
The perceived severity or impact of HPV and cervical cancer was measured using a Likert 
scale ranging from 1 – no impact on my life, to 4 – high impact. Women rated the perceived 
severity of acquiring HPV and cervical cancer as similarly high, M = 3.39 (SD = .86) and M = 
3.68 (SD = .68), respectively. When data was dichotomized by ‘no to low impact” vs “some to 
high”, 9 (8.3%) participants felt HPV would have no to low impact while 11 (9.8%) stated that 
cervical cancer would have no to low impact on their lives. Overall, the severity or negative 
impact that acquiring HPV or developing cervical cancer was rated very high by participants.  
Effectiveness beliefs were measured regarding the HPV vaccine. A Likert scale ranging from 
‘Not Very likely’ to ‘Very likely’ was used for this question. When asked how likely the 
participants thought the HPV vaccine would reduce their chances of becoming infected with 
HPV and developing cervical cancer, most women expressed believing the vaccine to be highly 
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efficacious with preventing both HPV (M=3.53; SD = 82) and cervical cancer (M = 3.47; SD = 
.816). Data was dichotomized to “no/little belief “vs “fairly/high belief” that the HPV vaccine 
will prevent HPV and cervical cancer, demonstrating that 100 (91.7%) and 101 (90.2%) 
participants had fairly high efficacy beliefs about the preventive properties of the vaccine against 
HPV and cervical cancer.  
Factors Associated with Perceived Risk 
 
Chi-square tests of independence were used to calculate and compare the frequency of risk 
perception (high vs. low) of both 1) acquiring HPV and 2) developing cervical cancer with age, 
sexual orientation, income level, student status, housing type, head of household, HIV status, 
condom use consistency, stress and resiliency scores, and number of sexual partners. No factors 
listed were found to be significantly associated to risk perception for acquiring HPV or 
developing cervical cancer.  
Factors Influencing Willingness to Participate in Self-Sample Collection 
 
Most participants said they would be willing to participate in self-sample collection (N = 103; 
85.1%), with 15 (12.4%) would not, and the remaining 3 (2.5%) women stating, “I don’t know”. 
A Chi-square test of independence was run to compare the frequency of HPV self-sample 
collection acceptability (yes vs. no) with: age, sexual orientation, income level, student status, 
housing type, stress and resiliency scores, HIV status, sexual partners, sources of information 
about 1) HPV, 2) cervical cancer and 3) cervical screening, knowledge or awareness about 
topics, and perceptions of 1) risk for HPV and cervical cancer and 2) perceived severity of HPV 
and cervical cancer. However, no significant associations were found in the analysis, therefore 
binomial logistic regression analysis was not used to explore predictors in HPV self-sample 
testing acceptability.   
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Uptake of Cervical Cancer Prevention Services 
The cohort of AYA women (16-24 years) in our study are part of an extraordinarily important 
group of women who are at the highest-risk of developing cervical cancer. Whether participants 
had ever received the HPV vaccine or cervical screening was measured and further cross 
tabulated with HIV status15. Out of the entire cohort of AYA participants, only 2 (1.6%) had 
received an HPV vaccine, while 2 stated they did not know if they had. Eight (6.6%) women said 
they had received testing or screening for cervical cancer. Several reasons were listed for having 
screening including, experiencing pain and/or other symptoms (N = 5), because they had heard 
about the test and wanted to get checked (N = 2), and follow-up from abnormal results (1). The 
eight women were living with HIV (WHIV) and ranged from 19-2416 years. None of the WHIV 
had received an HPV vaccine, with one saying she did not know if she had. Only 1 out of 8 
WHIV had received Pap testing because of reported pain and other symptoms.  
Participant Feedback 
Participants were asked to provide feedback of the AYAZAZI youth study at the 12-month 
point (at time of HPV survey). The AYA were asked, 1) what have you liked about the 
AYAZAZI study overall, and 2) If we received additional funding to continue AYAZAZI, what 
services would you like use to offer. When asked what they liked about the study, from the 76 
participants (male and female) who filled out the survey, 47 (61%) identified AYAZAZI as 
being a direct and key source of health (SRH; emotional; physical) support, education and 
services. Below are some of the responses from participants about how AYAZAZI (and using a 
youth engagement approach) had benefitted their lives:  
                                                          
15 The WHO recommends cervical screening directly following HIV diagnosis. HPV vaccination also 
recommended. 
16 Half of the WHIV were 19 years of age (N=4) 
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1. Everything especially the way they treat us and the knowledge we are getting as 
youth; 
2. AYAZAZI staff members are very kind and friendly. I have learned a lot in terms of 
my health; 
3. The care and patience towards my health and the fact that I get regular checkups; 
4. It encouraged the youth to continue protecting themselves from unprotected sex and 
free from STIs. Furthermore it helps one to know his/her status (HIV); 
5. They make sure we are find and they treat us as the member of the study. The 
services are very good; 
6. Everything about AYAZAZI is amazing! I like the friendly stuff and the information 
they provide for us as youth is quite amazing; 
7. It changed my lifestyle; 
8. The fact that the staff is very friendly and makes it easier for us to open up about our 
health problem; 
9. Each time I come in to visit they just seem to amaze me with all the information I did 
not know about; 
10. I have liked everything about AYAZAZI the staff is amazing they treat their clients 
with care and love; 
11. AYAZAZI study is more helpful to the youth and really helped me a lot about my life 
they teach me everything about how to take care of my personal life; 
12. Everything how you guys treat clients and care you have about youth health; 
13. I learned how to keep myself healthy and I love the way you treat us as youth you 
keep us free from stress. 
One participant stated they she “liked that they taught me about HPV, I didn’t know about it”. In 
terms of what participants would want for services if additional funding was given to AYAZAZI, 
8 (11%) of respondents said they would want to see HPV vaccines or further cancer studies:  
1. Include a cancer study; 
2. Cancer testing; 
3. It shouldn’t be just about HIV & STI. I would like others services like checking for 
cancer etc.;   
4. Cancer services and still HIV; 
5. Pap smears for under 30 years because they are also sexually active; 
6. Cancer testing, youth book clubs and support groups; 
7. Vaccines for HPV, more studies about it; 
8. The machine to check for cervical cancer. 
Findings from the post-survey with participants demonstrate the important role that trust plays in 
optimal SRH services for AYA involved in this study. This research study and team made it 
possible for many of the AYA to access SRH services they may not have otherwise, gain 
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awareness and feel empowered about SRH topics, and feel well-supported in a youth-engaged 
project where they were able to become active participants in their own health care. AYA 
expressed wanting to not only know more about HPV, but also to have cancer related studies and 
testing and HPV vaccines if they were to participate in future research studies.    
Summary 
Participants in this study were female AYA enrolled in a study site in downtown Durban. The 
cohort of 122 AYA were mostly heterosexual and in relationships. Many AYA were currently 
students and working towards post-secondary credentials. Formal housing was most common 
housing situation with many participants reporting, on average, low monthly personal income 
amounts. Homes of participants were predominantly headed by females with a considerable 
number of AYA females with a child or children and/or currently pregnant. A small portion of 
participants were living with HIV at the time of survey administration. Both mothers, who are 
making decisions for their children about HPV vaccines, and WHIV, those at highest-risk of 
acquiring HPV and developing cervical cancer, are particularly important women to focus on.   
A small portion of AYA reported smoking cigarettes and just over half had experimented with 
non-medicinal drugs at some point in their lives. Most AYA reported being sexually active, with 
most saying they did not use a condom during their first consensual sexual experience and all 
said they inconsistently used condoms. Ages of first consensual sex and number of partners 
ranged considerably within this cohort. However, most participants who were sexually active had 
been with ≥ 2 sexual partners with a couple AYA saying they had been with 20+ partners. The 
inconsistent condom use among all participants paired with higher numbers of sexual partners 
are alarming findings, as this population of young women are at the highest-risk from suffering 
from an array of unfavourable SRH health outcomes. Despite the high numbers of STI’s locally 
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and among the population, the data demonstrated that participants have a considerably low 
perceived level of risk for acquiring HPV, HIV, or developing cervical cancer perhaps 
explaining why AYA are engaging in unusually risky sexual health behaviours.  
Most of the women reported to have no medical aid, however reported needing unique health 
services including services for mental health, sexual and physical assault, traditional and spiritual 
healing services. As sexual assault and assault in general tends to be highly underreported in SA, 
the low rates of reporting these incidents within the cohort may not reflect realistic rates. Some 
participants said “prefer not to answer” to questions pertaining to violence, therefore higher rates 
than what are reported in the cohort are assumed. Mental health indicators reported were 
perceived stress and resiliency scales, with most women reporting to have low-levels of stress 
and high-levels of resilience or ability to adapt, cope, and have a positive outlook on life.    
Sources for SRH knowledge ranged considerably, however the most influential sources for 
information overall were health care professionals, communication/media, and family/friends. 
However, AYAZAZI was most influential in teaching AYA about contraceptives compared to 
any other sources. When it comes to recommendations for receiving the HPV vaccine, health 
care professionals played a significant role in women’s considerations to receive the vaccine 
compared to friends/family. An additional significant factor in the decision to receive the HPV 
vaccine was affordability, as it is a tremendous cost currently in SA. Most women said that if the 
vaccine was free they would get it, however with the current cost (2300ZAR), which translates to 
roughly $230CND, and very few participants having access to medical aid the HPV vaccine is 
not currently a reality for most women. Recommendation sources for and affordability of the 
HPV vaccine mattered to women.  
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  Awareness about HPV and its association to cervical cancer as well as the HPV vaccine was 
very low among women in this study. Few women had heard about HPV prior to the study, and 
few knew that an HPV vaccine existed to protect them against genital warts and cancers. As 
previously stated, despite very low knowledge levels the acceptance rate of the HPV vaccine 
remained very high. Beliefs about effectiveness regarding the HPV vaccine were also high. This 
is important because although AYA women in the cohort had very little practical awareness 
about these topics, they still believed the vaccine would be effective and all expressed interest in 
receiving or having their (future) children receive it to protect against HPV. There are several 
plausible factors for a favourable attitude towards the HPV vaccine including the trust that had 
been established with the AYAZAZI staff and HCPs prior to the questionnaire as well as the 
high-levels of cervical cancer locally. HPV vaccine acceptance for self and (future) children was 
very high. All current mothers and pregnant women stated they would have their child receive 
the HPV vaccine. Most women said they would prefer to collect their sample at a clinic as 
opposed to at home. Almost all of the AYA stated they would want the HPV vaccine to protect 
against genital warts as well as cancers. The protective factors were equally important to women 
which is important given the current HPV vaccine being rolled out in SA only protects against 2 
oncogenic HPV types but not genital warts. In general, risk perception for acquiring HPV, HIV, 
and developing cervical cancer was low among participants compared to how they perceived risk 
levels for other women in their communities. This factor did not, however, play a role in 
women’s acceptance of the HPV vaccine or self-sample testing. HPV vaccine efficacy beliefs 
were rated high by participants. There were no significant associations found in relation to 
perceived risk level of acquiring HPV or developing cervical cancer. Similarly, no factors were 
found to be associated with participants’ willingness to participate in HPV self-sample 
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collection. The reported uptake of cervical cancer prevention services (Pap testing and HPV 
vaccines) were almost non-existent among this cohort, this was also the case among WHIV who 
are most at-risk for cervical cancer.  
Finally, the post-questionnaire survey overwhelmingly showed that AYAZAZI played an 
important, if not key, role in AYA’s understanding and awareness about SRH topics. AYA 
expressed feeling valued, loved, listened to, and trusting of staff for education and STI testing 
needs. AYA expressed wanting to not only know more about HPV, but also to have cancer 
related studies and testing as well as HPV vaccines, if they were to participate in future research 
studies with the AYAZAZI team. It was clear from the feedback that this study and team really 
mattered to participants.    
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Chapter 5: Discussion 
 
In this chapter AYA women’s awareness about HPV and attitudes towards the HPV vaccine 
as well as self-sample acceptability are discussed. After a concise introduction, a discussion of 
the outcomes is presented in a way that addresses the proposed research questions for this study. 
The sections will include: description of the cohort; knowledge about HPV, cervical cancer, and 
the HPV vaccine; acceptability of the HPV vaccine (self and children) and HPV self-sample 
testing; acceptability; SRH information sources; and perceptions of risk. A summary and 
implications are presented to end the chapter.  
Introduction 
Cervical cancer is an entirely preventable disease. It is a pivotal time in cervical cancer 
prevention for young South African women. It is a reality for many young women to suffer from 
array of SRH challenges, this is particularly the case for cervical cancer (Ebrahim et al., 2016; 
Richter, 2015). HPV related cancers and HIV/AIDS are major public health problems in SA 
(Bruni et al., 2016; UNAIDS, 2015). One of the most important advances in cervical cancer 
prevention is the HPV vaccination, and will have a significant impact in countries like SA with 
high HPV prevalence rates, low screening rates and limited resources to manage HPV associated 
lesions and cancers. Secondary prevention, including innovative approaches such as HPV self-
sample testing, are equally important to invest in and focus on in areas of the world with high 
rates of cervical cancer. Due to the fact that the HPV vaccine has only recently been rolled out in 
SA at a national level, this study about awareness and vaccine acceptability is timely and will 
contribute to policy and decision making moving forward for a population at the highest-risk of 
acquiring HPV. This study aimed to describe AYA females’ awareness about HPV and cervical 
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cancer, as well as explore associations and predictors of HPV vaccine and self-sample 
acceptability.   
Description of the Cohort 
 
Women who participated in this study were representative of a population at the highest risk 
of HPV, HIV, and cervical cancer in SA. The demographics of study participants were 
representative of the SA reality, with many AYA already having begun childbearing, with 27% 
of mothers overall in the study. Youth mothers (16-19 years) represented 10% of the overall 
cohort, 7% of whom already had children and 3% currently pregnant. This is comparable to the 
most recent SA Demographic and Health Key Indicator’s Report (2017), showing that 16% of 
women age 15-19 in South Africa have begun childbearing: 12% have given birth, and another 
3% were pregnant at time of survey collection.   
Sexual health behaviours, such as number of partners and condom use, were also found to be 
similar between our cohort and the national average. The sexual practices that AYA females in 
this study reported to be participating in show cause for concern, as these behaviours put them at 
a considerable higher-risk for acquiring STIs. For example, over half of the participants in this 
study reported not to use a condom the first time they had consensual intercourse and all reported 
inconsistent condom use over the past six months. Further to this, many AYA reported having 
multiple sexual partners (68%) with a mean of 3.27 lifetime partners. These findings are also 
consistent with national data showing that 39% of the female AYA (15-24 years) reported not to 
use a condom the last time they had intercourse. Data also showed that 4.6% of the participants 
had ≥2 sexual partners (over the past year) with a mean of 2.9 lifetime partners (NDoH, Stats 
SA, SAMRC, & ICF, 2017).   
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Finally, in comparison to the overall AYAZAZI cohort in both Soweto and Durban (N=425) 
the female AYA who participated in this study were fairly representative in terms of age, student 
status, and sexual behaviours. The AYAZI cohort in both sites consisted of 40% males and 60% 
females, with the most common age group between 18-21 years (60%). This is similar to the 
AYA females in this study with a mean age of 20.3 year with a slightly larger representation of 
young adults (20-25 years) at 55%. Most participants in the HPV study were currently attending 
school (N=78; 78%), which was also the case for most participants in the AYAZAZI study at 
71% (303/425). Reported sexual behaviours of the female AYA in this study did differ from the 
overall cohort, with 70% reporting to be sexually active in Soweto and 76% in Durban, 
respectively. However, 80.3% of HPV study participants reported to have been sexually active 
with most stating they had been with more than 2 sexual partners (68%) in comparison to the 
overall AYAZAZI cohort at 21% in Soweto and 17% in Durban. In addition, consistent condom 
use was not reported by any female AYAs in the HPV study, while this it was reported by 30% 
of participants in Soweto and 30% in Durban. These comparisons tell us several things about the 
AYA females participating in this sub-study, 1) many are currently enrolled in formal education, 
2) sexual practices (number of partners and inconsistent condom use) were vastly different 
between the HPV sub-study and AYAZAZI participants, and 3) due to sexual health practices 
participants are at the greatest risk-for acquiring HIV and developing problematic SRH 
outcomes. Education level can play a role in health decision-making, however in this sub-cohort 
despite comparable ages and education levels, sexual health behaviours did not reflect this.  
HIV rates found in our study were slightly lower at 7%, compared to the estimated national 
average for young women (15-24 years) at 10.4% (UNAIDS, 2016). Of the 8 WHIV in the 
cohort, half were youth (16-19 years) and half young adults (20-15). There were 3 WHIV in our 
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study who were mothers and none who were currently pregnant. In comparison, 30.8% of all 
women nationally who participated in antenatal care were HIV positive (National Department of 
Health, 2015). Although the inclusion criteria upon enrollment for the AYAZAZI study was HIV 
negative status or unknown, a plausible explanation for the lower rates of HIV among AYA in 
our study, for some, was their early involvement with the AYAZAZI research team at a pivotal 
time in their lives for HIV acquisition. Having the opportunity to learn about SRH topics from a 
health team that they trusted, have access to STI testing and being empowered to play a role in 
managing their own health, all could have contributed to the lower HIV rates found among our 
participants.  
In terms of types of healthcare utilization descriptors, very few AYA females in our study had 
access to medical aid (16.4%). Similarly, the Institute of Race Relations (IRR) reported in 2017 
that 17.4% of the overall SA population had access to private medical aid programs. AYA 
females in SA face unique and challenging health circumstances, often requiring access to an 
array of health services. Within our cohort, participants reported experiencing physical and 
sexual violence and requiring health services for assault, as well as mental health and addictions 
services. Keeping in mind that an estimated 1 in 9 assaults are reported, this calculates to an 
unacceptable number of women who have experienced assault. The 2016 Demographic and 
Health Survey reports that 1 in 5 women in SA have experienced physical violence. In particular, 
young women (18-24 years) experienced highest rates of violence, with 17% of respondents 
reporting to have been survivors of abuse. The high levels of violence towards women is a major 
public health concern in SA and needs to be considered in SRH services for young women.   
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Knowledge about HPV, Cervical Cancer, and the HPV Vaccine 
Results from this study demonstrated that participants’ awareness about HPV and the HPV 
vaccine was very low, with most AYA stating they had never heard of HPV prior to the study. 
Further to this, most participants did not know that an association existed between HPV, cervical 
cancer and genital warts, they could transmit HPV to their partner if they were asymptomatic, 
and were unsure if HPV caused herpes. The HPV vaccine has been available in SA since 2010, 
however most AYA did not know that a vaccine existed that protected against HPV or HPV 
related cancers, nor were they aware that it was available locally. These findings are consistent 
with previous studies where awareness about these topics were generally low among both AYA 
females and caregivers, particularly in relation to the lack of awareness about HPV and its 
association to cervical cancer (Cunningham et al., 2014; Perlman et al., 2014).  
In contrast, most AYA participants had heard of cervical cancer prior to this study. Several 
factors that were not measured on the survey can be attributed to AYA’s having heard about 
cervical cancer including knowing someone with cervical cancer and the influence of a television 
series. The research assistants for this study reported that participants commonly spoke about 
knowing or hearing about someone or having a family member who had been diagnosed with 
cervical cancer. In addition to the personal effect that cervical cancer had in some of the 
women’s lives, a number of participants also reported that a local popular television series had 
recently featured a character who was diagnosed with cervical cancer with the story line 
including her treatment and recovery. These findings are consistent with communications and 
media being the main source of information about cervical cancer for AYA. Even though 
awareness was low, participants indicated on the post-survey they wanted to learn more about 
HPV as well as have the opportunity to engage in screening and have access to HPV vaccines.       
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Acceptability of the HPV Vaccine: Self  
Acceptability reported for the HPV vaccine among this cohort of female AYA (97%) was 
comparable to previously reported studies about acceptability in an African setting ranging from 
59-100% (Cunningham et al., 2014). With such high acceptability rates, finding associative or 
predictive factors as originally proposed was not feasible. Factors associated with acceptability 
of the HPV vaccine according to Health Belief and Vaccine Hesitancy Models, as well as the 
literature, measured in this study included: knowledge and awareness, beliefs about 
susceptibility, perceptions of HPV vaccine efficacy, family/parental attitudes, HCP influence, 
knowing someone with cervical cancer, and the quality or comprehensiveness of a vaccination 
program (Dubé et al., 2013; Perlman et al., 2014; Turiho et al., 2014).  
A number of studies have shown awareness, risk perception, and vaccine efficacy beliefs to 
be significant factors in the acceptance of the HPV vaccine (Chidyaonga-Maseko et al., 2015; Gu 
et al., 2015; Perlman et al., 2014; Wamai et al., 2012). This was not the case in this study, where 
AYA had very little, if any, awareness about these topics prior to the study and relatively low 
perceptions of risk of acquiring HPV and developing cervical cancer. This finding could be 
attributed to the high rates of cervical cancer seen locally as well as because the information 
about these topics was relayed by trusted health care staff (AYAZAZI team). Efficacy beliefs, 
however, regarding the HPV vaccine were very high among our participants with HCP’s being 
the most common source of information about the vaccine. Opinions and recommendation from 
HCPs in this study played a significant role in participants’ consideration to receive the HPV 
vaccine. A considerable amount of research conducted in LMICs demonstrated similar findings, 
that HCP opinions and recommendation mattered and played an influential role for both AYA 
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and caretakers in making decisions about their health, this included decisions about receiving the 
HPV vaccine (Gallagher et al., 2017; Tsu et al., 2014).  
Finally, knowing someone with cervical cancer was also found to be associated with HPV 
vaccine acceptance (Cunningham et al., 2014). Although this factor was not captured on the 
questionnaire, feedback from the research assistants on this study was that participants regularly 
reported knowing or hearing about someone who had been diagnosed with cervical cancer and/or 
had watched a popular local television series that had recently featured a character with cervical 
cancer. Knowing about cervical cancer was commonly associated with knowing someone who 
had been diagnosed. Additional locale specific factors driving HPV vaccine acceptability in SA 
are the high rates of HIV, sexual violence, and poverty as well as households predominantly led 
by women (Katz et al., 2013).   
In this study, a mentionable number of our AYA reporting to have experienced sexual and/or 
physical violence, low monthly incomes, and predominantly female-headed households. Keeping 
in mind that sexual violence has been found to be highly underreported in SA, rates reported in 
this study should be interpreted with caution. The aforementioned locale specific factors were 
also plausible contributors in the high HPV vaccine acceptance rates found.    
It is important to note that although acceptability rates for the HPV vaccine for this cohort of 
AYA women was very high, with many living with low income and having no access to health 
insurance benefits, access to the vaccine would be very challenging for most participants. In this 
study, cost was found be play a significant role in participants decisions to receive the vaccine, 
with most stating they would receive it if it were free and significantly fewer if the vaccine cost 
current the current local market price of 2300ZAR. Cost as a barrier to the HPV vaccine has also 
been reported as a barrier in a variety of other studies (Cunningham et al., 2014; Harries et al., 
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2009). South Africa is unique in an African context, as it is classified as a middle-income 
country therefore does not qualify for GAVI or other International HPV vaccination 
subsidization programs17. 
With the national roll-out of the HPV vaccine involving only some girls in public education 
schools, this does not include a public health component or free distribution of the vaccine for 
those outside the chosen schools or grades. Cost, therefore, remains a very real issues for AYA 
females in this cohort, as well as in general throughout SA. A mentionable number of 
participants had not yet had sexual intercourse (20%) in this cohort. Similar studies about HPV 
vaccine acceptability have also shown that a number of AYA had not yet engaged in sexual 
activity and therefore were still ideal candidates to receive the HPV vaccine (Dreyer et al., 2015; 
Mugisha et al., 2015). Findings from this study demonstrate favourable acceptability towards the 
HPV vaccine among a population who are at the highest risk of developing HPV related cancers 
and unable to afford the vaccine. This study outlines the urgent need to expand the national HPV 
vaccine program in SA, in particular to include AYA who have not yet been exposed to HPV.      
Acceptability of HPV Vaccine: Children 
Parents and caretakers are critical decision-makers in health care decision-making processes, 
this is particularly the case for the HPV vaccine as it is recommended to be administered 
between 9-12 years. Participants in this study reported having highly favourable attitudes about 
the HPV vaccine, with most (95%) stating they would have their children or future children 
vaccinated against HPV. All participants who were currently mothers (N=34) or pregnant (N=17) 
said they would have their children vaccinated against HPV, if it were available to them. Due to 
high acceptance rates, no factors could be determined to be associated with HPV vaccine 
acceptance. Research conducted in similar settings demonstrated caretaker HPV vaccine 
                                                          
17 https://www.gavi.org/support/sustainability/countries-eligible-for-support/ 
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acceptance for their daughters between 44-96%. The most common reasons for caregivers 
(predominantly female) to refuse the HPV vaccine for their daughters included, fears about 
vaccine efficacy and safety, low education and awareness about HPV and its association to 
cervical cancer and the high cost of the vaccine  (Mouallif et al., 2014; Perkins et al., 2011; 
Vincente et al., 2015; Zhang et al., 2013). 
Efficacy beliefs about the HPV vaccine were high among participants in this study, however 
awareness about HPV and cervical cancer were very low as was perceived risk for acquiring 
HPV and developing cervical cancer. It is also important to note that AYA reported living in 
predominantly female headed households (69%), this is a higher proportion than the reported 
national average of 41.36% of households headed by women in the ‘Living Conditions of 
Household Survey 2015’ (Statistics South Africa, 2017). These findings outline the important 
role and central influence that mothers and grandmothers play in the lives of young women. As 
outlined in the previous section, cost was also an important factor in HPV vaccine acceptability 
with most participants in the study reporting not be able to afford to purchase the vaccine. With 
the national roll-out of the HPV vaccine involving only select schools, there is a chance that 
participants’ children attend or will attend a participating school. Now that participants have 
information about HPV and its connection to cervical cancer from this study, there is the hope 
that this will influence their decisions about HPV vaccination for their children in the future.   
Acceptability of HPV Self-Sample Testing 
In a wide variety of settings, HPV self-sample testing has been demonstrated to not only be 
highly efficacious, but also an acceptable alternative to cytology-based screening (Farmer et al., 
2010; Mustafa et al., 2016). This is particularly the case in areas with challenging access to 
health and screening services such as SA (Phiri et al., 2016; Tsu et al., 2014). In this study, 
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participants were highly favourable towards collecting a sample by themselves if given 
directions, with most women reporting to feel most comfortable taking the sample at the clinic 
rather than in their homes. Diffidence and feelings of embarrassment among women was also a 
theme found in the literature about self-collection (Mitchell et al., 2011; Sievers & White, 2016). 
This may partially explain why women in this study said they would prefer to collect the sample 
in a clinic setting, to ensure proper collection techniques and privacy that they may not otherwise 
have in their homes.   
A variety of sociodemographic and behavioural variables have been found to influence testing 
acceptance, therefore tests were run to examine associations, but no variables were found to be 
significantly associated with acceptance. Similar to HPV vaccine acceptance, knowledge and 
awareness was the most significant predictor in the literature found to be associated with 
women’s participation in cervical cancer screening services (Bukirwa et al., 2015; Chidyaonga-
Maseko et al., 2015). Despite AYA participants in this study reporting to have very little 
awareness about these topics, most still reported to be HPV self-sample acceptant with a few 
stating they were unsure. Self-sample acceptability rates in this study are comparable to those 
found in the literature among women living in similar low-resource settings (Moses et al., 2015; 
Ogilvie et al., 2013). Again, the high level of acceptance towards self-sample testing could be 
associated with the level of trust established prior within this AYAZAZI cohort with staff and 
HCPs.   
Finally, all WHIV in this study reported to be self-sample acceptant, which is also consistent 
with the literature about the success of integrating cervical cancer prevention tools, such as HPV 
self-collection, with existing HIV health services (Adamson, Huchko, Moss, Kinkel, & Medina-
Marino, 2015; Mahomed et al., 2014; Mitchell et al., 2017; Moses et al., 2015). This is an 
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extremely important target population for cervical cancer screening, as WHIV generally present 
with cervical cancer and pre-cancer approximately a decade earlier than HIV negative women, 
quite often beginning to present in their late twenties (Denny et al., 2012). The high acceptance 
of vaginal self-sample testing, particularly among WHIV, shows that an excellent opportunity 
exists to integrate cervical cancer prevention services into existing primary care structures.  
Sexual and Reproductive Health Information Sources 
Both questionnaire data and post-questionnaire survey results demonstrated that AYA relied 
heavily on the knowledge they received about SRH, in particular contraceptives, from the 
AYAZAZI team. Youth engagement approaches for health interventions or health research 
projects have proven to be a successful way to involve youth and ensure retention as well as 
adherence to the intervention or health research projects (Powers & Tiffany, 2006; Wood et al., 
2014). Involving those who are most affected by the issue being studied is key to successful 
outcomes. AYA participants in our study reported to be highly trusting of AYAZAZI staff for 
STI testing and health information needs and expressed feeling valued, listened to, and well 
informed by the research study staff.     
Most AYA females in this study had heard about cervical cancer most commonly from the 
internet, television, and radio. As previously discussed, many participants related to the 
researchers that they had become aware of cervical cancer from a local television series popular 
among young people. Health care professionals were also very influential sources of information 
for AYA about cervical cancer, screening, and although most participants had not heard about 
the HPV or the vaccine prior to the study, if they had, HCPs were the most common source of 
information. When all SRH topics were combined, the most influential information source in this 
study overall was HCPs. These findings are consistent with other studies about HPV vaccine and 
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cervical cancer screening acceptance in LMIC’s, where HCPs are noted to play an instrumental 
role in education and health decision making for women, this was particularly the case for 
sensitization campaigns prior to the administration of the vaccine (Chidyaonga-Maseko et al., 
2015; Gallagher et al., 2017; Perlman et al., 2014).  
A multigenerational approach to cervical cancer prevention efforts within this population 
could also be advantageous. A range of studies in similar settings indicate the important role that 
both mothers and grandmothers play in the health care decision-making process (Francis et al., 
2011; Perlman et al., 2014). Cervical cancer prevention programs combining pubescent 
vaccination with screening for older women (caregivers) have been found to be somewhat 
successful (Dreyer et al., 2015; Snyman, Dreyer, Botha, van der Merwe, et al., 2015). Richter 
(2015), an HPV specialist in SA, calls these types of multigenerational programs “crucial” (p.3) 
to decreasing HPV related cancers nationally, as both HPV vaccines and screening are needed 
synergistically to effectively decrease cervical cancer rates. These approaches would need to be 
combined, as they will not be effective for all populations. This is also why effective community 
engagement strategies are critical to better understand what a community needs prior to 
education campaigns and the rolling out of any health program, particularly for vaccines.   
Perceptions of Risk  
This study demonstrated that AYA women had fairly low perceptions of risk for acquiring 
HIV, HPV, and developing cervical cancer. However, participants rated other women in their 
community to be at a significantly higher risk than themselves in all three domains. Our findings 
about AYA females having low perceptions of risk acquiring STI’s is consistent with the 
literature about AYA in similar settings (Maughan-Brown & Venkataramani, 2018; Sychareun, 
Thomsen, Chaleunvong, & Faxelid, 2013). Sociodemographic and behavioural variables were 
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tested to explore associations between high- and low-risk perceptions groups and yielded nothing 
reportable. This lack of significance between the two groups could be attributable to the small 
sample size. Despite participants’ perceptions of risk being generally low, most still reported 
wanting to participate in HPV self-sample testing and receive the HPV vaccine. Perceptions of 
risk did not appear to play a role in health behaviour decision-making for our cohort of women, 
as hypothesized at the onset of this study. However, the low risk perception may cause AYA to 
engage in high-risk behaviours which are likely to endanger their sexual and reproductive health.  
Summary 
The vast inequities in cervical cancer outcomes between women from LMICs and HICs 
demonstrates the need for innovative, creative, and regional appropriate efforts in global cancer 
control. Cervical cancer is a preventable global health concern. South Africa and, in particular, 
KZN with the highly dense population of female adolescents and young adults in combination 
with the extremely high rates of HIV and cervical cancer demonstrate the urgent need for 
research to better understand acceptability of primary and secondary prevention efforts among 
this population. With young women at a significant risk of acquiring HIV and HPV infections, it 
is a pivotal time in global cervical cancer prevention. HPV vaccine uptake rates remain 
despairingly low in SA. 
Participants in this study represented those highest at-risk for acquiring HPV and developing 
cervical cancer: AYA females in childrearing age and WHIV. Sexual health behaviours reported 
by participants are alarming and similar to those reported nationally. Although high rates of 
acceptability were found for the HPV vaccine for self and (future) children as well as HPV self-
sample collection, no variables originally proposed were found to be associated with 
acceptability. Findings from this study also outline the important role that HCP’s, trusted 
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interventions such as AYAZAZI, and female caretakers play as sources for SRH information and 
in guiding health decision making. Cervical cancer prevention approaches that use a 
multigenerational approach have been found to improve screening and vaccine uptake, 
particularly among women who would not have otherwise participated in these prevention 
efforts. This study outlines the urgent need to expand the HPV vaccination program to a wider 
variety of ages, particularly for those who have not yet been exposed to HPV, enhance HPV self-
sample testing for WHIV as it is highly acceptable, and design interventions that help to increase 
adolescents’ perceived risks. Several important implications of this study follow. 
Recommendations  
Expansion of the HPV Vaccine Program – Investing in Primary Prevention 
Expanding the HPV vaccine program in SA is an ethically and fiscally responsible next move 
in addressing the cervical cancer epidemic. Cervical cancer is eminently preventable and utilizes 
a considerable amount of health resources. The HPV vaccine is the most cost effective, safe, and 
efficacious prevention tool with promising outcomes and the only vaccine available worldwide 
shown to prevent cancers, however in SA uptake (due to lack of availability) remains 
despairingly low. In an area of the world with the highest deaths associated with cervical cancer, 
it is imperative the government consider expanding the existing national HPV vaccine program. 
The reality is that 70% of the population will need to be vaccinated to see an effect within the 
population, or ‘herd immunity’(Brisson et al., 2016). SA is far away from achieving this goal 
currently, with a current roll-out plan involving select schools and covering only a small 
percentage of eligible females. 
The significantly influential role of HCPs in AYA’s consideration to receive the HPV vaccine 
in this study is a very important finding. Due to the fact that the HPV vaccine is still fairly new 
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in SA, the recommendations from HCPs will be pivotal in encouraging women to receive that 
vaccine. It is therefore important that HCP’s are first well educated about the HPV vaccine and 
able to relay appropriate information to patients. Evidence overwhelmingly demonstrates the 
need to include a wider range of ages eligible to receive the HPV vaccine and particularly 
targeting: WHIV or those most vulnerable to acquire HIV (low SES, education, areas with high 
rates of gender-based violence), AYA who are pre-coitus and have therefore not yet acquired 
HPV, and AYA of childbearing age. All groups have demonstrated to be highly acceptant of the 
HPV vaccine (in theory and actual uptake). AYA females in these populations face number of 
contextual barriers to accessing the HPV vaccine for themselves and their children. Sadly, the 
reality is that the HPV vaccine is not accessible for most SA women, largely due to the high cost 
locally and challenging access to health care services in general and very few women have 
access to medical aid for vaccine benefits. 
Expansion of the HPV vaccine program in SA will require a concerted political commitment 
and allocated resources, both of which are challenging in a country with competing health 
priorities (HIV/AIDS & tuberculosis), and high levels of poverty and inequality. Cervical cancer 
prevention should not be viewed as separate from HIV/AIDS care, as the two are inextricably 
linked. As a result of national efforts to diagnose HIV and improve the uptake and adherence of 
ART medications, women are living longer and therefore are at a greater risk for developing 
cervical cancer (Ghebre, Grover, Xu, Chuang, & Simonds, 2017). In addition to the reduction of 
cervical cancer, the HPV vaccination also offers a chance to provide other SRH services targeted 
by AYA, such as HIV prevention efforts. The alarming cervical cancer rates, particularly among 
young women and often mothers, in SA calls for the government to prioritize and strengthen 
cervical cancer primary prevention efforts. We have the tool to protect girls from suffering 
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needlessly and dying from an entirely preventable disease. It is pivotal time in cervical cancer 
prevention and the global health community needs to help mobilize appropriate resources. 
Self-Sample Testing Options – Investing in Secondary Prevention 
Given the current climate in SA, investing in screening options for cervical cancer is also 
imperative. While the HPV vaccine is currently a primary prevention method for cervical cancer, 
the impact of the vaccine will not be seen for another 2-3 decades, nor does it cover those who 
are already infected with HPV. HPV vaccine coverage is still so low in SA that effects on the 
population will be minimal for quite some time. For these reasons, secondary prevention must be 
strengthened and women, particularly those most vulnerable, must be given options on how they 
would prefer to participate in screening. Currently the predominantly used screening method in 
SA is the Pap test, which is resource intensive and difficult to access for women with low follow-
up rates. Vaginal self-sample testing has proven to be an effective and acceptable alternative for 
women who are vulnerable due to histories of violence, feel embarrassed, have limited access to 
HCP’s and health services, and want to play a more active role in managing their health 
(Mitchell et al., 2017; Racey et al., 2013).  
 Similar to the HPV vaccine, improving secondary prevention or screening programs will take 
considerable investment from the government. An additional issue is that currently SA does not 
have an active cancer registry or reporting system and careful tracking and monitoring will be a 
key first step to addressing the cervical cancer epidemic. Nationally, all female residents are 
eligible to receive three Pap tests per lifetime beginning at 30 years of age however, 1) many 
women don’t know they are eligible for these tests, 2) WHIV require screening at a much earlier 
age than HIV negative women, 3) few women have access to screening due to financial and 
geographical constraints, and 4) a pelvic exam (Pap test) is a highly invasive procedure and often 
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one performed by a male HCP. There are a plethora of reasons for the low uptake of Pap testing 
in SA, however it is clear that new innovative, acceptable, effective, and more affordable testing 
option exists and needs to be explored as a screening option at a national level.   
HPV self-sample testing is a breakthrough in self-care and provides access to lifesaving 
testing for women in low-resource areas and investment in this type of testing will not only 
reduce costs to both women and the health system, but also save the lives of millions of women 
who are already infected with HPV. This study adds to the already comprehensive literature 
demonstrating highly favourable acceptance towards HPV self-sample testing among 
populations who are most vulnerable. Evidence also overwhelmingly shows how community- 
and youth-engagement approaches and integrating HPV services into existing SRH programs can 
be a highly successful and help to influence positive health behaviours, this is particularly the 
case among AYA as they are highly influential (Huchko, Maloba, Nakalembe, & Cohen, 2015; 
Phiri et al., 2016; Powers & Tiffany, 2006; Tsu et al., 2014). Investment into the expansion of 
both primary and secondary cervical cancer prevention efforts are required to address this global 
health crisis. Local and international financial investment and political commitment is paramount 
in the expansion of HPV prevention health services for SA women.     
Education about HPV: Investing in a Multigenerational Approach 
Findings from this study reinforce the urgent need for appropriate education about HPV and 
its association to cervical cancer while recognizing the key role that female caregivers play in the 
lives of young women. It’s important to recognize that AYA have special SRH needs that often 
remain unmet, commonly due to lack of knowledge, social stigma, and judgmental attitudes 
among service providers (Abdullahi et al., 2014; Bukirwa et al., 2015; Katz et al., 2013). HCPs 
are also highly trusted sources for information and recommendations and play an important role 
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in women’s decisions to participate in HPV vaccines and screening and SRH decisions in 
general. Awareness campaigns need to be culturally and age appropriate, engage multiples 
generations of women, as well as involve well informed HCPs and health team members who are 
non-judgemental and interested in developing positive relationships with women to help 
empower them to take ownership over their SRH.  
A challenge will be creating a campaign that addresses the needs of the local community. In 
some cases, this may mean outlining the benefits of the HPV vaccine using cancer prevention 
messaging, as opposed to STI focused messaging. Raising awareness and normalizing HPV will 
to help to change the conversation about HPV and reduce the social stigma attached to it. 
Mothers and grandmothers are highly influential in the younger generations’ health care 
decision-making and are an equally important group of women needing to be targeted for 
screening. Young women need support from their families and communities and access to 
nonjudgmental SRH services in order to make responsible choices and have safe and healthy 
sexual experiences.  
Individual barriers to engaging in HPV vaccines and testing is largely associated with a lack 
of awareness and knowledge about risk factors and prevention cervical cancer. Despite this study 
showing no association between awareness and acceptability, it is important to remember that 
our participants do not necessarily represent the general population of women in SA, as they 
have already had extensive (12+months) of engagement in a SRH research study and as a result 
had higher levels of trust with information they were receiving. A significant investment needs to 
be towards developing awareness programs and education materials that are locally and 
appropriately designed prior to the scale-up of HPV vaccine and testing programs.  
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The next chapter is a summary of the study. Study limitations and recommendations for 
further research are also presented. 
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Chapter 6: Conclusion 
Study Questions and Methods 
This study explored the knowledge and awareness about HPV, cervical cancer, and the HPV 
vaccine as well as acceptability of HPV vaccine and self-sample testing among a highly 
vulnerable population of female AYA living in the epicentre of the HIV crisis, Durban, SA. 
There was a special focus on finding determinants related to awareness, acceptability, and risk 
perception for participants and to assess the most influential sources of SRH information. The 
research method involved RA’s administering surveys to a cohort of female AYA involved in a 
longitudinal research study examining risk factors involved with HIV acquisition among AYA. 
A total of 122 AYA females participated in the study and quantitative analysis was performed 
after merging the data set with select variables from the 12-month AYAZAZI survey.       
Key Findings 
Findings from this study are important in designing effective cervical cancer control programs 
that can attract more AYA for HPV vaccines and screening. This study contributes to the field of 
cervical cancer prevention research by providing three main themes including, 1) awareness and 
knowledge about HPV and the vaccine were generally poor, 2) encouragingly high rates of 
acceptability towards the HPV vaccine and self-sample testing, and 3) key sources of SRH 
information and influences. The results indicate that awareness and knowledge about topics were 
generally low, as were perceptions of risk, and no personal and contextual factors played a role 
in the acceptability of either HPV vaccine or self-sample testing for AYA.  
The most influential sources SRH was HCPs, communication/media, and family/friends. 
AYAZAZI was most influential in teaching AYA about contraceptives. Professionals played a 
significant role in women’s considerations to receive the vaccine compared to friends/family. 
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Affordability was also rated as a significant factor in AYA’s decisions to receive the vaccine. 
Recommendation sources for and affordability of the HPV vaccine mattered to women. 
Awareness about HPV or it association to cervical cancer, as well as the HPV vaccine were very 
low among women in this study. In fact, most women had never heard about HPV or the vaccine 
prior to the study.  All mother and pregnant women stated they would have their child receive the 
HPV vaccine.  
In general, risk perception for acquiring HPV, HIV, and developing cervical cancer was low 
among participants compared to how they perceived risk levels for other women in their 
communities. This factor did not, however, play a role in women’s acceptance of the HPV 
vaccine or self-sample testing. HPV vaccine efficacy beliefs were rated high by participants. 
There were no significant associations found in relation to perceived risk level of acquiring HPV 
or developing cervical cancer. Similarly, no factors were found to be associated with 
participants’ willingness to participate in HPV self-sample collection.  
Anecdotally and feedback surveys indicated that AYA wanted to know more about HPV, be 
involved in cervical cancer prevention related studies and access to HPV vaccines and testing. It 
was clear from that this study mattered to participants and AYAZAZI was a safe space for AYA 
to receive information, receive STI testing and counselling, and have the opportunity to access 
non-judgemental HCPs and services.  
The population of AYA in this study were not overly representative of the general AYA 
population in SA, largely due to the fact that many were attending or had access to education as 
well were living in formal housing. The fact that the female AYA had built trusting relationships 
with HCPs and the AYAZAZI research team also put them at an advantage in comparison to 
many other AYA in SA for access to SRH services and health education, both of which could 
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have played a critical role in the acceptability of the HPV vaccine and self-sample testing. 
Ensuring AYA have access to appropriate health education in a setting where they feel 
welcomed, valued, and listened to, despite their education or income level, will play a pivotal 
role in SRH decision making.      
Limitations 
The results from this study may not be generalized to all contexts or all SA women, since 
women in this study were mostly from an urban setting and participants were predominantly 
Zulu. Limitations to this study also include the small sample size. The information provided by 
participants may have been under-reported, particularly concerning personal details such as 
sexual health behaviours or experiences with violence, due to being uncomfortable in sharing 
sensitive information. This may have been minimized because participants had long term and 
trusting relationship with the research assistants on the AYAZAZI team who were asking these 
sensitive questions. However, being a survivor of assault is a sensitive topic that many young 
women, even if they trust someone, may be difficult to discuss due to factors such as the 
consequences of disclosure or fear of repercussions. Finally, a factor that emerged from 
anecdotal discussion with research assistants was the role that knowing someone with cervical 
cancer had on participants’ acceptability of prevention options and risk perception however 
unfortunately this was not captured in the questionnaire.  
Recommendations for Future Research 
Based on findings from this study, recommendations for future research include: 
 Expansion of the current project to include a larger and more geographically diverse 
sample of AYA females to explore predictors of actual HPV vaccine uptake and SRH 
testing preferences; 
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 Interventions aimed at educating the general public as well as key populations about 
HPV, cervical cancer, and the HPV vaccine that are locally developed and culturally as 
well as age appropriate; 
 Increased involvement of AYA in projects relating to SRH services and needs; 
 Better understanding how to create and implement multigenerational cervical cancer 
prevention projects; 
 Modelling studies assessing HPV vaccine and testing expansion using a cost-benefit lens.     
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Appendix A: MEDLINE (OVID) Literature Review Search Strategy 
 
Steps Key Search Terms Articles 
Yielded 
1 Immunization/  
2 Immunization Schedule/  
3 Immunization, Secondary/  
4 Immunotherapy, Active/  
5 Mass Immunization/  
6 Immunization Programs/  
7 Vaccination/  
8 or/1-7 14,3349 
9 Papillomavirus Infections/  
10 (human papilloma* or HPV).tiab.  
11 or/9-10 44,066 
12 8 AND 11 3281 
13 Papillomavirus vaccines/  
14 12 OR 13 7133 
15 exp Young Adult/  
16 Adolescent/  
17 Women/  
18 Men/  
19 or/15-18 2,186,170 
20 14 AND 19 3371 
21 (human papilloma* or HPV) adj ((vaccinat* or revaccinat* or 
immunization or immunisation) adj3 (“adolescent”[MeSH 
Terms] OR 
“young adult”[MeSH Terms] OR “women”[MeSH Terms] OR 
“men”[MeSH Terms] OR “child”[MeSH Terms] OR child OR 
children OR boy OR boys 
OR girl OR girls OR adult OR men OR male OR female OR 
women OR teenager OR adolescent OR adolescence)).ti,ab. 
 
22 ((human papilloma* or HPV) adj (immunization or 
immunisation or vaccination) adj (program* or rate* or coverage 
or adher* or uptak*)).ti. 
 
23 20 or 21 or 22 7137 
24 Developing Countries.sh,kf.  
25 (Africa or Asia or Caribbean or West Indies or South America or 
Latin America or Central America).hw,kf,ti,ab,cp. 
 
26 (Afghanistan or Albania or Algeria or Angola or Antigua or 
Barbuda or Argentina or Armenia or Armenian or Aruba or 
Azerbaijan or Bahrain or Bangladesh or Barbados or Benin or 
Byelarus or Byelorussian or Belarus or Belorussian or Belorussia 
or Belize or Bhutan or Bolivia or Bosnia or Herzegovina or 
Hercegovina or Botswana or Brazil or Brasil or Bulgaria or 
 
 143 
 
Burkina Faso or Burkina Fasso or Upper Volta or Burundi or 
Urundi or Cambodia or Khmer Republic or Kampuchea or 
Cameroon or Cameroons or Cameron or Camerons or Cape 
Verde or Central African Republic or Chad or Chile or China or 
Colombia or Comoros or Comoro Islands or Comores or 
Mayotte or Congo or Zaire or Costa Rica or Cote d'Ivoire or 
Ivory Coast or Croatia or Cuba or Cyprus or Czechoslovakia or 
Czech Republic or Slovakia or Slovak Republic or Djibouti or 
French Somaliland or Dominica or Dominican Republic or East 
Timor or East Timur or Timor Leste or Ecuador or Egypt or El 
Salvador or Eritrea or Estonia or Ethiopia or Fiji or Gabon or 
Gabonese Republic or Gambia or Gaza or Georgia Republic or 
Georgian Republic or Ghana or Gold Coast or Greece or 
Grenada or Guatemala or Guinea or Guam or Guiana or Guyana 
or Haiti or Honduras or Hungary or India or Maldives or 
Indonesia or Iran or Iraq or Isle of Man or Jamaica or Jordan or 
Kazakhstan or Kazakh or Kenya or Kiribati or Korea or Kosovo 
or Kyrgyzstan or Kirghizia or Kyrgyz Republic or Kirghiz or 
Kirgizstan or Lao PDR or Laos or Latvia or Lebanon or Lesotho 
or Basutoland or Liberia or Libya or Lithuania or Macedonia or 
Madagascar or Malagasy Republic or Malaysia or Malaya or 
Malay or Sabah or Sarawak or Malawi or Nyasaland or Mali or 
Malta or Marshall Islands or Mauritania or Mauritius or Agalega 
Islands or Mexico or Micronesia or Middle East or Moldova or 
Moldovia or Moldovian or Mongolia or Montenegro or Morocco 
or Ifni or Mozambique or Myanmar or Myanma or Burma or 
Namibia or Nepal or Netherlands Antilles or New Caledonia or 
Nicaragua or Niger or Nigeria or Northern Mariana Islands or 
Oman or Muscat or Pakistan or Palau or Palestine or Panama or 
Paraguay or Peru or Philippines or Philipines or Phillipines or 
Phillippines or Poland or Portugal or Puerto Rico or Romania or 
Rumania or Roumania or Russia or Russian or Rwanda or 
Ruanda or Saint Kitts or St Kitts or Nevis or Saint Lucia or St 
Lucia or Saint Vincent or St Vincent or Grenadines or Samoa or 
Samoan Islands or Navigator Island or Navigator Islands or Sao 
Tome or Saudi Arabia or Senegal or Serbia or Montenegro or 
Seychelles or Sierra Leone or Slovenia or Sri Lanka or Ceylon or 
Solomon Islands or Somalia or Sudanor or South Africa or 
Suriname or Surinam or Swaziland or Syria or Tajikistan or 
Tadzhikistan or Tadjikistan or Tadzhik or Tanzania or Thailand 
or Togo or Togolese Republic or Tonga or Trinidad or Tobago or 
Tunisia or Turkey or Turkmenistan or Turkmen or Uganda or 
Ukraine or Uruguay or USSR or Soviet Union or Union of 
Soviet Socialist Republics or Uzbekistan or Uzbek or Vanuatu or 
New Hebrides or Venezuela or Vietnam or Viet Nam or West 
Bank or Yemen or Yugoslavia or Zambia or Zimbabwe or 
Rhodesia).hw,kf,ti,ab,cp. 
27 ((developing or less* developed or under developed or 
underdeveloped or middle income or low* income or 
underserved or deprived or poor*) adj (countr* or nation? or 
population? or world)).ti,ab. 
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28 ((developing or less* developed or under developed or 
underdeveloped or middle income or low* income) adj 
(economy or economies)).ti,ab. 
 
29 (low* adj (gdp or gnp or gross domestic or gross national)).ti,ab.  
30 (low adj3 middle adj3 countr*).ti,ab.  
31 (lmic or lmics or third world or lami countr*).ti,ab.  
32 transitional countr*.ti,ab.  
33 or/24-32 3,300,152 
34 23 and 33 647 
35 decision making/ or choice behaviour/  
36 patient acceptance of health care/  
37 health promotion/  
38 Patient Education as Topic/  
39 Health Education/  
40 school health services/  
41 (human papilloma* or HPV) adj ((vaccinat* or revaccinat* or 
immunization or immunisation) adj2 ( prevent* OR protect* OR 
“public health” OR educat* OR program* OR train* OR 
support* OR project*) 
 
42 or/35-41 326, 803 
43 34 AND 42 198 
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Appendix B: Search Strategy Flow Diagram 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Database searched: MEDLINE (OVID) 
Total number of articles (n=198) 
Number of articles following review of 
full articles (n=58) 
Excluded Articles  
Articles about Parental Acceptance 
of HPV Vaccine (N=28) 
Articles about AYA HPV Vaccine 
Acceptance and Awareness (N=17) 
Articles about HPV Vaccine Uptake 
(N=11) 
All articles excluded following review of 
abstracts for relevancy to research 
questions & search criteria (N=140) 
Review articles (N=2)  
Articles whose full text were not in 
English (N=7) 
Articles with male participants (N=19) 
Participants with age range of M=24+ 
years (N=39) 
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Appendix C: Consent Form 
 
AYAZAZI: Investigating Patterns of behavioural and biomedical risk for HIV acquisition and vaccine trial 
preparedness among adolescents and young adults in a priority setting 
 
INFORMED Consent form for Participants 18 years and older 
This study is funded by: The Canadian HIV Vaccine Initiative (CHVI), in collaboration with the Canadian Institutes of 
Health Research. 
 
The doctor in charge: Prof. Glenda Gray (Perinatal HIV Research Unit) 
Site Telephone Number: 011 989 9752 
 
To the potential Participant: This informed consent form may contain words that you do not understand. Please ask the study 
staff to explain them or re-phrase words or phrases to help you understand the information. We encourage you to take home an 
unsigned copy of this consent form to think about or discuss with family or friends before making your decision. 
 
Introduction 
Hello, my name is……………………………………..…; I am part of a research team from the Perinatal HIV Research 
Unit (PHRU) at the University of the Witwatersrand doing a study, called AYAZAZI, in partnership with Simon Fraser 
University in Canada to understand HIV risk among South African adolescents and young adults and to find ways to 
improve participation of young people in HIV vaccine research studies in South Africa. 
 
We would like to invite you to take part in this research study. The study will take place at the PHRU, Chris Hani 
Baragwanath Academic Hospital, Soweto and you are invited to participate in this study because you live in this 
community and are between the ages of 16-24 years. 
 
VOLUNTARY PARTICIPATION AND/OR WITHDRAWAL 
This consent form provides information about the study procedures and allows you the opportunity to decide if you 
are interested or not interested in taking part in this study. Before you agree to take part, you should understand this 
information. Please ask the study staff to explain any sections that are unclear to you and answer any questions you 
may have. If you agree to take part in this study, we will ask you to sign this consent form and you will get a copy to 
keep. Your participation is entirely voluntary. You may decide not to participate or withdraw from the study at any 
time. Thank you for taking time to hear about our research. 
BACKGROUND 
HIV risk among adolescents and young adults remains high and is likely influenced by various social, behavioural, 
historical/cultural and biological factors. However, a lack of research that links social, behavioural and clinical data, 
particularly in a priority setting and for populations most likely to be at risk of HIV, have hampered efforts to identify 
these factors in detail. 
PURPOSE OF THE STUDY 
The purpose of this study is to assess socio-behavioural and biological factors that may affect HIV risk among 
adolescents and young adults in South Africa. This study will continue for a period of 6 years for each participant and 
will include visits every 6 months for the duration of the 6 years. The data collected from this study will be used to try 
and understand:  
Social and behavioural factors that place young people at risk of acquiring HIV 
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Sexually acquired infections and/or biological processes that increase the risk of acquiring HIV in young people 
Ways to improve participation of young people in HIV vaccine research studies 
 
STUDY PROCEDURES 
This study will enrol up to 400 adolescents and young adults from Soweto that are both HIV-positive and HIV-
negative and follow them over 6 years. If you agree to participate in this study, you will be asked to come into the 
AYAZAZI clinic at PHRU every 6-months to fill out a questionnaire, undergo a physical exam to screen for sexually 
transmitted infections and provide biological samples. The first visit will consist of the following activities: 
First you will be asked to fill out a demographic form with your contact information (cell phone number or telephone 
number) in order for study staff to contact you throughout the study. 
Next you will be asked to complete an online social and behavioral questionnaire that will include questions about 
your demographics (e.g., age, education, where you live), lifestyle (e.g. drug-use), reproductive health, mental health, 
sexual health and orientation, thoughts around HIV vaccine research and use of health care and social services. The 
questionnaire will take place in a private room at the AYAZAZI clinic and will take approximately 60 to 90 minutes to 
complete. During this time a trained study staff member will be present to answer any questions you may have about 
the wording or content in the questionnaire. Data from the questionnaire will be captured on a secure/password 
protected online database that does not contain any personal identifying information such as your name. Only people 
involved in this research will have access to the database. You are not required to answer any questions that may 
make you feel uncomfortable, and you are welcome to skip questions or stop at any time. 
Following completion of the questionnaire, a project nurse will take you into a private examining room and ask you to 
fill out a medical history form. The nurse will then perform a short visual exam of your genitals to look for symptoms 
of sexually transmitted infections and collect a biological sample to test for the following sexually transmitted 
infections: Chlamydia trachomatis, Trichomonas vaginalis, Neisseria gonorrhoeae, and Mycoplasma genitalium. 
Females will also be tested for Bacterial Vaginosis and Yeast infection. For females collecting a biological sample will 
consist of gently swabbing the inner wall of the vagina and for males this will consist of a urine sample. Additionally, 
the nurse will draw a sample of your blood (approximately 50 ml or 5 tubes or 12 1/2 teaspoons). Both genital swabs 
and urine samples will be transported to protocol approved laboratories laboratory where trained laboratory staff will 
test for HIV/sexually transmitted infections.  The collected blood samples will be used for testing to explore biological 
factors that may put young people at risk of infection with HIV and other diseases. These tests will also be done at 
protocol approved laboratories. If you agree, the nurse will also perform a rapid, on-site HIV test (for HIV-negative 
participants) and a pregnancy test (for female participants). Pre-test counselling will be provided before the rapid HIV 
test is performed and post-test counselling will be provided after the results are available. Counselling will cover the 
meaning of a positive or negative HIV and/or sexually transmitted infection test result, methods for preventing HIV 
and/or sexually transmitted infections for yourself and others, referral in the event of a positive test and treatment 
information for HIV and/or STIs. Again you are not required to take part in any tests that make you feel 
uncomfortable, and you are welcome to ask the nurse to stop at any time. 
After your first visit, appointments for follow-up visits will be scheduled for every 6 months. During follow-up visits you 
will again be asked to fill out a questionnaire, undergo a physical exam to screen for symptoms of sexually 
transmitted infections and provide biological samples for laboratory testing. Laboratory results for HIV tests and/or 
tests for sexually transmitted infections will be made available to you within two weeks after your visit at the AYAZAZI 
clinic. Throughout the duration of the study you will be assigned a unique study ID that will be used to collect test 
results. This will ensure that personal identifying information such as your name will not be linked to your results. 
Only the nurse who examined you and collected your samples will know your results. Again you will be provided with 
voluntary counseling when receiving your laboratory test results. Over the duration of the study you will also be asked 
to keep your contact information up-to-date so study staff can keep in contact with you about your next visit. 
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GENETIC TESTING USING BLOOD SAMPLES 
Biological testing using your blood samples may also involve genetic testing. This part of the study is entirely 
voluntary and if you agree to participate in this part of the study, it will be explained to you and you will be required to 
sign a separate consent form. 
BENEFITS TO PARTICIPATING IN THIS STUDY 
This study may not benefit you directly. However, your participation and the information learned may help explain the 
socio-behavioural and biological factors that put young people at risk of HIV and ways to improve participation of 
young people in HIV vaccine research studies. 
RISKS OR DISCOMFORTS ASSOCIATED WITH PARTICIPATING IN THIS STUDY 
There are very few risks associated with participating in this study. However, some participants have reported 
stigmatization as a result of being in a research study. Family or friends may worry about you or get upset that you 
have agreed to participate. They may assume that if you are participating in this study that you have been infected 
with HIV and stigmatize you. If this happens to you, we can discuss the situation and how best to handle it moving 
forward.  
You may also find some of the questions that we ask in the questionnaire are personal and make you feel 
uncomfortable or embarrassed. You are not required to answer any questions that make you feel uncomfortable, and 
you are welcome to skip questions or stop the questionnaire at any time. Additionally, you may feel uncomfortable or 
nervous during the physical examination and biological sample collection. This will involve exposing your genitals to a 
medical professional and drawing blood, which may make you feel awkward. The risks of drawing blood may also 
include feeling dizzy, being sore or having a bruise or swelling at the site where blood is drawn. Again you are not 
required to take part in any procedures that make you feel uncomfortable and may stop at any time. Lastly, you may 
feel nervous or scared waiting for results from HIV/STI laboratory tests. If you are feeling this way, please tell us. The 
study staff and nurses are always here to help make you feel more comfortable and discuss any concerns you have 
about the study or procedures at any time. We will additionally have a trained counsellor/social worker available if 
you need any further support. 
RESEARCH RELATED INJURIES 
If you are injured as a result of participation in this study, the study clinic will give you immediate access to necessary 
treatment and the cost of this treatment will not be charged to you. You will then be told where you may receive 
additional treatment for these injuries. 
ALTERNATIVES TO PARTICIPATING IN THIS STUDY 
The alternative to participating in this study is not to participate. If you choose not to participate in this study, you will 
still be offered free Voluntary Counselling and Testing at the AYAZAZI clinic. Your decision will have no impact on 
your health care at this or other facilities. 
COSTS AND COMPENSATION 
There are no financial costs to you or your family for taking part in this research study. To compensate you for your 
time, you will receive R150.00 for each scheduled visit that you attend. The payment for scheduled visits is to cover 
the cost for transport, refreshments and possibly some of the time spent in the clinic. 
STATEMENT OF CONFIDENTIALITY 
All information collected during this study will be kept strictly confidential. To protect your personal identity, all 
information you share will be identified using a unique study ID. Your name and other personal information will not 
appear on the questionnaire, on laboratory test results or in any publications or reports produced by this study. You 
will also use your unique ID number when you go to collect your laboratory test results. Only authorized research 
personnel will have access to all study materials over the course of the study. 
NEW FINDINGS 
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The study staff will share with you any new research findings that may develop while you are participating in this 
study.  
RIGHT TO DECLINE/WITHDRAW FROM THIS STUDY 
Your participation in this research study is completely voluntary. Even if you decide to participate now, you have the 
right to withdraw from this research study at any time. Your decision to participate or withdraw from this study will 
have no impact on your access to services at PHRU’s clinics or other health care facilities. 
WHAT HAPPENS IF YOU DECIDE TO DISCONTINUE PARTICIPATION 
If you decide to withdraw early from the study you have a right to choose whether you want your questionnaire 
information and biological samples to be kept or destroyed. Your decision to stop taking part in this study will not 
have any negative consequences. 
WHO TO CONTACT IF YOU HAVE QUESTIONS OR PROBLEMS 
If you have any questions, comments, or concerns about participation in this study, feel free to talk to the study staff 
or contact any of the investigators listed below. We are here to support you. 
Contacts for questions or problems: Throughout the duration of the study, if you do not understand something that is 
being done or have any questions please do not hesitate to contact one of the following: 
Prof. Glenda Gray, Principal Investigator, PHRU, Soweto, South Africa; Telephone: (011) 989-9703 
Dr. Janan Dietrich, Co-investigator, PHRU, Soweto, South Africa; Telephone: (011) 989-9757 
Contacts at Simon Fraser University: If you have any additional questions, comments, or concerns about this 
research you may contact our collaborators in at the Simon Fraser University in Canada: 
Prof. Mark Brockman, Principal Investigator, Simon Fraser University, Burnaby, Canada; Telephone: (+1) 778-782-
3341; Email: mark_brockman@sfu.ca 
Dr. Angela Kaida, Co-investigator, Simon Fraser University, Burnaby, Canada; Telephone: (+1) 778-782-9068; 
Email: angela_kaida@sfu.ca 
Dr. Jeffrey Toward, Director, Office of Research Ethics, Simone Fraser University; Telephone: (+1) 778-782-6593; 
Email: jtoward@sfu.ca 
 
Who can I call for Information about my Rights? 
This clinical study protocol has been submitted to the University of the Witwatersrand Human Research Ethics 
Committee (Wits HREC - Medical) and written approval has been granted by that committee.  The study has been 
structured in accordance with the Declaration of Helsinki (last updated: October 2013) which deals with the 
recommendations guiding doctors in biomedical research involving human participants.  A copy may be obtained 
from me should you wish to review it. 
If you want any information regarding your rights as a research participant, or have complaints regarding this 
research study, you may contact: 
Johannesburg: 
Prof. Cleaton-Jones, Chairperson 
The University of the Witwatersrand 
Human Research Ethics Committee 
Telephone number:  (011) 717 2301 
This independent committee is established to help protect the rights of research participants and gave written 
approval for the study protocol. 
SIGNATURE PAGE 
I have read this informed consent form and understand that signing this form means that: 
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I have had the opportunity to ask questions and all my questions have been answered to my satisfaction. 
I have been given sufficient time to consider the above information regarding the purpose of this study, the 
procedures as well as the possible benefits and risks. 
I can withdraw from this study at any point should I not want to continue and this decision will have no negative 
consequences for me. 
 
I have not waivered any of my human rights. 
I have voluntarily made an informed decision to participate in this study without being forced to do so in any way. 
 
          
Participant’s Name and Surname 
(Print) 
 
 
 
 Participant’s Signature  Date  Time 
 
          
Clinic Staff conducting consent 
discussion Name and Surname 
(Print)  
 
Clinic Staff Signature 
 
Date 
(dd/mmm/yyyy)  
Time 
 
*For individuals who are unable to read or write, also complete the signature block below: 
 
          
Witness’ Name and Surname 
(Print)  
 Witness’ Signature  Date  Time 
*Witness is impartial and was present for the consent process. 
As part of this study we will be doing a number of smaller research studies. Would it be okay for staff from AYAZAZI 
to contact you in the future about these sub-studies? 
Yes  
No 
Don’t know 
Prefer not to answer 
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Appendix D: Adolescent Assent Form 
 
AYAZAZI: Investigating Patterns of behavioural and biomedical risk for HIV acquisition and vaccine trial 
preparedness among adolescents and young adults in a priority setting  
Adolescent assent form 
This study is funded by: The Canadian HIV Vaccine Initiative (CHVI), in collaboration with the Canadian Institutes of 
Health Research. 
 
The doctor in charge: Prof Glenda Gray (Perinatal HIV Research Unit) 
Site Telephone Number: 011 989 9752 
 
To the potential Participant: This assent form may contain words that you do not understand. Please ask the study staff to 
explain them or re-phrase words or phrases to help you understand the information. We encourage you to take home an 
unsigned copy of this assent form to think about or discuss with family or friends before making your decision. 
Introduction 
Hello, my name is……………………………………..…; I am part of a research team from the Perinatal HIV Research 
Unit (PHRU) at the University of the Witwatersrand doing a study, called AYAZAZI, in partnership with Simon Fraser 
University in Canada to understand HIV risk among South African adolescents and young adults and to find ways to 
improve participation of young people in HIV vaccine research studies in South Africa. 
We would like to invite you to take part in this research study. The study will take place at the PHRU, Chris Hani 
Baragwanath Academic Hospital, Soweto and you are invited to participate in this study because you live in this 
community and are between the ages of 16-24 years. 
 
VOLUNTARY PARTICIPATION AND/OR WITHDRAWAL 
This is an assent form and provides information about the study procedures and allows you the opportunity to decide 
if you are interested or not interested in taking part in this study. Before you agree to take part, you should 
understand this information. Please ask the study staff to explain any sections that are unclear to you and answer 
any questions you may have. If you agree to take part in this study, we will ask you to sign this assent form and you 
will get a copy to keep. Your participation is entirely voluntary. You may decide not to participate or withdraw from the 
study at any time. Because you are younger than 18 years, we will also need your parent/legal guardian to give 
permission for you to take part in this study until you are 18 years and sign a separate consent form.  Both you and 
your parent/legal guardian need to be in agreement in order for you to be enrolled in this study. Thank you for taking 
time to hear about our research. 
BACKGROUND 
HIV risk among adolescents and young adults (AYA) remains high and is likely influenced by various social, 
behavioural, historical/cultural, and biological factors. However, a lack of research that links social, behavioural and 
clinical data, particularly in a priority setting and for populations most likely to be at risk of HIV, have hampered efforts 
to identify these factors in detail. 
PURPOSE OF THE STUDY 
The purpose of this study is to assess socio-behavioural and biological factors that may affect HIV risk among 
adolescents and young adults in South Africa. This study will continue for a period of 6 years for each participant and 
will include visits every 6 months for the duration of the 6 years. The data collected from this study will be used to try 
and understand:  
Social and behavioural factors that place young people at risk of acquiring HIV 
Sexually acquired infections and/or biological processes that increase the risk of acquiring HIV in young people 
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Ways to improve participation of young people in HIV vaccine research studies 
 
STUDY PROCEDURES 
This study will enrol up to 400 adolescents and young adults from Soweto that are both HIV-positive and HIV-
negative and follow them over 6 years. If you agree to participate in this study, you will be asked to come into the 
AYAZAZI clinic at PHRU every 6-months to fill out a questionnaire, undergo a physical exam to screen for sexually 
transmitted infections and provide biological samples.  The first visit will consist of the following activities: 
First you will be asked to fill out a demographic form with your contact information (cell phone number or telephone 
number) in order for study staff to contact you throughout the study. 
Next you will be asked to complete an online social and behavioral questionnaire that will include questions about 
your demographics (e.g., age, education, where you live), lifestyle (e.g. drug-use), reproductive health, mental health, 
sexual health and orientation, thoughts around HIV vaccine research and use of health care and social services. The 
questionnaire will take place in a private room at the AYAZAZI clinic and will take approximately 60 to 90 minutes to 
complete. During this time a trained study staff member will be present to answer any questions you may have about 
the wording or content in the questionnaire. Data from the questionnaire will be captured on a secure/password 
protected online database that does not contain any personal identifying information such as your name. Only people 
involved in this research will have access to the database. You are not required to answer any questions that may 
make you feel uncomfortable, and you are welcome to skip questions or stop at any time. 
Following completion of the questionnaire, a project nurse will take you into a private examining room and ask you to 
fill out a medical history form. The nurse will then perform a short visual exam of your genitals to look for symptoms 
of sexually transmitted infections and collect a biological sample to test for the following sexually transmitted 
infections: Chlamydia trachomatis, Trichomonas vaginalis, Neisseria gonorrhoeae, and Mycoplasma genitalium. 
Females will also be tested for Bacterial Vaginosis and Yeast infection. For females collecting a biological sample will 
consist of gently swabbing the inner wall of the vagina and for males this will consist of a urine sample. Additionally, 
the nurse will draw a sample of your blood (approximately 50 ml, or 5 tubes, which is 12 1/2 teaspoons). Both genital 
swabs and urine samples will be transported to protocol approved laboratories where trained laboratory staff will test 
for HIV/sexually transmitted infections. The collected blood samples will be used for testing to explore biological 
factors that may put young people at risk of infection with HIV and other diseases. These tests will also be done at 
protocol approved laboratories. If you agree, the nurse will also perform a rapid, on-site HIV test (for HIV-negative 
participants) and a pregnancy test (for female participants). Pre-test counselling will be provided before the rapid HIV 
test is performed and post-test counselling will be provided after the results are available. Counselling will cover the 
meaning of a positive or negative HIV and/or sexually transmitted infection test result, methods for preventing HIV 
and/or sexually transmitted infections for yourself and others, referral in the event of a positive test and treatment 
information for HIV and/or sexually transmitted infections. Again you are not required to take part in any tests that 
make you feel uncomfortable, and you are welcome to ask the nurse to stop at any time. 
After your first visit, appointments for follow-up visits will be scheduled for every 6 months. During follow-up visits you 
will again be asked to fill out a questionnaire, undergo a physical exam to screen for symptoms of sexually 
transmitted infections and provide biological samples for laboratory testing. Laboratory results for HIV tests and/or 
tests for sexually transmitted infections will be made available to you within two weeks after your visit at the AYAZAZI 
clinic. Throughout the duration of the study you will be assigned a unique study ID that will be used to collect test 
results. This will ensure that personal identifying information such as your name will not be linked to your results. 
Only the nurse who examined you and collected your samples will know your results. Again you will be provided with 
voluntary counseling when receiving your laboratory test results. Over the duration of the study you will also be asked 
to keep your contact information up-to-date so study staff can keep in contact with you about your next visit. 
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GENETIC TESTING USING BLOOD SAMPLES 
Biological testing using your blood samples may also involve genetic testing. This part of the study is entirely 
voluntary and if you agree to participate in this part of the study, it will be explained to you and you will be required to 
sign a separate assent form. 
BENEFITS TO PARTICIPATING IN THIS STUDY 
This study may not benefit you directly. However, your participation and the information learned may help explain the 
socio-behavioural and biological factors that put young people at risk of HIV and ways to improve participation of 
young people in HIV vaccine research studies. 
RISKS OR DISCOMFORTS ASSOCIATED WITH PARTICIPATING IN THIS STUDY 
There are very few risks associated with participating in this study. However, some participants have reported 
stigmatization as a result of being in a research study. Family or friends may worry about you or get upset that you 
have agreed to participate. They may assume that if you are participating in this study that you have been infected 
with HIV and stigmatize you. If this happens to you, we can discuss the situation and how best to handle it moving 
forward.  
You may also find some of the questions that we ask in the questionnaire are personal and make you feel 
uncomfortable or embarrassed. You are not required to answer any questions that make you feel uncomfortable, and 
you are welcome to skip questions or stop the questionnaire at any time. Additionally, you may feel uncomfortable or 
nervous during the physical examination and biological sample collection. This will involve exposing your genitals to a 
medical professional and drawing blood, which may make you feel awkward. The risks of drawing blood may also 
include feeling dizzy, being sore or having a bruise or swelling at the site where blood is drawn. Again you are not 
required to take part in any procedures that make you feel uncomfortable and may stop at any time. Lastly, you may 
feel nervous or scared waiting for results from HIV/sexually transmitted infection laboratory tests. If you are feeling 
this way, please tell us. The study staff and nurses are always here to help make you feel more comfortable and 
discuss any concerns you have about the study or procedures at any time. We will additionally have a trained 
counsellor/social worker available if you need any further support. 
RESEARCH RELATED INJURIES 
If you are injured as a result of participation in this study, the study clinic will give you immediate access to necessary 
treatment and the cost of this treatment will not be charged to you. You will then be told where you may receive 
additional treatment for these injuries. 
ALTERNATIVES TO PARTICIPATING IN THIS STUDY 
The alternative to participating in this study is not to participate. If you choose not to participate in this study, you will 
still be offered free Voluntary Counselling and Testing at the AYAZAZI clinic. Your decision will have no impact on 
your health care at this or other facilities. 
COSTS AND COMPENSATION 
There are no financial costs to you or your family for taking part in this research study. To compensate you for your 
time, you will receive R150.00 for each scheduled visit that you attend. The payment for scheduled visits is to cover 
the cost for transport, refreshments and possibly some of the time spent in the clinic. 
 
STATEMENT OF CONFIDENTIALITY 
All information collected during this study will be kept strictly confidential. To protect your personal identity, all 
information you share will be identified using a unique study ID. Your name and other personal information will not 
appear on the questionnaire, on laboratory test results or in any publications or reports produced by this study. You 
will also use your unique ID number when you go to collect your laboratory test results. Only authorized research 
personnel will have access to all study materials over the course of the study. 
We will keep the information listed below, private and will not share this information with your parents/legal guardian:  
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Your attitudes towards sexual behaviour and reasons for staying in the study. 
Your answers to questions in the questionnaire, including questions about sexual behaviour and whether you are 
having sex. 
The results of laboratory sexually transmitted infection/HIV tests and treatments that you receive over the duration of 
the study. 
The results of pregnancy tests that you receive over the duration of the study (females). 
However, to protect you from harm, we will ask you to tell a trusted adult (not necessarily your parents/legal 
guardian) if you test positive for HIV or an sexually transmitted infection or if you become pregnant (females). The 
study staff are here to provide you with support and counsel you in the event that these situations arise. Additionally, 
the law requires us to tell authorities if you are being sexually or physically abused. The law also requires us to report 
sexual offenses like rape. The authorities can help you get out of that situation. We will tell you if we are going to 
inform the authorities about any situations. In all cases the study staff are there to provide you with support and help. 
We also encourage you to talk to your parents/legal guardian so that they can help you deal with these situations. 
 
NEW FINDINGS 
The study staff will share with you any new research findings that may develop while you are participating in this 
study.  
 
RIGHT TO DECLINE/WITHDRAW FROM THIS STUDY 
Your participation in this research study is completely voluntary. Even if you decide to participate now, you have the 
right to withdraw from this research study at any time. Your decision to participate or withdraw from this study will 
have no impact on your access to services at PHRU’s clinics or other health care facilities. 
 
RE-CONSENTING AT AGE 18 
Because you are younger than 18 years, we also need your parent/legal guardian to give permission for you to take 
part in this study and sign a separate consent form; however, when you reach 18 years of age you no longer need 
your parent/legal guardian to give permission for you to participate. At that time we will ask you to sign a separate 
consent form and you will have the opportunity to decide if you are still interested or not interested in continuing to 
participate in this study as an adult. 
WHAT HAPPENS IF YOU DECIDE TO DISCONTINUE PARTICIPATION 
If you decide to withdraw early from the study you have a right to choose whether you want your questionnaire 
information and biological samples to be kept or destroyed. Your decision to stop taking part in this study will not 
have any negative consequences. 
 
WHO TO CONTACT IF YOU HAVE QUESTIONS OR PROBLEMS 
If you have any questions, comments, or concerns about participation in this study, feel free to talk to the study staff 
or contact any of the investigators listed below. We are here to support you. 
Contacts for questions or problems: Throughout the duration of the study, if you do not understand something that is 
being done or have any questions please do not hesitate to contact one of the following: 
Prof. Glenda Gray, Principal Investigator, PHRU, Soweto, South Africa; Telephone: (011) 989-9703 
Dr. Janan Dietrich, Co-investigator, PHRU, Soweto, South Africa; Telephone: (011) 989-9757 
Contacts at Simon Fraser University: If you have any additional questions, comments, or concerns about this 
research you may contact our collaborators in at the Simon Fraser University in Canada: 
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Prof. Mark Brockman, Principal Investigator, Simon Fraser University, Burnaby, Canada; Telephone: (+1) 778-782-
3341; Email: mark_brockman@sfu.ca 
Dr. Angela Kaida, Co-investigator, Simon Fraser University, Burnaby, Canada; Telephone: (+1) 778-782-9068; 
Email: angela_kaida@sfu.ca 
Dr. Jeffrey Toward, Director, Office of Research Ethics, Simone Fraser University; Telephone: (+1) 778-782-6593; 
Email: jtoward@sfu.ca 
 
Who can I call for Information about my Rights? 
This clinical study protocol has been submitted to the University of the Witwatersrand Human Research Ethics 
Committee (Wits HREC - Medical) and written approval has been granted by that committee.  The study has been 
structured in accordance with the Declaration of Helsinki (last updated: October 2013) which deals with the 
recommendations guiding doctors in biomedical research involving human participants.  A copy may be obtained 
from me should you wish to review it. 
If you want any information regarding your rights as a research participant, or have complaints regarding this 
research study, you may contact: 
Johannesburg: 
Prof. Cleaton-Jones, Chairperson 
The University of the Witwatersrand 
Human Research Ethics Committee 
Telephone number:  (011) 717 2301 
 
This independent committee is established to help protect the rights of research participants and gave written 
approval for the study protocol. 
SIGNATURE PAGE: ASSENT FOR PARTICIPATION 
I have read this assent form and understand that signing this form means that: 
I have had the opportunity to ask questions and all my questions have been answered to my satisfaction. 
I have been given sufficient time to consider the above information regarding the purpose of this study, the 
procedures as well as the possible benefits and risks. 
I can withdraw from this study at any point should I not want to continue and this decision will have no negative 
consequences for me. 
I have not waivered any of my human rights. 
I have voluntarily made an informed decision to participate in this study without being forced to do so in any way. 
          
Participant’s Name and Surname 
(Print) 
 
 Participant’s Signature  Date  Time 
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Clinic Staff conducting assent 
discussion Name and Surname 
(Print)  
 
Clinic Staff Signature 
 
Date 
(dd/mmm/yyyy)  
Time 
*For individuals who are unable to read or write, also complete the signature block below: 
 
          
Witness’ Name and Surname 
(Print)  
 Witness’ Signature  Date  Time 
# Witness is impartial and was present for the assent process. 
As part of this study we will be doing a number of smaller research studies. Would it be okay for staff from AYAZAZI 
to contact you in the future about these sub-studies? 
Yes  
No 
Don’t know 
Prefer not to answer 
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Appendix E: Parental Consent Form 
 
AYAZAZI: Investigating Patterns of behavioural and biomedical risk for HIV acquisition and vaccine trial 
preparedness among adolescents and young adults in a priority setting  
Parent/ Legal guardian Informed consent form 
This study is funded by: The Canadian HIV Vaccine Initiative (CHVI), in collaboration with the Canadian Institutes of 
Health Research 
The doctor in charge: Prof. Glenda Gray (Perinatal HIV Research Unit) 
Site Telephone Number: 011 989 9752 
To the Parent/ Legal Guardian: This informed consent form may contain words that you do not understand. Please contact/ask 
the study staff to explain them or re-phrase words or phrases to help you understand the information. We encourage you to think 
about or discuss this form with family or friends before making your decision. 
INTRODUCTION 
Hello, my name is……………………………….……; I am part of a research team from the Perinatal HIV Research 
Unit (PHRU) at the University of the Witwatersrand doing a study, called AYAZAZI, in partnership with Simon Fraser 
University in Canada to understand HIV risk among South African adolescents and young adults and to find ways to 
improve participation of young people in HIV vaccine research studies in South Africa. 
We would like to invite your child to take part in this research study. The study will take place at the PHRU, Chris 
Hani Baragwanath Academic Hospital, Soweto and your child is invited to participate in this study because he/she 
lives in this community and is between the ages of 16-24 years. You have been given this consent form because 
your child is younger than 18 years and as a parent/legal guardian your permission is required for your child to 
participate. 
VOLUNTARY PARTICIPATION AND/OR WITHDRAWAL 
This consent form provides information about the study procedures and allows you the opportunity to decide if you 
are interested or not interested in consenting to your child’s participation in this study. Before you agree to allow your 
child to take part, you should understand this information. Please ask the study staff to explain any sections that are 
unclear to you and answer any questions you may have. If you agree to your child’s participation in this study, we will 
ask you to sign this consent form and you will get a copy to keep. Your child’s participation is entirely voluntary. Your 
child may decide not to participate or withdraw from the study at any time. Because your child is younger than 18 
years of age we will need your consent along with their assent in order for him/her to take part in this study until 
he/she is 18 years old. Both you and your child need to be in agreement in order for him/her to be enrolled in this 
study. Thank you for taking time to hear about our research. 
BACKGROUND 
HIV risk among adolescents and young adults (AYA) remains high and is likely influenced by various social, 
behavioural, historical/cultural and biological factors. However, a lack of research that links social, behavioural and 
clinical data, particularly in a priority setting and for populations most likely to be at risk for HIV, have hampered 
efforts to identify these factors in detail. 
PURPOSE OF THE STUDY 
The purpose of this study is to assess socio-behavioural and biological factors that may affect HIV risk among 
adolescents and young adults in South Africa. This study will continue for a period of 6 years for each participant and 
will include visits every 6 months for the duration of the 6 years. The data collected from this study will be used to try 
and understand:  
Social and behavioural factors that place young people at risk of acquiring HIV 
Sexually acquired infections and/or biological processes that increase the risk of acquiring HIV in young people 
Ways to improve participation of young people in HIV vaccine research studies 
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STUDY PROCEDURES 
This study will enrol up to 400 adolescents and young adults from Soweto that are both HIV-positive and HIV-
negative and follow them over 6 years. If you agree to your child’s participation in this study, he/she will be asked to 
come into the AYAZAZI clinic at PHRU every 6-months to fill out a questionnaire, undergo a physical exam to screen 
for sexually transmitted infections and provide biological samples.  The first visit will consist of the following activities: 
First, your child will be asked to fill out a demographic form with their contact information (cell phone number or 
telephone number) in order for study staff to contact him/her throughout the study. 
Next your child will be asked to complete an online social and behavioral questionnaire that will include questions 
about your child’s demographics (e.g., age, education, where he/she lives), lifestyle (e.g. drug-use), reproductive 
health, mental health, sexual health and orientation, thoughts around HIV vaccine research and use of health care 
and social services. The questionnaire will take place in a private room at the AYAZAZI clinic and will take 
approximately 60 to 90 minutes to complete. During this time, a trained study staff member will be present to answer 
any questions your child may have about the wording or content in the questionnaire. Data from the questionnaire will 
be captured on a secure/password protected online database that does not contain any personal identifying 
information such as your child’s name. Only people involved in this research will have access to the database. Your 
child is not required to answer any questions that may make him/her feel uncomfortable, and he/she is welcome to 
skip questions or stop at any time. 
Following completion of the questionnaire, a project nurse will take your child into a private examining room and ask 
him/her to fill out a medical history form. The nurse will then perform a short visual exam of your child’s genitals to 
look for symptoms of sexually transmitted infections and collect a biological sample to test for the following sexually 
transmitted infections: Chlamydia trachomatis, Trichomonas vaginalis, Neisseria gonorrhoeae, and Mycoplasma 
genitalium. Females will also be tested for Bacterial Vaginosis and Yeast infection. For females collecting a biological 
sample will consist of gently swabbing the inner wall of the vagina and for males this will consist of a urine sample. 
Additionally, the nurse will draw a sample of your child’s blood (approximately 50 ml or 5 tubes or 12 1/2 teaspoons). 
Both genital swabs and urine samples will be transported to protocol approved laboratories where trained laboratory 
staff will test for HIV/sexually transmitted infections. The collected blood samples will be used for testing to explore 
biological factors that may put young people at risk of infection with HIV and other diseases. These tests will also be 
done at protocol approved laboratories. If your child agrees, the nurse will also perform a rapid, on-site HIV test (for 
HIV-negative participants) and a pregnancy test (for female participants). Pre-test counselling will be provided before 
the rapid HIV test is performed and post-test counselling will be provided after the results are available. Counselling 
will cover the meaning of a positive or negative HIV and/or sexually transmitted infection test result, methods for 
preventing HIV and/or sexually transmitted infections for your child and others, referral in the event of a positive test 
and treatment information for hiv and/or sexually transmitted infections. Again your child is not required to take part in 
any tests that make him/her feel uncomfortable, and your child is welcome to ask the nurse to stop at any time. 
After your child’s first visit, appointments for follow-up visits will be scheduled for every 6 months. During follow-up 
visits your child will again be asked to fill out a questionnaire, undergo a physical exam to screen for symptoms of 
sexually transmitted infections and provide biological samples for laboratory testing. Laboratory results for 
HIV/sexually transmitted infections tests will be made available to your child at the AYAZAZI clinic within two weeks 
after his/her visit. Throughout the duration of the study your child will be assigned a unique study ID that he/she will 
use to collect test results. This will ensure that personal identifying information such as your child’s name will not be 
linked to their test results. Only the nurse who examined your child and collected your child’s samples will know 
his/her results. Again your child will be provided with voluntary counseling when receiving his/her laboratory test 
results. Over the duration of the study your child will also be asked to keep their contact information up-to-date so 
that study staff can keep in contact about their next visit. 
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GENETIC TESTING USING BLOOD SAMPLES 
Biological testing using your blood samples may also involve genetic testing. This part of the study is entirely 
voluntary and if you and your child agree to participate in this part of the study, it will be explained to you and you will 
be required to sign a separate consent form. 
BENEFITS TO PARTICIPATING IN THIS STUDY 
This study may not benefit your child directly. However, your child’s participation and the information learned may 
help explain the socio-behavioral and biological factors that put young people at risk of HIV and ways to improve 
participation of young people in HIV vaccine research studies. 
RISKS OR DISCOMFORTS ASSOCIATED WITH PARTICIPATING IN THIS STUDY 
There are very few risks associated with participating in this study. However, some participants have reported 
stigmatization as a result of being in a research study. Family or friends may worry about your child or get upset that 
they have agreed to participate. They may assume that if your child is participating in this study that they have been 
infected with HIV and stigmatize them. If this happens to your child, we can discuss the situation and how best to 
handle it moving forward.  
Your child may also find some of the questions that we ask in the questionnaire are personal and make him/her feel 
uncomfortable or embarrassed. Your child is not required to answer any questions that make him/her feel 
uncomfortable, and he/she is welcome to skip questions or stop the questionnaire at any time. Additionally, your child 
may feel uncomfortable or nervous during the physical examination and biological sample collection. This will involve 
exposing your child’s genitals to a medical professional and drawing blood, which may make your child feel awkward. 
The risks of drawing blood may also include feeling dizzy, being sore or having a bruise or swelling at the site where 
blood is drawn. Again your child is not required to take part in any procedures that make him/her feel uncomfortable 
and may stop at any time. lastly, your child may feel nervous or scared waiting for results from HIV/sexually 
transmitted infection laboratory tests. If your child is feeling this way, please tell us. The study staff and nurses are 
always there to help make your child feel more comfortable and discuss any concerns he/she has about the study or 
procedures at any time. We will additionally have a trained counsellor/social worker available if your child needs any 
further support. 
RESEARCH RELATED INJURIES 
If your child is injured as a result of participation in this study, the study clinic will give him/her immediate access to 
necessary treatment and the cost of this treatment will not be charged to you. Your child will then be told where 
he/she may receive additional treatment for these injuries. 
ALTERNATIVES TO PARTICIPATING IN THIS STUDY 
The alternative to consenting to your child’s participation in this study is not to consent to their participation. If you 
choose not to consent to your child’s participation in this study, your child will still be offered free Voluntary 
Counselling and Testing  at the AYAZAZI clinic. Your decision will have no impact on your child’s health care at this 
or other facilities. 
COSTS AND COMPENSATION 
There are no financial costs to you or your family for taking part in this research study. To compensate your child for 
their time, he/she will receive R150.00 for each scheduled visit that he/she attends. The payment for scheduled visits 
is to cover the cost for transport, refreshments and possibly some of the time spent in the clinic. 
STATEMENT OF CONFIDENTIALITY 
All information collected during this study will be kept strictly confidential. To protect your child’s personal identity, all 
information he/she shares will be identified using a unique study ID. Your child’s name and other personal 
information will not appear on the questionnaire, on laboratory test results or in any publications or reports produced 
by this study. Your child will also use his/her unique ID number when he/she goes to collect his/her laboratory test 
results. Only authorized research personnel will have access to all study materials over the course of the study. 
We will keep the information listed below, private and will not share this information with you: 
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Your child’s attitudes towards sexual behaviour and reasons for staying in the study. 
Your child’s answers to questions in the questionnaire, including questions about sexual behaviour and whether your 
child is having sex. 
The results of laboratory sexually transmitted infection/HIV tests and treatments that your child receives over the 
duration of the study. 
The results of pregnancy tests that your child receives over the duration of the study (females). 
However, to protect your child from harm, we will encourage him/her to tell a trusted adult (not necessarily yourself) if 
he/she tests positive for hiv or an sexually transmitted infection or if she becomes pregnant (females). The study staff 
are there to provide your child with support and counsel your child in the event that these situations arise. 
Additionally, the law requires us to tell authorities if your child is being sexually or physically abused. The law also 
requires us to report sexual offenses like rape. The authorities can help your child get out of that situation. We will tell 
your child if we are going to inform the authorities about any situations. In all cases the study staff are there to 
provide your child with support and help. We will also encourage your child to talk to you so that you can help them 
deal with these situations. 
NEW FINDINGS 
The study staff will share with you and your child any new research findings that may develop while your child is 
participating in this study.  
 
RIGHT TO DECLINE/WITHDRAW FROM THIS STUDY 
Your child’s participation in this research study is completely voluntary. Even if he/she decides to participate now, 
he/she has the right to withdraw from this research study at any time. Your decision to consent to your child’s 
participation or your child’s decision to withdrawal from this study will have no impact on his/her access to services at 
PHRU’s clinics or other health care facilities. 
RE-CONSENTING AT AGE 18 
Because your child is younger than 18 years of age we also need your consent along with their assent in order for 
him/her to take part in this study, however, when your child reaches 18 years of age he/she no longer needs your 
permission to participate. At that time we will ask your child to sign a separate consent form and he/she will have the 
opportunity to decided if he/she is ll interested or not interested in continuing to participate in this study as an adult. 
WHAT HAPPENS IF YOUR CHILD DECIDES TO DISCONTINUE PARTICIPATION 
If your child decides to withdraw early from the study he/she has a right to choose whether he/she wants his/her 
questionnaire information and biological samples to be kept or destroyed. Your child’s decision to stop taking part in 
this study will not have any negative consequences. 
WHO TO CONTACT IF YOU HAVE QUESTIONS OR PROBLEMS 
If you have any questions, comments, or concerns about participation in this study, feel free to talk to the study staff 
or contact any of the investigators listed below. We are here to support you. 
Contacts for questions or problems: Throughout the duration of the study, if you do not understand something that is 
being done or have any questions please do not hesitate to contact one of the following: 
Dr. Glenda Gray, Principal Investigator, PHRU, Soweto, South Africa; Telephone: (011) 989-9703 
Dr Janan Dietrich, Co-investigator, PHRU, Soweto, South Africa; Telephone: (011) 989-9757 
Contacts at Simon Fraser University: If you have any additional questions, comments, or concerns about this 
research you may contact our collaborators in at the Simon Fraser University in Canada: 
Prof. Mark Brockman, Principal Investigator, Simon Fraser University, Burnaby, Canada; Telephone: (+1) 778-782-
3341; Email: mark_brockman@sfu.ca 
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Dr. Angela Kaida, Co-investigator, Simon Fraser University, Burnaby, Canada; Telephone: (+1) 778-782-9068; 
Email: angela_kaida@sfu.ca 
Dr. Jeffrey Toward, Director, Office of Research Ethics, Simone Fraser University; Telephone: (+1) 778-782-6593; 
Email: jtoward@sfu.ca 
Who can I call for Information about my Rights? 
This clinical study protocol has been submitted to the University of the Witwatersrand Human Research Ethics 
Committee (Wits HREC - Medical) and written approval has been granted by that committee.  The study has been 
structured in accordance with the Declaration of Helsinki (last updated: October 2013) which deals with the 
recommendations guiding doctors in biomedical research involving human participants.  A copy may be obtained 
from me should you wish to review it. 
If you want any information regarding your rights as a research participant, or have complaints regarding this 
research study, you may contact: 
Johannesburg: 
Prof. Cleaton-Jones, Chairperson 
The University of the Witwatersrand 
Human Research Ethics Committee 
Telephone number:  (011) 717 2301 
This independent committee is established to help protect the rights of research participants and gave written 
approval for the study protocol. 
SIGNATURE PAGE 
I have read and understood the participant information sheet and I hereby agree and I understand that: 
My child is participating freely and without being forced in any way to do so.  
I have had the opportunity to ask questions and all my questions have been answered to my satisfaction. 
I have been given sufficient time to consider the above information regarding the purpose of this study, the 
procedures as well as the possible benefits and risks. 
My child can withdraw from this study at any point should he/she not want to continue and this decision will have no 
negative consequences for me/my child. 
I can withdraw my child from this study at any point should I not want to continue and this decision will have no 
negative consequences for me/my child. 
I have not waivered any of my human rights. 
I have voluntarily made an informed decision to allow my child to participate in this study without being forced to do 
so in any way. 
______________________________________________________________________ 
Participant’s Name and Surname (Print) 
          
Parent/Legal Guardian’s Name 
and Surname (Print) 
 Parent/Legal Guardian’s 
Signature 
 Date  Time 
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Clinic Staff conducting consent 
discussion Name and 
Surname(Print)  
 
Clinic Staff Signature 
 
Date 
(dd/mmm/yyyy)  
Time 
*For individuals who are unable to read or write, also complete the signature block below: 
 
          
Witness’ Name and Surname 
(Print)  
 Witness’ Signature  Date  Time 
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Appendix F: Research Ethics Board Approval 
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Appendix G: Study Questionnaire 
 
Section 13: HPV & Cervical Cancer Awareness (All AYA Women) 
Q1. Have you heard of the Human Papillomavirus or HPV?  
 Yes →  Skip to S13-Q2 
 No →  Skip to S13-Q3 
 Don’t know 
 Prefer not to answer 
 
Q2. Where did you hear about HPV? Allow participant to respond without reading options. (Check all that apply): 
 Mother 
 Father 
 Aunt 
 Sibling 
 Grandmother 
 Boyfriend/partner 
 School 
 Doctor or nurse 
 Counsellor 
 Online/Internet 
 TV 
 Other (specify): _______________________ 
 Don’t Know 
 Prefer not to answer 
 
Q3. Have you heard of cervical cancer?  
 Yes →  Skip to S13-Q4 
 No  →  Skip to S13-Q5 
 Don't know  
 Prefer not to answer 
 
Q4. Where did you hear about Cervical Cancer? Allow participant to respond without reading options.  
(Check all that apply): 
 Mother 
 Father 
 Aunt 
 Sibling 
 Grandmother 
 Boyfriend/partner 
 School 
 Doctor or nurse 
 Counsellor 
 Online/Internet 
 TV 
 Other (specify): _______________________ 
 Don’t Know 
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 Prefer not to answer 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Q5. Awareness about HPV Agree Disagree Don’t Know 
i. HPV can cause herpes       
ii. Genital warts are caused by HPV       
iii. HPV can cause cervical cancer       
iv. Many people with HPV have no visible signs or symptoms       
v. I can transmit HPV to my partner even if I do not have symptoms       
vi. Having one type of HPV means that you cannot acquire new types       
vii. A vaccine exists to prevent HPV infections and cervical cancer       
viii. The HPV vaccine is approved and available in South Africa       
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HPV is short for human papillomavirus. HPV is a group of more than 150 viruses. HPV can cause genital 
warts and some HPVs can lead to cancer, particularly cervical cancer. There are more than 40 HPV types 
that can infect the genital areas of males and females. You can get HPV by having vaginal, anal, or oral 
sex with someone who has the virus. HPV is a very common sexually transmitted infection (STI). Anyone 
who is sexually active can get HPV, even if you have had sex with only one person. HPV is so common 
that nearly all sexually active men and women get it at some point in their lives. HPV can be passed even 
when an infected person has no signs or symptoms. You can develop symptoms years after you have sex 
with someone who is infected, making it hard to know when you first became infected. 
 
Q6. How much at risk do you think you are of becoming infected with HPV?  
 Not at all at risk of becoming infected with HPV 
 Low risk 
 Medium risk 
 High risk 
 Don’t know 
 Prefer not to answer 
 
Q7. How much at risk do you think other young women in your community are of becoming infected with 
HPV? 
 Not at all at risk of becoming infected with HPV 
 Low risk 
 Medium risk 
 High risk 
 Don’t know 
 Prefer not to answer 
 
Q8. How much at risk do you think you are of developing cervical cancer?  
 Not at all at risk of developing cervical cancer 
 Low risk 
 Medium risk 
 High risk 
 Don’t know 
 Prefer not to answer 
 
Q9. How much at risk do you think other young women in your community are of developing cervical 
cancer? 
 Not at all at risk of developing cervical cancer 
 Low risk 
 Medium risk 
 High risk 
 Don’t know 
 Prefer not to answer 
 
Q10. How much of a negative impact would having an HPV infection have on you and your life?  
 No impact at all 
 Low impact 
 Medium impact 
 High impact 
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 Don’t know 
 Prefer not to answer 
 
Q11. How much of a negative impact would having cervical cancer have on you and your life? 
 No impact at all 
 Low impact 
 Medium impact 
 High impact 
 Don’t know 
 Prefer not to answer 
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Section 14: Vaccine Awareness & Willingness 
Q12. Have you heard of the HPV or cervical cancer vaccine?  
 Yes →  Skip to S14-Q13 
 No  →  Skip to S14-Q14 
 Don't know  
 Prefer not to answer 
 
Q13. Where did you hear about HPV or cervical cancer vaccine?  
Allow participant to respond without reading options. (Check all that apply): 
 Mother 
 Father 
 Aunt 
 Sibling 
 Grandmother 
 Boyfriend/partner 
 School 
 Doctor or nurse 
 Counsellor 
 Online/Internet 
 TV 
 Other (specify): _______________________ 
 Don’t Know 
 Prefer not to answer 
 
Q14. How likely do you think the HPV vaccine will reduce your chance of getting infected with HPV?  
 Very likely 
 Fairly likely 
 Not likely 
 Very unlikely 
 Don’t know 
 Prefer not to answer 
 
Q15. How likely do you think the HPV vaccine would reduce your chance of developing cervical cancer? 
 Very likely 
 Fairly likely 
 Not likely 
 Very unlikely 
 Don’t know 
 Prefer not to answer 
 
Q16. Would you be willing to receive a vaccine to help prevent HPV infections and cervical cancer?  
 Yes 
 No 
 Don’t know 
 Prefer not to answer 
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Q17. How important is it to you that the HPV vaccine: 
 
Q18. Would you consider getting an HPV vaccine if: 
 
 
Q19. Would you want your child/ren (or future children) to receive the HPV vaccine?  
 Very 
Important 
Important Moderately 
Important 
Of Little 
Importance 
 
Not 
important at 
all 
 
Don’t Know 
a) Prevent cancer             
b) Prevent genital 
warts 
            
c) Prevent both 
genital warts and 
cancer 
            
d) Be recommended 
by your doctor or a 
nurse 
            
e) Be recommended 
by family or friends 
            
f) Is affordable             
 Definitely 
would not 
Probably 
would not 
Neutral Probably 
would 
Definitely 
would 
Don’t 
Know 
Prefer not 
to answer 
a) It cost you R2300 to 
purchase  
              
 b) It was free               
c) It was recommended by 
your doctor or a nurse 
              
d) It was recommended by 
family or friends 
              
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 Yes 
 No 
 Don’t know 
 Prefer not to answer 
 
Q20a. Have you received the cervical cancer vaccine? 
 Yes → Skip to S14-Q20b 
 No →  Skip to S14-Q21 
 Don't know  
 Prefer not to answer 
 
Q20b. How many shots/doses did you receive?  
 1  
 2  
 3  
 Don't know  
 Prefer not to answer 
 
Q20c. At what age did you receive your first vaccination for HPV/cervical cancer? 
 Don’t know 
 Prefer not to answer 
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Section 15: Cervical Cancer Screening 
 
Q21. Have you heard of a test to check for cervical cancer? 
 Yes →  Skip to S15-Q22 
 No  →  Skip to S15-Q23a  
 Don't know  
 Prefer not to answer 
 
Q22. If you have heard about a test to check for cervical cancer, or Pap test, where did you hear about it?  
Allow participant to respond without reading options. (Select all that apply): 
 Mother 
 Father 
 Aunt 
 Sibling 
 Grandmother 
 Boyfriend/partner 
 School 
 Doctor or nurse 
 Counsellor 
 Online/Internet 
 TV 
 Other (specify): _______________________ 
 Don’t Know 
 
Q23a. Would you be willing to collect a sample by yourself to test for cervical cancer if you were given 
instructions on how to collect the sample? 
 Yes →  Skip to S15-Q23b 
 No →  Skip to S15-Q24 
 Don’t know 
 Prefer not to answer 
 
Q23b. Where would you feel most comfortable collecting a sample? 
 Healthcare clinic 
 Your home 
 Don’t know 
 Prefer not to answer 
 
Q24. Has a healthcare worker ever tested you for cervical cancer?    
 Yes  →  Skip to S15-Q25  
 No  →  Survey completed 
 Don’t know 
 Prefer not to answer 
 
Q25. At what age were you first tested for cervical cancer?  
 
Q26. When was your last (most recent) test for cervical cancer?    
             Year           Month 
 Don’t know 
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 Prefer not to answer    
 
Q27. What is the MAIN reason you had your last test for cervical cancer? 
 Following up on abnormal or inconclusive result 
 Recruited for testing by health care provider 
 Experiencing pain or other symptoms 
 Heard about the test and wanted to get tested 
 Other _________________________ 
 Don’t Know 
 Prefer not to answer 
 
Q28. Where did you receive your last test for cervical cancer? 
 Mobile clinic 
 Community clinic 
 Government hospital 
 Private hospital/private clinic 
 Other (specify): _________________________ 
 Don’t know 
 Prefer not to answer 
 
Q29. What was the result of your last (most recent) test for cervical cancer?    
 Did not receive result  
 Normal/Negative      
 Abnormal/Positive  
 Suspect cancer   
 Inconclusive  
 Don't know 
 Prefer not to answer 
 
Q30. Did you have any follow-up visits because of your test results? 
 Yes  
 No   
 Don't know  
 Prefer not to answer 
 
 
Thank you for your time. The survey is now complete. 
 
 
